

Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review

Lancet, The

370, 319-328

DOI: [10.1016/s0140-6736\(07\)61162-3](https://doi.org/10.1016/s0140-6736(07)61162-3)

Citation Report

#	ARTICLE	IF	CITATIONS
3	A Classification of Sociomedical Health Indicators: Perspectives for Health Administrators and Health Planners. <i>International Journal of Health Services</i> , 1976, 6, 521-538.	1.2	14
4	Reefer madness. <i>Cmaj</i> , 2007, 177, 988-988.	0.9	0
5	High expressed emotion, severe mental illness and substance use disorder. <i>British Journal of Nursing</i> , 2007, 16, 1259-1262.	0.3	5
6	My cannabis, your skunk: Reader's response to "the cannabis potency question". <i>Drugs and Alcohol Today</i> , 2007, 7, 13-17.	0.3	9
7	Cannabis use and risk of psychosis in later life. <i>Lancet, The</i> , 2007, 370, 293-294.	6.3	21
8	Cannabis and psychosis. <i>Lancet, The</i> , 2007, 370, 1539.	6.3	13
9	Cannabis and psychosis " Authors' reply. <i>Lancet, The</i> , 2007, 370, 1539-1540.	6.3	10
10	Cannabis and psychosis. <i>Lancet, The</i> , 2007, 370, 1540.	6.3	14
11	Cannabis and psychosis. <i>Lancet, The</i> , 2007, 370, 1540.	6.3	2
12	Epidemiology: what it is and why it matters. <i>Advances in Psychiatric Treatment</i> , 2007, 13, 412-413.	0.6	0
13	Should drugs be decriminalised? No. <i>BMJ: British Medical Journal</i> , 2007, 335, 967-967.	2.4	6
14	Paliperidone: the evidence of its therapeutic value in schizophrenia. <i>Core Evidence</i> , 0, .	4.7	6
15	Cannabis, the mind and society: the hash realities. <i>Nature Reviews Neuroscience</i> , 2007, 8, 885-895.	4.9	275
17	Cannabisgebruik en de kans op psychotische of affectieve symptomen. <i>Medisch-farmaceutische Mededelingen</i> , 2007, 45, 291.	0.0	0
18	Behavioural and neurochemical effects of post-weaning social isolation in rodents"Relevance to developmental neuropsychiatric disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2008, 32, 1087-1102.	2.9	752
19	What is the mechanism whereby cannabis use increases risk of psychosis?. <i>Neurotoxicity Research</i> , 2008, 14, 105-112.	1.3	53
20	What predicts illicit drug use versus police-registered drug offending?. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2008, 43, 697-704.	1.6	6
21	Design paper: The CapOpus trial: A randomized, parallel-group, observer-blinded clinical trial of specialized addiction treatment versus treatment as usual for young patients with cannabis abuse and psychosis. <i>Trials</i> , 2008, 9, 42.	0.7	13

#	ARTICLE	IF	CITATIONS
22	Flying a kite " observations on dual (and triple) diagnosis. <i>Criminal Behaviour and Mental Health</i> , 2008, 18, 145-152.	0.4	7
23	Polydrug use, cannabis, and psychosis-like symptoms. <i>Human Psychopharmacology</i> , 2008, 23, 475-485.	0.7	24
24	Early exposure to cannabis and risk for psychosis in young adolescents in Trinidad. <i>Acta Psychiatrica Scandinavica</i> , 2008, 118, 209-213.	2.2	88
25	The level of illicit drug use is related to symptoms and premorbid functioning in severe mental illness. <i>Acta Psychiatrica Scandinavica</i> , 2008, 118, 297-304.	2.2	50
26	Does cannabis use lead to depression and suicidal behaviours? A population-based longitudinal study. <i>Acta Psychiatrica Scandinavica</i> , 2008, 118, 395-403.	2.2	120
27	Marijuana as Medicine: Does It Have a Future?. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 515-517.	2.3	0
28	Smoked Marijuana as Medicine: Not Much Future. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 517-519.	2.3	15
29	Drugs, mental health and the adolescent brain: implications for early intervention. <i>Microbial Biotechnology</i> , 2008, 2, 63-66.	0.9	9
30	A role for p53 in the regulation of lysosomal permeability by δ^9 -tetrahydrocannabinol in rat cortical neurones: implications for neurodegeneration. <i>Journal of Neurochemistry</i> , 2008, 105, 1513-1524.	2.1	32
31	Mental illness and substance use: An Australian perspective. <i>International Journal of Mental Health Nursing</i> , 2008, 17, 255-260.	2.1	15
32	[Commentary] ADOLESCENT CANNABIS USE AND ADULT LIFE CHANCES. <i>Addiction</i> , 2008, 103, 977-978.	1.7	36
33	Cannabis and the developing brain: Insights from behavior. <i>European Journal of Pharmacology</i> , 2008, 585, 441-452.	1.7	111
35	Personality traits and their associations with substance use among adolescents. <i>Personality and Individual Differences</i> , 2008, 45, 356-360.	1.6	27
36	Genetic mediation of the link between schizophrenia and cannabis use. <i>Psychiatry (Abingdon, England)</i> , 2008, 7, 511-515.	0.2	1
37	Emerging Opportunities for Antipsychotic Drug Discovery in the Postgenomic Era. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 1077-1107.	2.9	51
38	A Randomized, Placebo-Controlled, Crossover Trial of Cannabis Cigarettes in Neuropathic Pain. <i>Journal of Pain</i> , 2008, 9, 506-521.	0.7	270
39	Schizophrenia, "Just the Facts" What we know in 2008. <i>Schizophrenia Research</i> , 2008, 100, 4-19.	1.1	298
40	Temporal association of cannabis use with symptoms in individuals at clinical high risk for psychosis. <i>Schizophrenia Research</i> , 2008, 106, 286-293.	1.1	71

#	ARTICLE	IF	CITATIONS
41	Marijuana Use Disorders and DSM-V. Journal of the American Academy of Child and Adolescent Psychiatry, 2008, 47, 121-122.	0.3	5
45	Cannabis, Cannabinoids and Schizophrenia: Integration of the Evidence. Australian and New Zealand Journal of Psychiatry, 2008, 42, 357-368.	1.3	80
47	Hypoalgesia in schizophrenia is independent of antipsychotic drugs: A systematic quantitative review of experimental studies. Pain, 2008, 138, 70-78.	2.0	88
48	Functional neuroimaging in schizophrenia: diagnosis and drug discovery. Trends in Pharmacological Sciences, 2008, 29, 91-98.	4.0	138
49	Gene-Environment Interplay Between Cannabis and Psychosis. Schizophrenia Bulletin, 2008, 34, 1111-1121.	2.3	211
50	Role of individual, peer and family factors in the use of cannabis and other illicit drugs: A longitudinal analysis among Finnish adolescent twins. Drug and Alcohol Dependence, 2008, 97, 33-43.	1.6	89
51	Schizophrenia, "Just the Facts" What we know in 2008. 2. Epidemiology and etiology. Schizophrenia Research, 2008, 102, 1-18.	1.1	610
52	Regional Brain Abnormalities Associated With Long-term Heavy Cannabis Use. Archives of General Psychiatry, 2008, 65, 694.	13.8	410
53	Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. British Journal of Psychiatry, 2008, 192, 306-307.	1.7	267
54	Reasons for Cannabis Use: Patients with Schizophrenia Versus Matched Healthy Controls. Australian and New Zealand Journal of Psychiatry, 2008, 42, 1060-1065.	1.3	36
55	Cannabis and lung cancer. European Respiratory Journal, 2008, 32, 238-239.	3.1	1
56	Familial Predisposition for Psychiatric Disorder. Archives of General Psychiatry, 2008, 65, 1269.	13.8	56
57	An intriguing association between dental and mental pathology in addicted and control subjects: a cross-sectional survey. British Dental Journal, 2008, 205, E22-E22.	0.3	11
58	Should cannabinoids be used as analgesics for neuropathic pain?. Nature Clinical Practice Neurology, 2008, 4, 654-655.	2.7	18
59	The adverse effects of cannabinoids: implications for use of medical marijuana. Cmaj, 2008, 178, 1685-1686.	0.9	28
60	Association of cannabis use with prodromal symptoms of psychosis in adolescence. British Journal of Psychiatry, 2008, 192, 470-471.	1.7	78
61	Familial Psychopathology in the First Episode Psychosis Outcome Study. Australian and New Zealand Journal of Psychiatry, 2008, 42, 617-626.	1.3	6
62	Adolescent Cannabis Problems and Young Adult Depression: Male-Female Stratified Propensity Score Analyses. American Journal of Epidemiology, 2008, 168, 592-601.	1.6	57

#	ARTICLE	IF	CITATIONS
63	Reduced Cortical Cannabinoid 1 Receptor Messenger RNA and Protein Expression in Schizophrenia. Archives of General Psychiatry, 2008, 65, 772.	13.8	208
64	Differences in prevalence and patterns of substance use in schizophrenia and bipolar disorder. Psychological Medicine, 2008, 38, 1241-1249.	2.7	81
65	Cannabis, Inhibitory Neurons, and the Progressive Course of Schizophrenia. American Journal of Psychiatry, 2008, 165, 416-419.	4.0	10
66	The cannabinoid CB ₁ receptor and the endocannabinoid anandamide: possible antidepressant targets. Expert Opinion on Therapeutic Targets, 2008, 12, 1347-1366.	1.5	70
67	Pharmacotherapy and psychotherapy in cannabis withdrawal and dependence. Expert Review of Neurotherapeutics, 2008, 8, 479-491.	1.4	46
68	Clinical manifestations of mental disorders among Sesotho speakers. International Journal of Psychiatry in Clinical Practice, 2008, 12, 171-179.	1.2	2
69	Effects of cannabis use on outcomes of psychotic disorders: systematic review. British Journal of Psychiatry, 2008, 193, 357-363.	1.7	237
70	Cannabis use and the risk of developing a psychotic disorder. World Psychiatry, 2008, 7, 68-71.	4.8	109
71	Psychosocial Stress and Psychosis. A Review of the Neurobiological Mechanisms and the Evidence for Gene-Stress Interaction. Schizophrenia Bulletin, 2008, 34, 1095-1105.	2.3	405
72	Adverse effects of medical cannabinoids: a systematic review. Cmaj, 2008, 178, 1669-1678.	0.9	288
73	Letter to the Editor: The coherence of the evidence linking cannabis with psychosis. Psychological Medicine, 2008, 38, 461-464.	2.7	7
74	Cannabis use and genetic predisposition for schizophrenia: a case-control study. Psychological Medicine, 2008, 38, 1251-1256.	2.7	35
75	Is cannabis bad for mental health?. Advances in Dual Diagnosis, 2008, 1, 37-40.	0.3	1
76	Saying No to Marijuana: Why American Youth Report Quitting or Abstaining. Journal of Studies on Alcohol and Drugs, 2008, 69, 796-805.	0.6	26
77	Cognitive Impairment in Schizophrenia: a Review of Developmental and Genetic Models, and Pro-cognitive Profile of the Optimised D3 & D2 Antagonist, S33138. Therapie, 2008, 63, 187-229.	0.6	44
79	Forum: decriminalization of cannabis. Current Opinion in Psychiatry, 2008, 21, 122-126.	3.1	18
80	The debate about marijuana usage in transplant candidates: recent medical evidence on marijuana health effects. Current Opinion in Organ Transplantation, 2008, 13, 189-195.	0.8	46
82	Cannabis use by people with severe mental illness – is it important?. Advances in Psychiatric Treatment, 2008, 14, 423-431.	0.6	12

#	ARTICLE	IF	CITATIONS
83	Severe mental illness and substance abuse. , 2008, , 247-264.		0
84	Mental health problems: treatment in schizophrenia. Dental Nursing, 2008, 4, 684-688.	0.0	0
85	The Case for Policy Reform in Cannabis Control. Canadian Journal of Psychiatry, 2008, 53, 795-797.	0.9	2
86	Obstacles to a Regulated Cannabis Market. Canadian Journal of Psychiatry, 2008, 53, 798-798.	0.9	1
87	Should We Recriminalize Cannabis Use? The Case against. Canadian Journal of Psychiatry, 2008, 53, 793-794.	0.9	3
88	A Retrospective Study Of Cannabis Use-Associated Psychopathology In A Southern Nigeria Treatment Facility. African Journal of Drug and Alcohol Studies, 2009, 8, .	0.2	2
89	Psychiatric symptoms and disorders in HIV infected mine workers in South Africa A retrospective descriptive study of acute first admissions. African Journal of Psychiatry, 2009, 12, 206-12.	0.1	14
90	Characterising novel pathways to schizophrenia. Medical Journal of Australia, 2009, 190, S5-6.	0.8	3
91	Phytocannabinoids and Endocannabinoids. Current Drug Abuse Reviews, 2009, 2, 51-75.	3.4	45
92	Cannabis use and cognition in schizophrenia. Frontiers in Human Neuroscience, 2009, 3, 53.	1.0	73
93	Cannabis Use: Subcultural Opposition or Social Marginality?. Acta Sociologica, 2009, 52, 135-148.	1.1	48
94	Cannabis Use and Deliberate Self-Harm in Adolescence: A Comparative Analysis of Associations in England and Norway. Archives of Suicide Research, 2009, 13, 340-348.	1.2	27
95	The acute effects of synthetic intravenous Δ^9 -tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychological Medicine, 2009, 39, 1607.	2.7	259
96	Δ^9 -Tetrahydrocannabinol Induces Dopamine Release in the Human Striatum. Neuropsychopharmacology, 2009, 34, 759-766.	2.8	341
97	Cannabinoids and psychosis. International Review of Psychiatry, 2009, 21, 152-162.	1.4	68
98	Addiction and the pharmacology of cannabis: implications for medicine and the law. Medicine, Science and the Law, 2009, 49, 1-17.	0.6	7
99	Acute cannabis use causes increased psychotomimetic experiences in individuals prone to psychosis. Psychological Medicine, 2009, 39, 951-956.	2.7	67
100	Subjective Effects of Cannabis Before the First Psychotic Episode. Australian and New Zealand Journal of Psychiatry, 2009, 43, 1155-1162.	1.3	29

#	ARTICLE	IF	CITATIONS
101	Cannabis and risk. <i>British Journal of General Practice</i> , 2009, 59, 157-158.	0.7	14
102	Reasons for Cannabis Use and Effects of Cannabis Use as Reported by Patients with Psychotic Disorders. <i>Psychopathology</i> , 2009, 42, 350-360.	1.1	53
103	Should Burden of Disease Estimates Include Cannabis Use as a Risk Factor for Psychosis?. <i>PLoS Medicine</i> , 2009, 6, e1000133.	3.9	41
104	Is the incidence of psychotic disorder in decline? Epidemiological evidence from two decades of research. <i>International Journal of Epidemiology</i> , 2009, 38, 1255-1264.	0.9	33
105	Modulation of Mediotemporal and Ventrostriatal Function in Humans by δ^9 -Tetrahydrocannabinol. <i>Archives of General Psychiatry</i> , 2009, 66, 442.	13.8	226
106	Association of Pre-Onset Cannabis, Alcohol, and Tobacco Use With Age at Onset of Prodrome and Age at Onset of Psychosis in First-Episode Patients. <i>American Journal of Psychiatry</i> , 2009, 166, 1251-1257.	4.0	162
108	Marijuana: Use Among Young Males and Health Outcomes. <i>American Journal of Men's Health</i> , 2009, 3, 265-274.	0.7	12
109	Epigenetic Mediation of Environmental Influences in Major Psychotic Disorders. <i>Schizophrenia Bulletin</i> , 2009, 35, 1045-1056.	2.3	224
110	The adverse health effects of cannabis use: What are they, and what are their implications for policy?. <i>International Journal of Drug Policy</i> , 2009, 20, 458-466.	1.6	160
111	Novedades sobre el cannabis. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2009, 16, 204-212.	0.0	1
112	A pilot study using nabilone for symptomatic treatment in Huntington's disease. <i>Movement Disorders</i> , 2009, 24, 2254-2259.	2.2	124
113	Substance misuse amongst young people in non-school settings: challenges to practitioners and policy makers. <i>Child Abuse Review</i> , 2009, 18, 240-253.	0.4	2
114	Cannabis and psychosis/schizophrenia: human studies. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009, 259, 413-431.	1.8	221
115	Adolescent Cannabis Use, Psychosis and Catechol-O-Methyltransferase Genotype in African Americans and Caucasians. <i>Psychiatric Quarterly</i> , 2009, 80, 213-218.	1.1	34
116	The role of cannabis in cognitive functioning of patients with schizophrenia. <i>Psychopharmacology</i> , 2009, 205, 45-52.	1.5	87
117	Superstitious conditioning as a model of delusion formation following chronic but not acute ketamine in humans. <i>Psychopharmacology</i> , 2009, 206, 563-573.	1.5	18
118	The endocannabinoid system as a target for modelling psychosis. <i>Psychopharmacology</i> , 2009, 206, 551-561.	1.5	42
119	Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. <i>Psychopharmacology</i> , 2009, 206, 313-324.	1.5	108

#	ARTICLE	IF	CITATIONS
120	Role of cannabis and endocannabinoids in the genesis of schizophrenia. <i>Psychopharmacology</i> , 2009, 206, 531-549.	1.5	123
121	Relief-oriented use of marijuana by teens. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2009, 4, 7.	1.0	53
122	Smoking, nicotine dependence and mental health among young adults: a 13-year population-based longitudinal study. <i>Addiction</i> , 2009, 104, 129-137.	1.7	120
123	Adult versus adolescent onset of smoking: how are mood disorders and other risk factors involved?. <i>Addiction</i> , 2009, 104, 1411-1419.	1.7	25
124	Hypothalamic-pituitary-adrenal axis and smoking and drinking onset among adolescents: the longitudinal cohort TRacking Adolescents' Individual Lives Survey (TRAILS). <i>Addiction</i> , 2009, 104, 1927-1936.	1.7	21
125	If cannabis caused schizophrenia—how many cannabis users may need to be prevented in order to prevent one case of schizophrenia? England and Wales calculations. <i>Addiction</i> , 2009, 104, 1856-1861.	1.7	51
126	Commentary on Hickman <i>et al.</i> (2009): The place of risk in drug policies. <i>Addiction</i> , 2009, 104, 1862-1863.	1.7	1
127	Early psychosis intervention service for children and youth: a retrospective chart review of the first four years. <i>Microbial Biotechnology</i> , 2009, 3, 99-107.	0.9	3
128	Schizophrenia: genetics, prevention and rehabilitation. <i>Acta Neuropsychiatrica</i> , 2009, 21, 109-120.	1.0	9
130	Mental health consequences of cannabis use. <i>Acta Psychiatrica Scandinavica</i> , 2009, 119, 411-411.	2.2	3
131	An overview of systematic reviews on cannabis and psychosis: Discussing apparently conflicting results. <i>Drug and Alcohol Review</i> , 2010, 29, 304-317.	1.1	64
132	D ₂ receptor-mediated inhibition of dopamine release in the rat striatum <i>in vitro</i> is modulated by CB ₁ receptors: studies using fast cyclic voltammetry. <i>Journal of Neurochemistry</i> , 2009, 108, 545-551.	2.1	20
133	High-potency cannabis and the risk of psychosis. <i>British Journal of Psychiatry</i> , 2009, 195, 488-491.	1.7	465
134	Chronic toxicology of cannabis. <i>Clinical Toxicology</i> , 2009, 47, 517-524.	0.8	82
135	Marijuana Effectiveness as an HIV Self-Care Strategy. <i>Clinical Nursing Research</i> , 2009, 18, 172-193.	0.7	47
136	Psychiatric Comorbidities and Schizophrenia. <i>Schizophrenia Bulletin</i> , 2009, 35, 383-402.	2.3	867
137	Clinical characteristics influencing age at onset in psychotic disorders. <i>Comprehensive Psychiatry</i> , 2009, 50, 13-19.	1.5	76
138	Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: Comparison at intake and 6 months later. <i>Drug and Alcohol Dependence</i> , 2009, 99, 280-295.	1.6	579

#	ARTICLE	IF	CITATIONS
140	No association between chronic cannabis use and loudness dependence of auditory evoked potentials as indicator of central serotonergic neurotransmission. <i>Neuroscience Letters</i> , 2009, 465, 113-117.	1.0	6
143	Substance use behaviors, mental health problems, and use of mental health services in a probability sample of college students. <i>Addictive Behaviors</i> , 2009, 34, 134-145.	1.7	214
144	Treatment of cannabis use disorders in people with schizophrenia spectrum disorders " A systematic review. <i>Addictive Behaviors</i> , 2009, 34, 520-525.	1.7	39
145	Reprint of "Treatment of cannabis use disorders in people with schizophrenia spectrum disorders " A systematic review". <i>Addictive Behaviors</i> , 2009, 34, 846-851.	1.7	16
146	The social context of cannabis use: Relationship to cannabis use disorders and depressive symptoms among college students. <i>Addictive Behaviors</i> , 2009, 34, 764-768.	1.7	52
147	The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway. <i>Schizophrenia Bulletin</i> , 2009, 35, 549-562.	2.3	2,149
148	Neurobiological alterations at adult age triggered by adolescent exposure to cannabinoids. <i>Pharmacological Research</i> , 2009, 60, 132-138.	3.1	78
149	Cannabis use in children and adolescents with first episode psychosis: Influence on psychopathology and short-term outcome (CAFEPS study). <i>Schizophrenia Research</i> , 2009, 113, 129-137.	1.1	86
150	Assessing the impact of cannabis use on trends in diagnosed schizophrenia in the United Kingdom from 1996 to 2005. <i>Schizophrenia Research</i> , 2009, 113, 123-128.	1.1	45
151	Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: A meta-analysis. <i>Schizophrenia Research</i> , 2009, 113, 181-188.	1.1	35
152	Structural Brain Alterations in Cannabis Users: Association with Cognitive Deficits and Psychiatric Symptoms. , 2009, , 215-225.		2
153	Psychosocial Treatments for People with Co-occurring Severe Mental Illnesses and Substance Use Disorders (Dual Diagnosis): A Review of Empirical Evidence. <i>Harvard Review of Psychiatry</i> , 2009, 17, 24-34.	0.9	184
155	Variabilidad en el gen COMT y modificaci3n del riesgo de esquizofrenia conferido por consumo de cannabis. <i>Revista De PsiquiatrAa Y Salud Mental</i> , 2009, 2, 89-94.	1.0	8
156	Variability of the COMT gene and modification of the risk of schizophrenia conferred by cannabis consumption. <i>Revista De PsiquiatrAa Y Salud Mental (English Edition)</i> , 2009, 2, 89-94.	0.2	4
157	Smoked Medicinal Cannabis for Neuropathic Pain in HIV: A Randomized, Crossover Clinical Trial. <i>Neuropsychopharmacology</i> , 2009, 34, 672-680.	2.8	392
158	Neuregulin-1 signaling in schizophrenia: "Jack of all trades" or master of some?. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 1-3.	1.4	16
159	Drawing the line on risky use of cannabis: Assessing problematic use with the ASSIST. <i>Addiction Research and Theory</i> , 2009, 17, 322-332.	1.2	20
161	Cannabis use and age of diagnosis of schizophrenia. <i>European Psychiatry</i> , 2009, 24, 282-286.	0.1	41

#	ARTICLE	IF	CITATIONS
162	Can recreational doses of THC produce significant dopamine release in the human striatum?. <i>NeuroImage</i> , 2009, 48, 186-190.	2.1	124
163	P.3.02 Opposite neural effects of the main psychoactive ingredients of cannabis – implications for therapeutics. <i>European Neuropsychopharmacology</i> , 2009, 19, S63-S64.	0.3	1
164	P.3.03 A double-blind, placebo-controlled, parallel group study of the effect of Org 25935 on cognitive performance. <i>European Neuropsychopharmacology</i> , 2009, 19, S64-S65.	0.3	0
165	P.4.16 Cannabis use and subclinical psychotic symptoms: is the public mental health at risk?. <i>European Neuropsychopharmacology</i> , 2009, 19, S92-S93.	0.3	0
166	Schizophrenia. <i>Lancet, The</i> , 2009, 374, 635-645.	6.3	1,820
167	Adverse health effects of non-medical cannabis use. <i>Lancet, The</i> , 2009, 374, 1383-1391.	6.3	941
169	Cannabinoid CB1 receptors in rat medial prefrontal cortex are colocalized with calbindin but not parvalbumin- and calretinin-positive GABA-ergic neurons. <i>Pharmacological Reports</i> , 2009, 61, 1000-1007.	1.5	41
170	Very Early Interventions in Psychotic Disorders. <i>Psychiatric Clinics of North America</i> , 2009, 32, 81-94.	0.7	3
171	The association between early cannabis use and psychotic-like experiences in a community adolescent sample. <i>Schizophrenia Research</i> , 2009, 112, 130-135.	1.1	59
172	The challenges in developing a rational cannabis policy. <i>Current Opinion in Psychiatry</i> , 2009, 22, 258-262.	3.1	33
174	A Multi-Method Evaluation of a Substance Misuse Program in a Medium Secure Forensic Mental Health Unit. <i>Journal of Addictions Nursing</i> , 2009, 20, 132-141.	0.2	17
175	Brief intervention addressing excessive cannabis use in young people consulting their GP: a pilot study. <i>British Journal of General Practice</i> , 2009, 59, 166-172.	0.7	25
176	Depression and anxiety Antidepressants. , 2009, , 171-266.		1
177	Cannabis and suicide: longitudinal study. <i>British Journal of Psychiatry</i> , 2009, 195, 492-497.	1.7	76
178	Health consequences of illegal drug use. <i>Current Opinion in Psychiatry</i> , 2009, 22, 287-292.	3.1	86
179	Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. <i>Yearbook of Pediatrics</i> , 2009, 2009, 570-574.	0.2	2
180	Neuroimaging Studies of Substance Abuse in Schizophrenia. <i>Current Psychiatry Reviews</i> , 2009, 5, 250-260.	0.9	3
181	Variable individual sensitivity to cannabis in patients with schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 1145-1154.	1.0	24

#	ARTICLE	IF	CITATIONS
182	Objectively Assessed Secondhand Smoke Exposure and Mental Health in Adults. Archives of General Psychiatry, 2010, 67, 850.	13.8	75
183	Prefrontal Cortical Circuits in Schizophrenia. Current Topics in Behavioral Neurosciences, 2010, 4, 485-508.	0.8	90
184	Cognitive Functioning in Children and Adolescents in Their First Episode of Psychosis. Journal of Nervous and Mental Disease, 2010, 198, 159-162.	0.5	36
185	Cannabis and psychosis. British Journal of Psychiatry, 2010, 197, 333-333.	1.7	1
186	Age of Onset of Cannabis Use is Associated with Age of Onset of High-Risk Symptoms for Psychosis. Canadian Journal of Psychiatry, 2010, 55, 165-171.	0.9	60
187	Failure to communicate effectively or failure of feedback?. British Journal of Psychiatry, 2010, 197, 332-333.	1.7	0
188	Outcomes of occasional cannabis use in adolescence: 10-year follow-up study in Victoria, Australia. British Journal of Psychiatry, 2010, 196, 290-295.	1.7	101
191	Cannabis constituents modulate Δ^9 -tetrahydrocannabinol-induced hyperphagia in rats. Psychopharmacology, 2010, 210, 97-106.	1.5	19
192	A follow-up study: acute behavioural effects of Δ^9 -THC in female heterozygous Neuregulin 1 transmembrane domain mutant mice. Psychopharmacology, 2010, 211, 277-289.	1.5	62
193	The revolving door phenomenon in psychiatry: comparing low-frequency and high-frequency users of psychiatric inpatient services in a developing country. Social Psychiatry and Psychiatric Epidemiology, 2010, 45, 461-468.	1.6	78
194	Clinical Staging in the Pathophysiology of Psychotic and Affective Disorders: Facilitation of Prognosis and Treatment. Neurotoxicity Research, 2010, 18, 211-228.	1.3	12
196	Temporal relationship of first-episode non-affective psychosis with cannabis use: A clinical verification of an epidemiological hypothesis. Journal of Psychiatric Research, 2010, 44, 413-420.	1.5	37
197	Diffusion tensor imaging in the early phase of schizophrenia: What have we learned?. Journal of Psychiatric Research, 2010, 44, 993-1004.	1.5	137
198	Cannabis use and callosal white matter structure and integrity in recent-onset schizophrenia. Psychiatry Research - Neuroimaging, 2010, 181, 51-56.	0.9	49
199	Assessing evidence for a causal link between cannabis and psychosis: A review of cohort studies. International Journal of Drug Policy, 2010, 21, 10-19.	1.6	59
201	GABAA receptor density is altered by cannabinoid treatment in the hippocampus of adult but not adolescent rats. Brain Research, 2010, 1351, 238-245.	1.1	17
202	Typologies of cannabis users and associated characteristics relevant for public health: a latent class analysis of data from a nationally representative Canadian adult survey. International Journal of Methods in Psychiatric Research, 2010, 19, 110-124.	1.1	32
203	Do patients think cannabis causes schizophrenia? - A qualitative study on the causal beliefs of cannabis using patients with schizophrenia. Harm Reduction Journal, 2010, 7, 22.	1.3	29

#	ARTICLE	IF	CITATIONS
204	Medical marijuana users in substance abuse treatment. Harm Reduction Journal, 2010, 7, 3.	1.3	67
205	Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models. British Journal of Pharmacology, 2010, 160, 511-522.	2.7	186
206	Illicit substance use and its correlates in first episode psychosis. Acta Psychiatrica Scandinavica, 2010, 121, 351-358.	2.2	56
207	Cannabis and crime: findings from a longitudinal study. Addiction, 2010, 105, 109-118.	1.7	93
208	How ideology shapes the evidence and the policy: what do we know about cannabis use and what should we do?. Addiction, 2010, 105, 1326-1330.	1.7	29
209	WHAT ARE THE POLICY IMPLICATIONS OF THE EVIDENCE ON CANNABIS USE AND PSYCHOSIS?. Addiction, 2010, 105, 1332-1333.	1.7	5
210	IS THERE A CAUSAL LINKAGE BETWEEN CANNABIS USE AND INCREASED RISKS OF PSYCHOTIC SYMPTOMS?. Addiction, 2010, 105, 1336-1337.	1.7	7
211	RESPONSE TO COMMENTARIES: MOVING TOWARDS AN EVIDENCE-BASED POLICY AROUND CANNABIS USE. Addiction, 2010, 105, 1337-1339.	1.7	1
212	Leisure time activities that predict initiation, progression and reduction of cannabis use: A prospective, population-based panel survey. Drug and Alcohol Review, 2010, 29, 378-384.	1.1	24
213	Contextualising psychological distress among regular ecstasy users: The importance of sociodemographic factors and patterns of drug use. Drug and Alcohol Review, 2010, 29, 243-249.	1.1	24
214	New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids. Therapeutics and Clinical Risk Management, 2010, 6, 59.	0.9	16
215	Efeitos comportamentais, cognitivos e psicofisiológicos dos canabinoides: relevância para a psicose e a esquizofrenia. Revista Brasileira De Psiquiatria, 2010, 32, 515-530.	0.9	27
216	Schizophrenia and related disorders. , 2010, , 391-426.		1
217	Prevalence of Psychotic Symptoms and Their Risk Factors in Urban Tanzania. International Journal of Environmental Research and Public Health, 2010, 7, 2514-2525.	1.2	38
218	Interpretation of ecological data. British Journal of Psychiatry, 2010, 197, 332-332.	1.7	0
221	Abuso de cannabis em pacientes com transtornos psiquiátricos: atualização para uma antiga evidência. Revista Brasileira De Psiquiatria, 2010, 32, 541-545.	0.9	10
222	Cannabis Use in Patients with a First Psychotic Episode and Subjects at Ultra High Risk of Psychosis: Impact on Psychotic- and Pre-Psychotic Symptoms. Australian and New Zealand Journal of Psychiatry, 2010, 44, 721-728.	1.3	35
223	Review: pharmacological and psychological interventions decrease cannabis use in people with depressive and psychotic disorders in the short term. Evidence-Based Mental Health, 2010, 13, 124-124.	2.2	0

#	ARTICLE	IF	CITATIONS
224	Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia. <i>Psychological Medicine</i> , 2010, 40, 1337-1347.	2.7	60
225	Early Cannabis Use and Estimated Risk of Later Onset of Depression Spells: Epidemiologic Evidence From the Population-based World Health Organization World Mental Health Survey Initiative. <i>American Journal of Epidemiology</i> , 2010, 172, 149-159.	1.6	64
226	Beyond the first episode: Candidate factors for a risk prediction model of schizophrenia. <i>International Review of Psychiatry</i> , 2010, 22, 202-223.	1.4	5
227	Endocannabinoids and Schizophrenia. <i>Pharmaceuticals</i> , 2010, 3, 3101-3126.	1.7	27
228	Cannabis use and childhood trauma interact additively to increase the risk of psychotic symptoms in adolescence. <i>Psychological Medicine</i> , 2010, 40, 1627-1634.	2.7	162
229	Symptomatology and Neuropsychological Functioning in Cannabis Using Subjects at Ultra-High Risk for Developing Psychosis and Healthy Controls. <i>Australian and New Zealand Journal of Psychiatry</i> , 2010, 44, 230-236.	1.3	47
230	Development of Cannabinoid 1 Receptor Protein and Messenger RNA in Monkey Dorsolateral Prefrontal Cortex. <i>Cerebral Cortex</i> , 2010, 20, 1164-1174.	1.6	51
231	Migration, Ethnicity, and Psychosis: Toward a Sociodevelopmental Model. <i>Schizophrenia Bulletin</i> , 2010, 36, 655-664.	2.3	262
232	Anxiety and Mood Disorders and Cannabis Use. <i>American Journal of Drug and Alcohol Abuse</i> , 2010, 36, 118-122.	1.1	58
233	A Meta-Analytic Review of School-Based Prevention for Cannabis Use. <i>Health Education and Behavior</i> , 2010, 37, 709-723.	1.3	86
234	Rate of Cannabis Use Disorders in Clinical Samples of Patients With Schizophrenia: A Meta-analysis. <i>Schizophrenia Bulletin</i> , 2010, 36, 1115-1130.	2.3	275
235	Role of Cannabinoid Receptor Type 1 Desensitization in Greater Tetrahydrocannabinol Impairment of Memory in Adolescent Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 335, 294-301.	1.3	31
236	Does a lack of specificity rule out a causal relationship between cannabis use and schizophrenia?. <i>Addiction Research and Theory</i> , 2010, 18, 606-608.	1.2	1
237	Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. <i>British Journal of Psychiatry</i> , 2010, 197, 285-290.	1.7	263
238	Gamma Oscillation Deficits and the Onset and Early Progression of Schizophrenia. <i>Harvard Review of Psychiatry</i> , 2010, 18, 173-189.	0.9	86
239	Chronic Adolescent Exposure to δ^9 -Tetrahydrocannabinol in COMT Mutant Mice: Impact on Psychosis-Related and Other Phenotypes. <i>Neuropsychopharmacology</i> , 2010, 35, 2262-2273.	2.8	97
240	Vulnerability Factors for the Psychiatric and Behavioral Effects of Cannabis. <i>Pharmaceuticals</i> , 2010, 3, 2799-2820.	1.7	12
241	Fibroblast Growth Factors in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2010, 36, 1157-1166.	2.3	60

#	ARTICLE	IF	CITATIONS
242	Pharmacology and Toxicology of Cannabis Derivatives and Endocannabinoid Agonists. Recent Patents on CNS Drug Discovery, 2010, 5, 46-52.	0.9	30
243	Acute Psychotropic Effects of Oral Cannabis Extract with a Defined Content of Δ^9 -Tetrahydrocannabinol (THC) in Healthy Volunteers. Pharmacopsychiatry, 2010, 43, 24-32.	1.7	27
244	Individuals, Schools, and Neighborhood. Archives of General Psychiatry, 2010, 67, 914.	13.8	134
245	Early psychosis: raising awareness among non-mental health nurses. Nursing Standard (Royal College) Tj ETQq1 1 0,784314 rgBT /Overl 0,1	0.1	0
246	Assessment and management of cannabis use disorders in primary care. BMJ: British Medical Journal, 2010, 340, c1571-c1571.	2.4	27
250	Etiological and Clinical Features of Childhood Psychotic Symptoms. Archives of General Psychiatry, 2010, 67, 328.	13.8	214
251	Association Between Cannabis Use and Psychosis-Related Outcomes Using Sibling Pair Analysis in a Cohort of Young Adults. Archives of General Psychiatry, 2010, 67, 440.	13.8	211
253	Challenging the "Inoffensiveness" of Regular Cannabis Use by Its Associations with Other Current Risky Substance Use: A Census of 20-Year-Old Swiss Men. International Journal of Environmental Research and Public Health, 2010, 7, 46-59.	1.2	9
254	Δ^9 -THC. , 2010, , 383-392.		0
256	The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophrenia Research, 2010, 118, 309-310.	1.1	165
257	INTERIM ANALYSIS OF THE CAPOPIUS TRIAL: A RANDOMIZED, PARALLEL-GROUP, OBSERVER-BLINDED CLINICAL TRIAL OF SPECIALIZED ADDICTION TREATMENT VERSUS TREATMENT AS USUAL FOR YOUNG PATIENTS WITH CANNABIS ABUSE AND PSYCHOSIS. Schizophrenia Research, 2010, 117, 190.	1.1	4
258	Cannabis use disorders in schizophrenia: Effects on cognition and symptoms. Schizophrenia Research, 2010, 120, 95-100.	1.1	62
259	Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines. Schizophrenia Research, 2010, 121, 107-117.	1.1	100
260	Clinical and Cognitive Associations with Aggression in the First Episode of Psychosis. Australian and New Zealand Journal of Psychiatry, 2010, 44, 85-93.	1.3	63
261	Intervention for cannabis use in young people at ultra high risk for psychosis and in early psychosis. Mental Health and Substance Use: Dual Diagnosis, 2010, 3, 66-73.	0.5	15
262	What every adolescent needs to know: Cannabis can cause psychosis. Journal of Psychosomatic Research, 2010, 69, 533-539.	1.2	39
264	The influence of tobacco consumption on the relationship between schizotypy and hemispheric asymmetry. Journal of Behavior Therapy and Experimental Psychiatry, 2010, 41, 397-408.	0.6	16
265	Cannabis abuse and severity of psychotic and affective disorders in Israeli psychiatric inpatients. Comprehensive Psychiatry, 2010, 51, 37-41.	1.5	17

#	ARTICLE	IF	CITATIONS
266	Effects of risk perception of marijuana use on marijuana use and intentions to use among adolescents in Bogotá, Colombia. <i>Drug and Alcohol Dependence</i> , 2010, 109, 65-72.	1.6	58
267	Processing dynamic facial affect in frequent cannabis-users: Evidence of deficits in the speed of identifying emotional expressions. <i>Drug and Alcohol Dependence</i> , 2010, 112, 27-32.	1.6	55
268	Does heavy adolescent marijuana use lead to criminal involvement in adulthood? Evidence from a multiwave longitudinal study of urban African Americans. <i>Drug and Alcohol Dependence</i> , 2010, 112, 117-125.	1.6	83
269	Self-control and its relation to joint developmental trajectories of cannabis use and depressive mood symptoms. <i>Drug and Alcohol Dependence</i> , 2010, 112, 201-208.	1.6	23
270	Functional MRI evidence for inefficient attentional control in adolescent chronic cannabis abuse. <i>Behavioural Brain Research</i> , 2010, 215, 45-57.	1.2	96
271	Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. <i>Progress in Neurobiology</i> , 2010, 92, 370-385.	2.8	276
272	Cannabinoid administration increases 5HT1A receptor binding and mRNA expression in the hippocampus of adult but not adolescent rats. <i>Neuroscience</i> , 2010, 169, 315-324.	1.1	38
273	Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortex. <i>Neuroscience</i> , 2010, 169, 1651-1661.	1.1	65
274	Modulation of effective connectivity during emotional processing by δ^9 -tetrahydrocannabinol and cannabidiol. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 421.	1.0	134
275	Does cannabis use affect prospective memory in young adults?. <i>Journal of Psychopharmacology</i> , 2010, 24, 241-246.	2.0	51
276	Structural MRI Findings in Long-Term Cannabis Users: What Do We Know?. <i>Substance Use and Misuse</i> , 2010, 45, 1787-1808.	0.7	110
277	P.1.e.005 Delta9-tetrahydrocannabinol (THC) impairs working memory system capacity: a pharmacological MRI study. <i>European Neuropsychopharmacology</i> , 2010, 20, S290-S291.	0.3	0
281	P.3.a.006 Attitudes concerning depot medication in German general population – a representative telephone survey. <i>European Neuropsychopharmacology</i> , 2010, 20, S432-S433.	0.3	0
282	The endocannabinoid system and psychiatric disorders. <i>Experimental Neurology</i> , 2010, 224, 3-14.	2.0	124
283	A behavioural comparison of acute and chronic δ^9 -tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 861-876.	1.0	167
284	Opposite Effects of δ^9 -Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology. <i>Neuropsychopharmacology</i> , 2010, 35, 764-774.	2.8	595
286	Behavioral Neurobiology of Schizophrenia and Its Treatment. <i>Current Topics in Behavioral Neurosciences</i> , 2010, , .	0.8	8
287	Substance Use in Adolescence and Psychosis: Clarifying the Relationship. <i>Annual Review of Clinical Psychology</i> , 2010, 6, 365-389.	6.3	57

#	ARTICLE	IF	CITATIONS
288	A Comparison of Psychosocial and Cognitive Functioning Between Depressed and Non-Depressed Patients with Cannabis Dependence. <i>Journal of Addictive Diseases</i> , 2010, 29, 325-337.	0.8	11
289	Health Effects of Using Cannabis for Therapeutic Purposes: A Gender Analysis of Users's Perspectives. <i>Substance Use and Misuse</i> , 2011, 46, 769-780.	0.7	26
290	Consumo de cannabis, adolescencia y suicidio. <i>Trastornos Adictivos</i> , 2011, 13, 119-122.	0.1	0
291	Reduced Cortical Thickness as an Outcome of Differential Sensitivity to Environmental Risks in Schizophrenia. <i>Biological Psychiatry</i> , 2011, 69, 487-494.	0.7	122
292	Effects of cannabis use on age at onset in schizophrenia and bipolar disorder. <i>Schizophrenia Research</i> , 2011, 126, 270-276.	1.1	77
293	Pre-morbid Conduct Disorder symptoms are associated with cannabis use among individuals with a first episode of psychosis. <i>Schizophrenia Research</i> , 2011, 126, 81-86.	1.1	24
294	Interaction between COMT haplotypes and cannabis in schizophrenia: A case-only study in two samples from Spain. <i>Schizophrenia Research</i> , 2011, 127, 22-27.	1.1	57
295	Greater white and grey matter changes associated with early cannabis use in adolescent-onset schizophrenia (AOS). <i>Schizophrenia Research</i> , 2011, 128, 91-97.	1.1	86
296	Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia. <i>Schizophrenia Research</i> , 2011, 128, 66-75.	1.1	100
297	Cannabis use and striatal D2 receptor density in untreated first-episode psychosis: An in vivo SPECT study. <i>Schizophrenia Research</i> , 2011, 129, 169-171.	1.1	13
298	Cannabis with high cannabidiol content is associated with fewer psychotic experiences. <i>Schizophrenia Research</i> , 2011, 130, 216-221.	1.1	200
299	Differential effects of chronic cannabis use on preattentive cognitive functioning in abstinent schizophrenic patients and healthy subjects. <i>Schizophrenia Research</i> , 2011, 130, 222-227.	1.1	31
300	Pathways to psychosis: Help-seeking behavior in the prodromal phase. <i>Schizophrenia Research</i> , 2011, 132, 213-219.	1.1	54
301	Acute psychotic sequelae of "bath salts". <i>Schizophrenia Research</i> , 2011, 133, 259-260.	1.1	15
302	Alcohol and Substance Use by Patients with Psychosis Presenting to an Emergency Department: Changing Patterns. <i>Australasian Psychiatry</i> , 2011, 19, 354-359.	0.4	25
303	Chronic pubertal cannabinoid treatment as a behavioural model for aspects of schizophrenia: effects of the atypical antipsychotic quetiapine. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 43-51.	1.0	30
304	Psychometric properties of the Cannabis Abuse Screening Test (CAST) in a French sample of adolescents. <i>Drug and Alcohol Dependence</i> , 2011, 113, 229-235.	1.6	92
305	Validation of the Cannabis Expectancy Questionnaire (CEQ) in adult cannabis users in treatment. <i>Drug and Alcohol Dependence</i> , 2011, 115, 167-174.	1.6	53

#	ARTICLE	IF	CITATIONS
306	Cannabis use and development of externalizing and internalizing behaviour problems in early adolescence: A TRAILS study. <i>Drug and Alcohol Dependence</i> , 2011, 116, 11-17.	1.6	53
307	Synthetic cannabinoid JWH-018 and psychosis: An explorative study. <i>Drug and Alcohol Dependence</i> , 2011, 117, 152-157.	1.6	263
308	Conditional substance abuse and dependence by diagnosis of mood or anxiety disorder or schizophrenia in the U.S. population. <i>Drug and Alcohol Dependence</i> , 2011, 119, 28-36.	1.6	76
309	Disruption of Frontal Theta Coherence by Δ^9 -Tetrahydrocannabinol is Associated with Positive Psychotic Symptoms. <i>Neuropsychopharmacology</i> , 2011, 36, 827-836.	2.8	74
310	Is DNA methylation responsible for immune system dysfunction in schizophrenia?. <i>Medical Hypotheses</i> , 2011, 77, 573-579.	0.8	3
311	The environment and susceptibility to schizophrenia. <i>Progress in Neurobiology</i> , 2011, 93, 23-58.	2.8	539
312	Psychopharmacological comparison of schizophrenia spectrum disorder with and without cannabis dependency. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 212-217.	2.5	12
313	Effects of cannabinoid CB1 receptor agonism and antagonism on SKF81297-induced dyskinesia and haloperidol-induced dystonia in <i>Cebus apella</i> monkeys. <i>Neuropharmacology</i> , 2011, 60, 418-422.	2.0	6
314	Cannabis users differ from non-users on measures of personality and schizotypy. <i>Psychiatry Research</i> , 2011, 186, 46-52.	1.7	80
315	Risk factors at the low end of the psychosis continuum: Much the same as at the upper end?. <i>Psychiatry Research</i> , 2011, 189, 77-81.	1.7	22
316	Startle reactivity and prepulse inhibition in prodromal and early psychosis: Effects of age, antipsychotics, tobacco and cannabis in a vulnerable population. <i>Psychiatry Research</i> , 2011, 188, 208-216.	1.7	48
317	Recreational substance use patterns and co-morbid psychopathology in adults with intellectual disability. <i>Research in Developmental Disabilities</i> , 2011, 32, 2981-2986.	1.2	47
318	A systematic meta-review grading the evidence for non-genetic risk factors and putative antecedents of schizophrenia. <i>Schizophrenia Research</i> , 2011, 133, 133-142.	1.1	130
319	Effects of chronic bhang (cannabis) administration on the reproductive system of male mice. <i>Birth Defects Research Part B: Developmental and Reproductive Toxicology</i> , 2011, 92, 195-205.	1.4	48
320	Unsymmetrical Cyclotriazadisulfonamide (CADA) Compounds as Human CD4 Receptor Down-Modulating Agents. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 5712-5721.	2.9	16
321	Dysfunctional Brain Networks and Genetic Risk for Schizophrenia: Specific Neurotransmitter Systems. <i>CNS Neuroscience and Therapeutics</i> , 2011, 17, 89-96.	1.9	28
322	The need for close monitoring of early psychosis and co-occurring substance misuse. <i>The Psychiatrist</i> , 2011, 35, 241-243.	0.3	3
323	Lower Risk Cannabis Use Guidelines for Canada (LRCUG): A Narrative Review of Evidence and Recommendations. <i>Canadian Journal of Public Health</i> , 2011, 102, 324-327.	1.1	72

#	ARTICLE	IF	CITATIONS
324	Cannabinoids and the cerebellum: a potential role in the development of psychosis. , 0, , 144-159.		1
327	Cannabis in cultural and legal limbo. , 0, , 171-188.		4
328	The neural basis for the acute effects of cannabis on learning and psychosis. , 0, , 160-168.		1
329	What are the policy implications of the evidence on cannabis and psychosis?. , 0, , 55-65.		1
330	Which cannabis users develop psychosis?. , 2011, , 137-143.		1
331	Does cannabis use cause schizophrenia? The epidemiological evidence. , 0, , 169-183.		0
332	Understanding cannabis use in schizophrenia. , 0, , 218-224.		2
333	The manifold actions of endocannabinoids on female and male reproductive events. <i>Frontiers in Bioscience - Landmark</i> , 2011, 16, 498.	3.0	83
334	Drug-Induced Psychosis: How to Avoid Star Gazing in Schizophrenia Research by Looking at More Obvious Sources of Light. <i>Frontiers in Behavioral Neuroscience</i> , 2011, 5, 1.	1.0	167
335	Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. <i>Frontiers in Behavioral Neuroscience</i> , 2011, 5, 63.	1.0	101
336	Using a Mobile Laboratory to Study Mental Health, Addictions and Violence: A Research Plan. <i>Challenges</i> , 2011, 2, 1-18.	0.9	12
337	Environmental risk factors for schizophrenia: implications for prevention. <i>Neuropsychiatry</i> , 2011, 1, 457-466.	0.4	11
338	Putative diffusion tensor neuroimaging endophenotypes in schizophrenia: a review of the early evidence. <i>Future Neurology</i> , 2011, 6, 415-433.	0.9	3
339	A Longitudinal Study of Risk Factors for Incident Drug Use in Adults: Findings from a Representative Sample of the US Population. <i>Canadian Journal of Psychiatry</i> , 2011, 56, 686-695.	0.9	30
340	Is cannabis responsible for early onset psychotic illnesses?. <i>Neuropsychiatry</i> , 2011, 1, 203-207.	0.4	4
342	The association between cannabis use and depression: a review of the evidence. , 2011, , 114-128.		4
343	Early intervention in psychosis: clinical aspects of treatment. <i>Advances in Psychiatric Treatment</i> , 2011, 17, 408-416.	0.6	3
344	Detecting psychological symptoms related to substance use among Indigenous Australians. <i>Drug and Alcohol Review</i> , 2011, 30, 33-39.	1.1	16

#	ARTICLE	IF	CITATIONS
345	Review: The neuropathology of drug abuse. <i>Neuropathology and Applied Neurobiology</i> , 2011, 37, 118-134.	1.8	146
346	The "grass ceiling"™: limitations in the literature hinder our understanding of cannabis use and its consequences. <i>Addiction</i> , 2011, 106, 238-244.	1.7	64
347	THE GLASS CEILING ON EVIDENCE OF CANNABIS RELATED HARMS " FLAWED OR JUST FALSE?. <i>Addiction</i> , 2011, 106, 249-251.	1.7	2
348	Affective disorders and anxiety disorders predict the risk of drug harmful use and dependence. <i>Addiction</i> , 2011, 106, 1126-1134.	1.7	21
349	Cannabis and social welfare assistance: a longitudinal study. <i>Addiction</i> , 2011, 106, 1636-1643.	1.7	20
350	Cannabis use and non-clinical dimensions of psychosis in university students presenting to primary care. <i>Acta Psychiatrica Scandinavica</i> , 2011, 123, 21-27.	2.2	37
351	Association between cannabis and psychiatric hospitalization. <i>Acta Psychiatrica Scandinavica</i> , 2011, 123, 368-375.	2.2	22
352	Cannabis use and age at onset of psychosis: further evidence of interaction with COMT Val158Met polymorphism. <i>Acta Psychiatrica Scandinavica</i> , 2011, 123, 485-492.	2.2	73
353	MAKINGtheLINK: a school-based health promotion programme to increase help-seeking for cannabis and mental health issues among adolescents. <i>Microbial Biotechnology</i> , 2011, 5, 81-88.	0.9	12
354	Acute blockade of CB1 receptor leads to reinstatement of MDMA-induced conditioned place preference. <i>Pharmacology Biochemistry and Behavior</i> , 2011, 100, 33-39.	1.3	17
355	The association between delusional-like experiences, and tobacco, alcohol or cannabis use: a nationwide population-based survey. <i>BMC Psychiatry</i> , 2011, 11, 202.	1.1	46
356	Spontaneous regression of septum pellucidum/forniceal pilocytic astrocytomas" possible role of Cannabis inhalation. <i>Child's Nervous System</i> , 2011, 27, 671-679.	0.6	43
357	The association between substance misuse and first-episode psychosis in a defined UK geographical area during the 1990s. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2011, 46, 137-142.	1.6	17
358	Psychoses, PTSD, and depression in Somali refugees in Minnesota. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2011, 46, 481-493.	1.6	101
359	Structural models of the comorbidity of internalizing disorders and substance use disorders in a longitudinal birth cohort. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2011, 46, 933-942.	1.6	62
360	Is there an association between seeing incidents of alcohol or drug use in films and young Scottish adults' own alcohol or drug use? A cross sectional study. <i>BMC Public Health</i> , 2011, 11, 259.	1.2	16
361	Differential developmental trajectories for CB1 cannabinoid receptor expression in limbic/associative and sensorimotor cortical areas. <i>Synapse</i> , 2011, 65, 278-286.	0.6	128
362	Methods of the Pharmacological Imaging of the Cannabinoid System (<scp>PhICS</scp>) study: towards understanding the role of the brain endocannabinoid system in human cognition. <i>International Journal of Methods in Psychiatric Research</i> , 2011, 20, 10-27.	1.1	18

#	ARTICLE	IF	CITATIONS
363	The Dutch Cannabis Dependence (CanDep) study on the course of frequent cannabis use and dependence: objectives, methods and sample characteristics. <i>International Journal of Methods in Psychiatric Research</i> , 2011, 20, 169-181.	1.1	22
364	Cannabis use in young people: The risk for schizophrenia. <i>Neuroscience and Biobehavioral Reviews</i> , 2011, 35, 1779-1787.	2.9	166
365	Family-Based Analysis of Genetic Variation Underlying Psychosis-Inducing Effects of Cannabis_{title}Sibiling Analysis and Proband Follow-up_{title}<alt-title</alt>Genetic Variation Underlying Cannabis Effects</alt-title>. <i>Archives of General Psychiatry</i> , 2011, 68, 148.	13.8	175
366	Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. <i>BMJ: British Medical Journal</i> , 2011, 342, d738-d738.	2.4	241
367	Cannabis, <i>COMT</i> and psychotic experiences. <i>British Journal of Psychiatry</i> , 2011, 199, 380-385.	1.7	111
368	Cannabis and the increased incidence and persistence of psychosis. <i>BMJ: British Medical Journal</i> , 2011, 342, d719-d719.	2.4	19
369	Susceptibility Genes for Schizophrenia: Mutant Models, Endophenotypes and Psychobiology. <i>Current Topics in Behavioral Neurosciences</i> , 2011, 12, 209-250.	0.8	5
370	Do we have any solid evidence of clinical utility about the pathophysiology of schizophrenia?. <i>World Psychiatry</i> , 2011, 10, 19-31.	4.8	53
371	Young Cannabis Users in Residential Treatment: As Distressed as Other Clients. <i>Substance Use and Misuse</i> , 2011, 46, 1335-1345.	0.7	1
372	Gender Differences in Adolescent Marijuana Use and Associated Psychosocial Characteristics. <i>Journal of Addiction Medicine</i> , 2011, 5, 65-73.	1.4	125
373	Cannabis Use and Earlier Onset of Psychosis. <i>Archives of General Psychiatry</i> , 2011, 68, 555.	13.8	483
374	The Prevention of Schizophrenia. <i>Schizophrenia Bulletin</i> , 2011, 37, 257-261.	2.3	25
375	Postnatal Developmental Trajectories of Neural Circuits in the Primate Prefrontal Cortex: Identifying Sensitive Periods for Vulnerability to Schizophrenia. <i>Schizophrenia Bulletin</i> , 2011, 37, 493-503.	2.3	109
376	Incident cannabis use in adolescents and young adults is associated with an increased risk of developing psychotic symptoms. <i>Evidence-Based Mental Health</i> , 2011, 14, 70-70.	2.2	0
377	Cannabis use and psychosis: re-visiting the role of childhood trauma. <i>Psychological Medicine</i> , 2011, 41, 2339-2348.	2.7	59
378	The Impact of Substance Use on Brain Structure in People at High Risk of Developing Schizophrenia. <i>Schizophrenia Bulletin</i> , 2011, 37, 1066-1076.	2.3	66
379	Do cannabis and urbanicity co-participate in causing psychosis? Evidence from a 10-year follow-up cohort study. <i>Psychological Medicine</i> , 2011, 41, 2121-2129.	2.7	57
380	Administrative incidence of psychosis assessed in an early intervention service in England: first epidemiological evidence from a diverse, rural and urban setting. <i>Psychological Medicine</i> , 2011, 41, 949-958.	2.7	44

#	ARTICLE	IF	CITATIONS
381	Cannabis use at a young age is associated with psychotic experiences. <i>Psychological Medicine</i> , 2011, 41, 1301-1310.	2.7	67
382	Letter to the Editor: Poor childhood mental health may explain linkages between trauma, cannabis use and later psychotic experiences. <i>Psychological Medicine</i> , 2011, 41, 2012-2014.	2.7	4
383	Predictors of Substance Use Among Black Urban Adolescents with Asthma: A Longitudinal Assessment. <i>Journal of the National Medical Association</i> , 2011, 103, 392-399.	0.6	6
384	Misconceptions about gene-environment interactions in psychiatry. <i>Evidence-Based Mental Health</i> , 2011, 13, 65-68.	2.2	34
385	Concomitants of paranoia in the general population. <i>Psychological Medicine</i> , 2011, 41, 923-936.	2.7	217
386	Migration and psychotic disorders. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 65-76.	1.4	42
387	Childhood sexual abuse and psychosis: data from a cross-sectional national psychiatric survey in England. <i>British Journal of Psychiatry</i> , 2011, 199, 29-37.	1.7	233
388	Autoimmune Diseases and Severe Infections as Risk Factors for Schizophrenia: A 30-Year Population-Based Register Study. <i>American Journal of Psychiatry</i> , 2011, 168, 1303-1310.	4.0	459
390	Psychiatric morbidity associated with cannabis use: varying presentation. <i>Mental Health and Substance Use: Dual Diagnosis</i> , 2011, 4, 348-350.	0.5	1
391	AKT1 Moderation of Cannabis-Induced Cognitive Alterations in Psychotic Disorder. <i>Neuropsychopharmacology</i> , 2011, 36, 2529-2537.	2.8	80
392	Real-Time Electronic Ambulatory Monitoring of Substance Use and Symptom Expression in Schizophrenia. <i>American Journal of Psychiatry</i> , 2011, 168, 202-209.	4.0	101
393	Cannabinoids for the Treatment of Schizophrenia? A Balanced Neurochemical Framework for Both Adverse and Therapeutic Effects of Cannabis Use. <i>Schizophrenia Research and Treatment</i> , 2011, 2011, 1-9.	0.7	14
394	Characteristics and predictors of health problems from use among high-frequency cannabis users in a Canadian university student population. <i>Drugs: Education, Prevention and Policy</i> , 2012, 19, 49-58.	0.8	6
395	Exploration of the Comorbidity of Cannabis Use Disorders and Mental Health Disorders among Inpatients Presenting to All Hospitals in New South Wales, Australia. <i>American Journal of Drug and Alcohol Abuse</i> , 2012, 38, 567-574.	1.1	30
396	A "standard joint"? The role of quantity in predicting cannabis-related problems. <i>Addiction Research and Theory</i> , 2012, 20, 82-92.	1.2	77
397	Neurocognitive Function and Schizophrenia-Proneness in Individuals Dependent on Ketamine, on High Potency Cannabis ("Skunk") or on Cocaine. <i>Pharmacopsychiatry</i> , 2012, 45, 269-274.	1.7	24
398	Mental health literacy: Empowering the community to take action for better mental health.. <i>American Psychologist</i> , 2012, 67, 231-243.	3.8	1,065
399	The Effect of Chronic Cannabinoids on Broadband EEG Neural Oscillations in Humans. <i>Neuropsychopharmacology</i> , 2012, 37, 2184-2193.	2.8	42

#	ARTICLE	IF	CITATIONS
400	Chronic δ^9 -Tetrahydrocannabinol Exposure Induces a Sensitization of Dopamine D2/3 Receptors in the Mesoaccumbens and Nigrostriatal Systems. <i>Neuropsychopharmacology</i> , 2012, 37, 2355-2367.	2.8	52
401	Popular intoxicants: what lessons can be learned from the last 40 years of alcohol and cannabis regulation?. <i>Journal of Psychopharmacology</i> , 2012, 26, 213-220.	2.0	15
402	Cerebellar grey-matter deficits, cannabis use and first-episode schizophrenia in adolescents and young adults. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 297-307.	1.0	45
403	Does giving up substance use work for patients with psychosis? A systematic meta-analysis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2012, 46, 826-839.	1.3	42
404	Induction of Psychosis by δ^9 -Tetrahydrocannabinol Reflects Modulation of Prefrontal and Striatal Function During Attentional Salience Processing. <i>Archives of General Psychiatry</i> , 2012, 69, 27.	13.8	193
405	The Endocannabinoid System and Schizophrenia: Integration of Evidence. <i>Current Pharmaceutical Design</i> , 2012, 18, 4980-4990.	0.9	43
406	Physicians and Medical Marijuana. <i>American Journal of Psychiatry</i> , 2012, 169, 564-568.	4.0	49
407	Delay- and Dose-Dependent Effects of δ^9 -Tetrahydrocannabinol Administration on Spatial and Object Working Memory Tasks in Adolescent Rhesus Monkeys. <i>Neuropsychopharmacology</i> , 2012, 37, 1357-1366.	2.8	21
409	Is cannabis use normalized, celebrated or neutralized? Analysing talk as action. <i>Addiction Research and Theory</i> , 2012, 20, 372-381.	1.2	87
410	Schizophrenia risk gene ZNF804A does not influence macroscopic brain structure: an MRI study in 892 volunteers. <i>Molecular Psychiatry</i> , 2012, 17, 1155-1157.	4.1	33
411	History of cannabis use is not associated with alterations in striatal dopamine D ₂ /D ₃ receptor availability. <i>Journal of Psychopharmacology</i> , 2012, 26, 144-149.	2.0	57
412	Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. <i>Psychological Medicine</i> , 2012, 42, 391-400.	2.7	165
413	Hallucinations. , 2012, , .		16
414	T \pm bbi Esrar Psikiyatrik Bozukluklar \pm n Tedavisinde Kullan \pm labilir mi?. <i>Journal of Microbiology and Biotechnology</i> , 2012, 22, 98-109.	0.9	4
415	Prospective study of cannabis use in adolescents at clinical high risk for psychosis: impact on conversion to psychosis and functional outcome. <i>Psychological Medicine</i> , 2012, 42, 2485-2497.	2.7	75
416	Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort. <i>Psychological Medicine</i> , 2012, 42, 1321-1328.	2.7	120
417	Paradoxical Cognitive Capacities in Dual Diagnosis Schizophrenia: The Quest for Explanatory Factors. <i>Journal of Dual Diagnosis</i> , 2012, 8, 35-47.	0.7	22
418	Letter to the Editor: Childhood trauma may combine synergistically with stimulant use rather than cannabis use to predict psychosis. <i>Psychological Medicine</i> , 2012, 42, 445-446.	2.7	2

#	ARTICLE	IF	CITATIONS
419	Replication in two independent population-based samples that childhood maltreatment and cannabis use synergistically impact on psychosis risk. <i>Psychological Medicine</i> , 2012, 42, 149-159.	2.7	87
420	Genetic vs. pharmacological inactivation of COMT influences cannabinoid-induced expression of schizophrenia-related phenotypes. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 1331-1342.	1.0	55
421	Cannabis use and Duration of Untreated Psychosis: A Systematic Review and Meta-Analysis. <i>Current Pharmaceutical Design</i> , 2012, 18, 5093-5104.	0.9	21
422	Anandamide Dysfunction in Prodromal and Established Psychosis. <i>Current Pharmaceutical Design</i> , 2012, 18, 5188-5193.	0.9	30
423	Glutamate and Psychosis Risk. <i>Current Pharmaceutical Design</i> , 2012, 18, 466-478.	0.9	34
424	The Effect of Cannabis Use and Cognitive Reserve on Age at Onset and Psychosis Outcomes in First-Episode Schizophrenia. <i>Schizophrenia Bulletin</i> , 2012, 38, 873-880.	2.3	97
425	Childhood cognitive function and adult psychopathology: associations with psychotic and non-psychotic symptoms in the general population. <i>British Journal of Psychiatry</i> , 2012, 201, 124-130.	1.7	33
426	Neurocognitive Functioning and Cannabis Use in Schizophrenia. <i>Current Pharmaceutical Design</i> , 2012, 18, 4999-5007.	0.9	8
427	Gene-Environment Interactions Underlying the Effect of Cannabis in First Episode Psychosis. <i>Current Pharmaceutical Design</i> , 2012, 18, 5024-5035.	0.9	48
428	Cannabis in the Arm: What Can we Learn from Intravenous Cannabinoid Studies?. <i>Current Pharmaceutical Design</i> , 2012, 18, 4906-4914.	0.9	13
429	Genetic Variation Underlying Psychosis-inducing Effects of Cannabis: Critical Review and Future Directions. <i>Current Pharmaceutical Design</i> , 2012, 18, 5015-5023.	0.9	39
430	Cannabis Use and Psychosis: Theme Introduction. <i>Current Pharmaceutical Design</i> , 2012, 18, 4991-4998.	0.9	21
431	Psychosis incidence through the prism of early intervention services. <i>British Journal of Psychiatry</i> , 2012, 200, 156-157.	1.7	30
432	The Therapeutic Potential of Cannabis and Cannabinoids. <i>Deutsches A&#x0308;rztblatt International</i> , 2012, 109, 495-501.	0.6	227
433	Patientâ€™s Perceptions of the Cannabis-psychosis Link - A Systematic Review. <i>Current Pharmaceutical Design</i> , 2012, 18, 5105-5112.	0.9	9
435	Prevalence of cannabis use disorder diagnoses among veterans in 2002, 2008, and 2009.. <i>Psychological Services</i> , 2012, 9, 404-416.	0.9	124
436	Extent of illicit drug use and dependence, and their contribution to the global burden of disease. <i>Lancet, The</i> , 2012, 379, 55-70.	6.3	1,074
437	Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of Î-9-tetrahydrocannabinol on midbrain and striatal function. <i>Molecular Psychiatry</i> , 2012, 17, 1152-1155.	4.1	108

#	ARTICLE	IF	CITATIONS
438	Chronic Adolescent Exposure to Delta-9-Tetrahydrocannabinol in COMT Mutant Mice: Impact on Indices of Dopaminergic, Endocannabinoid and GABAergic Pathways. <i>Neuropsychopharmacology</i> , 2012, 37, 1773-1783.	2.8	61
439	The Impact of Cannabis Use on Cognitive Functioning in Patients With Schizophrenia: A Meta-analysis of Existing Findings and New Data in a First-Episode Sample. <i>Schizophrenia Bulletin</i> , 2012, 38, 316-330.	2.3	219
440	Synthetic legal intoxicating drugs: The emerging "incense" and "bath salt" phenomenon. <i>Cleveland Clinic Journal of Medicine</i> , 2012, 79, 258-264.	0.6	89
441	Neurocognitive functions of heavy cannabis using schizophrenia patients. <i>European Psychiatry</i> , 2012, 27, 365-368.	0.1	14
442	Clinical correlates of cannabis use among adolescent psychiatric inpatients. <i>European Psychiatry</i> , 2012, 27, 470-475.	0.1	11
443	Cannabis use and mental health-related quality of life among individuals with anxiety disorders. <i>Journal of Anxiety Disorders</i> , 2012, 26, 799-810.	1.5	31
444	Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder. <i>Psychiatry Research</i> , 2012, 200, 242-245.	1.7	38
445	Blurred Boundaries: The Therapeutics and Politics of Medical Marijuana. <i>Mayo Clinic Proceedings</i> , 2012, 87, 172-186.	1.4	227
446	BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. <i>Journal of Psychopharmacology</i> , 2012, 26, 899-952.	2.0	268
447	Cannabis, a complex plant: different compounds and different effects on individuals. <i>Therapeutic Advances in Psychopharmacology</i> , 2012, 2, 241-254.	1.2	357
448	Neural Mechanisms for the Cannabinoid Modulation of Cognition and Affect in Man: A Critical Review of Neuroimaging Studies. <i>Current Pharmaceutical Design</i> , 2012, 18, 5045-5054.	0.9	58
449	Cannabis-Induced Depersonalization Disorder in Adolescence. <i>Neuropsychobiology</i> , 2012, 65, 141-146.	0.9	20
450	¿Media la dopamina los efectos psicóticos del Cannabis? Revisión e integración de los hallazgos a través de disciplinas. <i>Psiquiatría Biológica</i> , 2012, 19, 49-58.	0.0	1
451	Cannabis Use in Patients at Clinical High Risk of Psychosis: Impact on Prodromal Symptoms and Transition to Psychosis. <i>Current Pharmaceutical Design</i> , 2012, 18, 5036-5044.	0.9	30
452	The Association between Cannabis Use and Earlier Age at Onset of Schizophrenia and other Psychoses: Meta-analysis of Possible Confounding Factors. <i>Current Pharmaceutical Design</i> , 2012, 18, 5055-5069.	0.9	58
453	Can Cannabis Increase the Suicide Risk in Psychosis? A Critical Review. <i>Current Pharmaceutical Design</i> , 2012, 18, 5165-5187.	0.9	81
454	Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. <i>Neuroscience</i> , 2012, 204, 207-229.	1.1	157
455	<i>Toxoplasma gondii</i> and Other Risk Factors for Schizophrenia: An Update. <i>Schizophrenia Bulletin</i> , 2012, 38, 642-647.	2.3	325

#	ARTICLE	IF	CITATIONS
456	Synthetic Cannabinoid Induced Psychosis in a Previously Nonpsychotic Patient. <i>American Journal on Addictions</i> , 2012, 21, 287-288.	1.3	40
457	Treatment of substance abusing patients with comorbid psychiatric disorders. <i>Addictive Behaviors</i> , 2012, 37, 11-24.	1.7	209
458	Characteristics of clinically anxious versus non-anxious regular, heavy marijuana users. <i>Addictive Behaviors</i> , 2012, 37, 1217-1223.	1.7	20
459	The effects of cannabis use on physical and mental health. <i>Journal of Health Economics</i> , 2012, 31, 564-577.	1.3	35
460	The Influence of Socioeconomic Status on Cannabis Use Among French Adolescents. <i>Journal of Adolescent Health</i> , 2012, 50, 395-402.	1.2	55
461	The theory of planned behavior: Precursors of marijuana use in early adolescence?. <i>Drug and Alcohol Dependence</i> , 2012, 123, 22-28.	1.6	68
462	Gender differences in health-related quality of life among cannabis users: Results from the national epidemiologic survey on alcohol and related conditions. <i>Drug and Alcohol Dependence</i> , 2012, 123, 190-200.	1.6	93
463	Craving for cannabis in patients with psychotic disorder, their non-affected siblings and healthy controls: psychometric analysis of the obsessive compulsive drug use scale. <i>International Journal of Methods in Psychiatric Research</i> , 2012, 21, 286-300.	1.1	15
464	12-month follow-up of an exploratory "brief intervention"™ for high-frequency cannabis users among Canadian university students. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2012, 7, 15.	1.0	20
465	Cannabis Psychosis: Examining the Evidence for a Distinctive Psychopathology in a Systematic and Narrative Review. <i>American Journal on Addictions</i> , 2012, 21, S88-98.	1.3	16
466	Animal Models of Schizophrenia. <i>Progress in Molecular Biology and Translational Science</i> , 2012, 105, 411-444.	0.9	10
467	The Neurodevelopmental Hypothesis of Schizophrenia. <i>Psychiatric Clinics of North America</i> , 2012, 35, 571-584.	0.7	74
468	Increased Stress-Induced Dopamine Release in Psychosis. <i>Biological Psychiatry</i> , 2012, 71, 561-567.	0.7	222
469	Dopamine Release in Chronic Cannabis Users: A [11C]Raclopride Positron Emission Tomography Study. <i>Biological Psychiatry</i> , 2012, 71, 677-683.	0.7	107
470	Effects of δ^9 -Tetrahydrocannabinol on Human Working Memory Function. <i>Biological Psychiatry</i> , 2012, 71, 693-699.	0.7	74
471	Cannabinoids, Working Memory, and Schizophrenia. <i>Biological Psychiatry</i> , 2012, 71, 662-663.	0.7	4
472	Linkage Analysis Followed by Association Show NRG1 Associated with Cannabis Dependence in African Americans. <i>Biological Psychiatry</i> , 2012, 72, 637-644.	0.7	46
473	Confirmation that the AKT1 (rs2494732) Genotype Influences the Risk of Psychosis in Cannabis Users. <i>Biological Psychiatry</i> , 2012, 72, 811-816.	0.7	212

#	ARTICLE	IF	CITATIONS
474	Marijuana use trajectories during the post-college transition: Health outcomes in young adulthood. <i>Drug and Alcohol Dependence</i> , 2012, 125, 267-275.	1.6	80
475	Transition to parenthood and substance use disorders: Findings from a 30-year longitudinal study. <i>Drug and Alcohol Dependence</i> , 2012, 125, 295-300.	1.6	43
476	The combined effects of parental divorce and parental history of depression on cannabis use in young adults in France. <i>Drug and Alcohol Dependence</i> , 2012, 126, 195-199.	1.6	10
477	Infectious agents associated with schizophrenia: A meta-analysis. <i>Schizophrenia Research</i> , 2012, 136, 128-136.	1.1	196
478	Effect of cannabis use on the course of schizophrenia in male patients: A prospective cohort study. <i>Schizophrenia Research</i> , 2012, 137, 50-57.	1.1	63
479	Early cannabis use and Schizotypal Personality Disorder Symptoms from adolescence to middle adulthood. <i>Schizophrenia Research</i> , 2012, 137, 45-49.	1.1	45
480	Alterations of theory of mind network activation in chronic cannabis users. <i>Schizophrenia Research</i> , 2012, 139, 19-26.	1.1	26
481	Trajectories of change in self-reported psychotic-like experiences in childhood and adolescence. <i>Schizophrenia Research</i> , 2012, 140, 104-109.	1.1	49
484	State of the Art Treatments for Cannabis Dependence. <i>Psychiatric Clinics of North America</i> , 2012, 35, 309-326.	0.7	106
485	Susceptibility of the adolescent brain to cannabinoids: long-term hippocampal effects and relevance to schizophrenia. <i>Translational Psychiatry</i> , 2012, 2, e199-e199.	2.4	69
486	Predicting Risk and the Emergence of Schizophrenia. <i>Psychiatric Clinics of North America</i> , 2012, 35, 585-612.	0.7	19
487	Upper body 3-dimensional kinematics during gait in psychotic patients: a pilot-study. <i>Experimental Brain Research</i> , 2012, 221, 393-401.	0.7	5
488	Amphetamine-induced psychosis - a separate diagnostic entity or primary psychosis triggered in the vulnerable?. <i>BMC Psychiatry</i> , 2012, 12, 221.	1.1	183
489	Cannabis use and depression: a longitudinal study of a national cohort of Swedish conscripts. <i>BMC Psychiatry</i> , 2012, 12, 112.	1.1	54
490	Incidence of Schizophrenia and Other Psychoses in England, 1950â€“2009: A Systematic Review and Meta-Analyses. <i>PLoS ONE</i> , 2012, 7, e31660.	1.1	385
491	Distinct Neurobehavioural Effects of Cannabidiol in Transmembrane Domain Neuregulin 1 Mutant Mice. <i>PLoS ONE</i> , 2012, 7, e34129.	1.1	80
492	Association of Cannabis Use during Adolescence, Prefrontal CB1 Receptor Signaling, and Schizophrenia. <i>Frontiers in Pharmacology</i> , 2012, 3, 101.	1.6	39
493	An fMRI Study of Neuronal Activation in Schizophrenia Patients with and without Previous Cannabis Use. <i>Frontiers in Psychiatry</i> , 2012, 3, 94.	1.3	20

#	ARTICLE	IF	CITATIONS
494	Medical Marijuana: Clearing Away the Smoke. <i>The Open Neurology Journal</i> , 2012, 6, 18-25.	0.4	94
495	Altering endocannabinoid neurotransmission at critical developmental ages: impact on rodent emotionality and cognitive performance. <i>Frontiers in Behavioral Neuroscience</i> , 2012, 6, 2.	1.0	55
496	Spice, Bath Salts, and the U.S. Military: The Emergence of Synthetic Cannabinoid Receptor Agonists and Cathinones in the U.S. Armed Forces. <i>Military Medicine</i> , 2012, 177, 1041-1048.	0.4	64
497	Clinical applications of schizophrenia genetics: genetic diagnosis, risk, and counseling in the molecular era. <i>The Application of Clinical Genetics</i> , 2012, 5, 1.	1.4	35
498	Old Obstacles on New Horizons: The Challenge of Implementing Gene X Environment Discoveries in Schizophrenia Research. , 2012, , .		1
499	Canabinoides sint�ticos: drogas de abuso emergentes. <i>Revista De Psiquiatria Clinica</i> , 2012, 39, 142-148.	0.6	8
500	Drug dependence and psychotic symptoms: a retrospective study of adolescents who abuse drugs at Al-Amal Hospital in Jeddah, Saudi Arabia. <i>Journal of Public Health in Africa</i> , 2012, 3, 5.	0.2	14
501	Exploring the perceptions of psychiatric patients regarding marijuana use. <i>Health SA Gesondheid</i> , 2012, 17, .	0.3	5
502	Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. <i>Molecular Psychiatry</i> , 2012, 17, 1206-1227.	4.1	479
503	Genetic Risk and Outcome of Psychosis (GROUP), a multi site longitudinal cohort study focused on gene�environment interaction: objectives, sample characteristics, recruitment and assessment methods. <i>International Journal of Methods in Psychiatric Research</i> , 2012, 21, 205-221.	1.1	224
504	Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models. <i>Psychopharmacology</i> , 2012, 220, 647-672.	1.5	92
505	Delayed preattentive functioning in early psychosis patients with cannabis use. <i>Psychopharmacology</i> , 2012, 222, 507-518.	1.5	20
506	Implications of Epidemiological Data for Identifying Persons with Substance Use and Other Mental Disorders. <i>American Journal on Addictions</i> , 2012, 21, 97-103.	1.3	16
507	Cannabis use and subclinical positive psychotic experiences in early adolescence: findings from a Dutch survey. <i>Addiction</i> , 2012, 107, 381-387.	1.7	41
508	Evidence of increasing age of onset of cannabis use among younger Australians. <i>Addiction</i> , 2012, 107, 650-657.	1.7	9
509	Young people's beliefs about the harmfulness of alcohol, cannabis and tobacco for mental disorders: findings from two Australian national youth surveys. <i>Addiction</i> , 2012, 107, 838-847.	1.7	13
510	Linking substance use with symptoms of subclinical psychosis in a community cohort over 30 years. <i>Addiction</i> , 2012, 107, 1174-1184.	1.7	55
511	Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis. <i>Acta Psychiatrica Scandinavica</i> , 2012, 125, 45-53.	2.2	82

#	ARTICLE	IF	CITATIONS
512	Are early-onset cannabis smokers at an increased risk of depression spells?. <i>Journal of Affective Disorders</i> , 2012, 138, 54-62.	2.0	26
513	Societal participation: examining the impact of a rehabilitation approach for young people with schizophrenia. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2012, 19, 792-798.	1.2	6
514	Drugs of abuse (amfetamines, BZP, cannabis, cocaine, GHB, LSD). <i>Medicine</i> , 2012, 40, 84-87.	0.2	2
515	Cortical circuit dysfunction and cognitive deficits in schizophrenia – implications for preemptive interventions. <i>European Journal of Neuroscience</i> , 2012, 35, 1871-1878.	1.2	130
516	Ethnicity, violent offending, and vulnerability to schizophrenia: A pilot study. <i>Psychology and Psychotherapy: Theory, Research and Practice</i> , 2012, 85, 143-149.	1.3	2
517	Pharmacological interventions in the treatment of the acute effects of cannabis: a systematic review of literature. <i>Harm Reduction Journal</i> , 2012, 9, 7.	1.3	33
518	Corticosteroid dependent and independent effects of a cannabinoid agonist on core temperature, motor activity, and prepulse inhibition of the acoustic startle reflex in Wistar rats. <i>Psychopharmacology</i> , 2012, 220, 405-415.	1.5	2
519	Neurological soft signs in non-psychotic patients with cannabis dependence. <i>Addiction Biology</i> , 2013, 18, 214-221.	1.4	20
520	Testing bidirectional effects between cannabis use and depressive symptoms: moderation by the serotonin transporter gene. <i>Addiction Biology</i> , 2013, 18, 826-835.	1.4	29
521	A qualitative inquiry into consumer beliefs about the causes of mental illness. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2013, 20, 442-447.	1.2	11
522	Association of abnormal semantic processing with delusion-like ideation in frequent cannabis users: an electrophysiological study. <i>Psychopharmacology</i> , 2013, 225, 95-104.	1.5	9
523	Involvement of the CA1 GABAA receptors in ACPA-induced impairment of spatial and non-spatial novelty detection in mice. <i>Neurobiology of Learning and Memory</i> , 2013, 100, 32-40.	1.0	35
524	“Spiceophrenia”: a systematic overview of “Spice”-related psychopathological issues and a case report. <i>Human Psychopharmacology</i> , 2013, 28, 379-389.	0.7	150
525	Predicting the transition from frequent cannabis use to cannabis dependence: A three-year prospective study. <i>Drug and Alcohol Dependence</i> , 2013, 133, 352-359.	1.6	143
526	The development of psychotic disorders in adolescence: A potential role for hormones. <i>Hormones and Behavior</i> , 2013, 64, 411-419.	1.0	47
527	Family Support Mediates the Association Between Substance Use Severity and Suicidal Ideation in Early Adult Emergency Department Patients. <i>International Journal of Mental Health and Addiction</i> , 2013, 11, 672-681.	4.4	2
528	Bipolar disorder and co-occurring cannabis use disorders: Characteristics, co-morbidities and clinical correlates. <i>Psychiatry Research</i> , 2013, 209, 459-465.	1.7	96
530	The impact of cannabis use on age of onset and clinical characteristics in first-episode psychotic patients. Data from the Psychosis Incident Cohort Outcome Study (PICOS). <i>Journal of Psychiatric Research</i> , 2013, 47, 438-444.	1.5	65

#	ARTICLE	IF	CITATIONS
531	A multi-center, randomized controlled trial of a group psychological intervention for psychosis with comorbid cannabis dependence over the early course of illness. <i>Schizophrenia Research</i> , 2013, 143, 138-142.	1.1	61
532	Mood variability predicts the course of suicidal ideation in individuals with first and second episode psychosis. <i>Psychiatry Research</i> , 2013, 206, 240-245.	1.7	16
533	Deconstructing sub-clinical psychosis into latent-state and trait variables over a 30-year time span. <i>Schizophrenia Research</i> , 2013, 150, 197-204.	1.1	23
534	Effects of cannabis use on event related potentials in subjects at ultra high risk for psychosis and healthy controls. <i>International Journal of Psychophysiology</i> , 2013, 88, 149-156.	0.5	11
535	The brain effects of cannabis in healthy adolescents and in adolescents with schizophrenia: a systematic review. <i>Psychiatry Research - Neuroimaging</i> , 2013, 214, 181-189.	0.9	43
536	The hippocampalâ€“prefrontal pathway: The weak link in psychiatric disorders?. <i>European Neuropsychopharmacology</i> , 2013, 23, 1165-1181.	0.3	354
537	Substance Abuse and Psychosis. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2013, 22, 643-654.	1.0	10
538	The effect of childhood maltreatment and cannabis use on adult psychotic symptoms is modified by the COMT Val158Met polymorphism. <i>Schizophrenia Research</i> , 2013, 150, 303-311.	1.1	62
539	Cannabis use is associated with increased CCL11 plasma levels in young healthy volunteers. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 46, 25-28.	2.5	21
540	Cannabis and psychosis: Have we found the missing links?. <i>Asian Journal of Psychiatry</i> , 2013, 6, 281-287.	0.9	27
541	Lâ€™impact du cannabis Ã lâ€™adolescence sur la transition psychotique de lâ€™adulte. <i>Neuropsychiatrie De L'Enfance Et De L'Adolescence</i> , 2013, 61, 224-230.	0.1	6
542	Practice Parameter for the Assessment and Treatment of Children and Adolescents With Schizophrenia. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2013, 52, 976-990.	0.3	213
543	Genes and environments in schizophrenia: The different pieces of a manifold puzzle. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 2424-2437.	2.9	44
544	Effects of cannabis and familial loading on subcortical brain volumes in first-episode schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 155-168.	1.8	24
545	Analyzing the impact of social factors on homelessness: a Fuzzy Cognitive Map approach. <i>BMC Medical Informatics and Decision Making</i> , 2013, 13, 94.	1.5	77
546	Weeding out the information: an ethnographic approach to exploring how young people make sense of the evidence on cannabis. <i>Harm Reduction Journal</i> , 2013, 10, 34.	1.3	23
547	Doseâ€“response effect between cannabis use and psychosis liability in a non-clinical population: Evidence from a snowball sample. <i>Journal of Psychiatric Research</i> , 2013, 47, 1036-1043.	1.5	30
548	Cannabis use and brain structural alterations of the cingulate cortex in early psychosis. <i>Psychiatry Research - Neuroimaging</i> , 2013, 214, 102-108.	0.9	28

#	ARTICLE	IF	CITATIONS
549	Developmental mechanisms in the prodrome to psychosis. <i>Development and Psychopathology</i> , 2013, 25, 1585-1600.	1.4	29
550	Feasibility and impact of brief interventions for frequent cannabis users in Canada. <i>Journal of Substance Abuse Treatment</i> , 2013, 44, 132-138.	1.5	38
551	Impulsivity, attention, memory, and decision-making among adolescent marijuana users. <i>Psychopharmacology</i> , 2013, 226, 307-319.	1.5	144
552	Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. <i>Journal of Neurology</i> , 2013, 260, 285-295.	1.8	95
553	Dopamine Response to Psychosocial Stress in Chronic Cannabis Users: A PET Study With [11C]-(+)-PHNO. <i>Neuropsychopharmacology</i> , 2013, 38, 673-682.	2.8	45
554	Medical use of cannabis. Cannabidiol: A new light for schizophrenia?. <i>Drug Testing and Analysis</i> , 2013, 5, 46-51.	1.6	40
555	Cannabinoid receptor agonists upregulate and enhance serotonin 2A (5-HT _{2A}) receptor activity via ERK1/2 signaling. <i>Synapse</i> , 2013, 67, 145-159.	0.6	48
556	A survey of attitudes towards patient substance abuse and addiction in the Emergency Centre. <i>African Journal of Emergency Medicine</i> , 2013, 3, 10-17.	0.4	6
557	Age at onset of schizophrenia: Cannabis, COMT gene, and their interactions. <i>Schizophrenia Research</i> , 2013, 151, 289-290.	1.1	17
558	Stress and neurodevelopmental processes in the emergence of psychosis. <i>Neuroscience</i> , 2013, 249, 172-191.	1.1	209
560	Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?. <i>Drug and Alcohol Dependence</i> , 2013, 130, 68-76.	1.6	29
561	Cannabis users have higher premorbid IQ than other patients with first onset psychosis. <i>Schizophrenia Research</i> , 2013, 150, 129-135.	1.1	50
563	Longitudinal associations of cannabis and illicit drug use with depression, suicidal ideation and suicidal attempts among Nova Scotia high school students. <i>Drug and Alcohol Dependence</i> , 2013, 129, 49-53.	1.6	75
564	Cannabis use and premorbid functioning as predictors of poorer neurocognition in schizophrenia spectrum disorder. <i>Schizophrenia Research</i> , 2013, 143, 84-89.	1.1	19
565	Persecutory ideation and a history of cannabis use. <i>Schizophrenia Research</i> , 2013, 148, 122-125.	1.1	9
566	The Prodrome and Clinical Risk for Psychotic Disorders. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2013, 22, 557-567.	1.0	22
567	Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia. <i>NeuroImage</i> , 2013, 79, 304-312.	2.1	93
568	Risk factors for cocaine-induced psychosis in cocaine-dependent patients. <i>European Psychiatry</i> , 2013, 28, 141-146.	0.1	36

#	ARTICLE	IF	CITATIONS
569	Sensory gating, Cannabinoids and Schizophrenia. <i>Neuropharmacology</i> , 2013, 67, 66-77.	2.0	28
570	The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. <i>Addiction</i> , 2013, 108, 124-133.	1.7	183
571	Cannabis use and cannabis use disorders among individuals with mental illness. <i>Comprehensive Psychiatry</i> , 2013, 54, 589-598.	1.5	100
573	Cannabis use and vulnerability for psychosis in early adolescenceâ€”a <sc>TRAILS</sc> study. <i>Addiction</i> , 2013, 108, 733-740.	1.7	60
574	Optimal scaling of the CAST and of SDS Scale in a national sample of adolescents. <i>Addictive Behaviors</i> , 2013, 38, 2060-2067.	1.7	28
575	Cannabis use as an indicator of risk for mental health problems in adolescents: a population-based study at secondary schools. <i>Psychological Medicine</i> , 2013, 43, 1849-1856.	2.7	25
576	Adolescence as a vulnerable period to alter rodent behavior. <i>Cell and Tissue Research</i> , 2013, 354, 99-106.	1.5	200
577	Plant-Based Medicines for Anxiety Disorders, Part 2: A Review of Clinical Studies with Supporting Preclinical Evidence. <i>CNS Drugs</i> , 2013, 27, 301-319.	2.7	111
578	Cannabis use, cognition and brain structure in first-episode psychosis. <i>Schizophrenia Research</i> , 2013, 147, 209-215.	1.1	46
579	Cannabis and Hallucinations: Studies in Human Subjects. , 2013, , 279-288.		0
580	Treated incidence and baseline characteristics of substance induced psychosis in a Norwegian catchment area. <i>BMC Psychiatry</i> , 2013, 13, 319.	1.1	28
581	Stressing schizotypy: The modulating role of stress-relieving behaviours and intellectual capacity on functional hemispheric asymmetry. <i>Laterality</i> , 2013, 18, 152-178.	0.5	7
582	Associations between symptoms, functioning and self-reported motivations for alcohol use and alcohol problems in patients with serious mental illness. <i>Mental Health and Substance Use: Dual Diagnosis</i> , 2013, 6, 237-249.	0.5	1
583	Combined Grey Matter VBM and White Matter TBSS Analysis in Young First Episode Psychosis Patients With and Without Cannabis Consumption. <i>Brain Topography</i> , 2013, 26, 641-647.	0.8	16
584	Does Change in Cannabis Use in Established Psychosis Affect Clinical Outcome?. <i>Schizophrenia Bulletin</i> , 2013, 39, 339-348.	2.3	30
585	Age at Initiation of Cannabis Use Predicts Age at Onset of Psychosis: The 7- to 8-Year Trend. <i>Schizophrenia Bulletin</i> , 2013, 39, 251-254.	2.3	78
586	Cannabis Use and the Development and Maintenance of Psychosis. , 2013, , 517-524.		1
587	Legitimacy through scaremongering: The discursive role of alcohol in online discussions of cannabis use and policy. <i>Addiction Research and Theory</i> , 2013, 21, 469-478.	1.2	18

#	ARTICLE	IF	CITATIONS
588	Colorado Family Physicians' Attitudes Toward Medical Marijuana. <i>Journal of the American Board of Family Medicine</i> , 2013, 26, 52-60.	0.8	181
589	Addressing substance use in primary care. <i>Nurse Practitioner</i> , 2013, 38, 45-53.	0.2	8
590	Early Intervention and the Treatment of Prodrome in Schizophrenia. <i>Journal of Psychiatric Practice</i> , 2013, 19, 375-385.	0.3	12
591	Alternative pharmacologic targets for the treatment of schizophrenia. <i>Current Opinion in Psychiatry</i> , 2013, 26, 158-165.	3.1	23
592	Cannabis use and family history in adolescent first episode psychosis in Durban, South Africa. <i>Journal of Child and Adolescent Mental Health</i> , 2013, 25, 61-68.	1.7	17
593	Motivation for Change and Barriers to Treatment among Young Cannabis Users. <i>European Addiction Research</i> , 2013, 19, 29-41.	1.3	24
594	Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ^9 -tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers. <i>Psychological Medicine</i> , 2013, 43, 1255-1267.	2.7	51
595	Commentary on <i>Griffiths et al.</i> (2013): Cross-lagging cannabis and psychosis vulnerability. <i>Addiction</i> , 2013, 108, 741-742.	1.7	0
596	Validation of self-reported cannabis dose and potency: an ecological study. <i>Addiction</i> , 2013, 108, 1801-1808.	1.7	69
597	Mental health differences between frequent cannabis users with and without dependence and the general population. <i>Addiction</i> , 2013, 108, 1459-1469.	1.7	69
598	The Neural Correlates of Mental Rotation Abilities in Cannabis-Abusing Patients with Schizophrenia: An fMRI Study. <i>Schizophrenia Research and Treatment</i> , 2013, 2013, 1-10.	0.7	11
599	Cigarette smoking and cannabis use are equally strongly associated with psychotic-like experiences: a cross-sectional study in 1929 young adults. <i>Psychological Medicine</i> , 2013, 43, 2393-2401.	2.7	43
600	Pathways from Cannabis to Psychosis: A Review of the Evidence. <i>Frontiers in Psychiatry</i> , 2013, 4, 128.	1.3	50
601	What can we learn about schizophrenia from studying the human model, drug-induced psychosis?. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2013, 162, 661-670.	1.1	53
602	Marijuana Use in America: Whither Are We Bound?. <i>Pharmacotherapy</i> , 2013, 33, 1009-1011.	1.2	2
603	Approaches for strengthening causal inference regarding prenatal risk factors for childhood behavioural and psychiatric disorders. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2013, 54, 1095-1108.	3.1	25
604	Inferring about individual drug and schizotypy effects on cognitive functioning in polydrug using mephedrone users before and after clubbing. <i>Human Psychopharmacology</i> , 2013, 28, 168-182.	0.7	19
605	Urbanicity, social adversity and psychosis. <i>World Psychiatry</i> , 2013, 12, 187-197.	4.8	182

#	ARTICLE	IF	CITATIONS
606	Peripheral Endocannabinoid System Dysregulation in First-Episode Psychosis. <i>Neuropsychopharmacology</i> , 2013, 38, 2568-2577.	2.8	73
608	Do former substance users with psychosis differ in their symptoms or function from non-substance users? A systematic meta-analysis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 524-537.	1.3	16
609	Cannabis use and abstinence in first-episode psychosis: the participants' view. <i>Mental Health and Substance Use: Dual Diagnosis</i> , 2013, 6, 47-58.	0.5	3
610	Providing a motivational interviewing (MI) informed intervention in conjunction with a cannabis drug urine screening for PICU service users: a feasibility project. <i>Advances in Dual Diagnosis</i> , 2013, 6, 121-131.	0.3	1
611	Craving in Patients with Schizophrenia and Cannabis Use Disorders. <i>Canadian Journal of Psychiatry</i> , 2013, 58, 646-649.	0.9	7
612	Improving physical health and reducing substance use in psychosis – randomised control trial (IMPACT RCT): study protocol for a cluster randomised controlled trial. <i>BMC Psychiatry</i> , 2013, 13, 263.	1.1	28
613	Transmembrane domain Nrg1 mutant mice show altered susceptibility to the neurobehavioural actions of repeated THC exposure in adolescence. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 163-175.	1.0	69
614	Delta-9-Tetrahydrocannabinol-Induced Dopamine Release as a Function of Psychosis Risk: 18F-Fallypride Positron Emission Tomography Study. <i>PLoS ONE</i> , 2013, 8, e70378.	1.1	67
615	The Global Epidemiology and Contribution of Cannabis Use and Dependence to the Global Burden of Disease: Results from the GBD 2010 Study. <i>PLoS ONE</i> , 2013, 8, e76635.	1.1	235
616	Polysubstance Use in Cannabis Users Referred for Treatment: Drug Use Profiles, Psychiatric Comorbidity and Cannabis-Related Beliefs. <i>Frontiers in Psychiatry</i> , 2013, 4, 79.	1.3	66
617	The Association between Cannabis Use, Mental Illness, and Suicidal Behavior: What is the Role of Hopelessness?. <i>Frontiers in Psychiatry</i> , 2013, 4, 125.	1.3	11
618	Does Cannabidiol Protect Against Adverse Psychological Effects of THC?. <i>Frontiers in Psychiatry</i> , 2013, 4, 130.	1.3	165
619	Organic and Synthetic Cannabinoid Use in Adolescents. <i>Pediatric Annals</i> , 2013, 42, 31-35.	0.3	8
620	Evidence for phenotypic plasticity in response to photic cues and the connection with genes of risk in schizophrenia. <i>Frontiers in Behavioral Neuroscience</i> , 2013, 7, 82.	1.0	14
621	Modulation of cognitive and emotional processing by cannabidiol: the role of the anterior cingulate cortex. <i>Frontiers in Human Neuroscience</i> , 2013, 7, 147.	1.0	14
622	The Choice of Screening Instrument Matters: The Case of Problematic Cannabis Use Screening in Spanish Population of Adolescents. <i>ISRN Addiction</i> , 2013, 2013, 1-13.	0.9	5
623	Cost Benefit Analysis of Two Policy Options for Cannabis: Status Quo and Legalisation. <i>PLoS ONE</i> , 2014, 9, e95569.	1.1	25
624	Acute and Long-Term Effects of Cannabis Use: A Review. <i>Current Pharmaceutical Design</i> , 2014, 20, 4112-4118.	0.9	200

#	ARTICLE	IF	CITATIONS
625	Substance Involvement and Physical Health. , 2014, , .		0
626	The Concept of Schizophrenia: From Unity to Diversity. <i>Advances in Psychiatry</i> , 2014, 2014, 1-39.	0.4	7
628	Antibacterial Properties of Hemp and Other Natural Fibre Plants: A Review. <i>BioResources</i> , 2014, 9, .	0.5	50
629	Illicit Drugs. , 2014, , .		0
630	Illegal Drug Use, Health Effects of. , 2014, , 1-9.		1
631	Aâ€Z of Substance Misuse and Drug Addiction. , 2014, , .		2
632	Psychopathological Mechanisms Linking Childhood Traumatic Experiences to Risk of Psychotic Symptoms: Analysis of a Large, Representative Population-Based Sample. <i>Schizophrenia Bulletin</i> , 2014, 40, S123-S130.	2.3	95
633	Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations. <i>Schizophrenia Bulletin</i> , 2014, 40, 729-736.	2.3	229
634	Can Marijuana Reduce Social Pain?. <i>Social Psychological and Personality Science</i> , 2014, 5, 131-139.	2.4	27
635	The emerging molecular architecture of schizophrenia, polygenic risk scores and the clinical implications for gXe research. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2014, 49, 1531-1534.	1.6	3
636	Sexual minority status and psychotic symptoms: findings from the Netherlands Mental Health Survey and Incidence Studies (NEMESIS). <i>Psychological Medicine</i> , 2014, 44, 421-433.	2.7	68
637	Genome-wide DNA methylation analysis of human brain tissue from schizophrenia patients. <i>Translational Psychiatry</i> , 2014, 4, e339-e339.	2.4	267
638	Alteration of imprinted Dlk1-Dio3 miRNA cluster expression in the entorhinal cortex induced by maternal immune activation and adolescent cannabinoid exposure. <i>Translational Psychiatry</i> , 2014, 4, e452-e452.	2.4	61
639	Exome sequence analysis of Finnish patients with clozapine-induced agranulocytosis. <i>Molecular Psychiatry</i> , 2014, 19, 403-405.	4.1	20
640	Cannabis and psychosis: Neurobiology. <i>Indian Journal of Psychiatry</i> , 2014, 56, 8.	0.4	31
641	Cognitive changes in patients with acute phase psychosisâ€Effects of illicit drug use. <i>Psychiatry Research</i> , 2014, 220, 818-824.	1.7	9
642	Neurocognitive moderation of associations between cannabis use and psychoneuroticism. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2014, 36, 794-805.	0.8	8
643	Cannabis, Cannabinoids, and the Association with Psychosis. , 2014, , 423-474.		8

#	ARTICLE	IF	CITATIONS
644	Alcohol and Relatively Pure Cannabis Use, but Not Schizotypy, are Associated with Cognitive Attenuations. <i>Frontiers in Psychiatry</i> , 2014, 5, 133.	1.3	5
645	Gene-Environment Interactions in Severe Mental Illness. <i>Frontiers in Psychiatry</i> , 2014, 5, 48.	1.3	204
646	Gone to Pot - A Review of the Association between Cannabis and Psychosis. <i>Frontiers in Psychiatry</i> , 2014, 5, 54.	1.3	235
647	The Cannabis Pathway to Non-Affective Psychosis may Reflect Less Neurobiological Vulnerability. <i>Frontiers in Psychiatry</i> , 2014, 5, 159.	1.3	30
648	Suicide and unintentional injury mortality among homeless people: a Danish nationwide register-based cohort study. <i>European Journal of Public Health</i> , 2014, 24, 50-56.	0.1	43
649	A service-level action research intervention to improve identification and treatment of cannabis and related mental health issues in young Indigenous Australians: a study protocol. <i>BMJ Open</i> , 2014, 4, e005689-e005689.	0.8	2
650	What's Special about the Ethical Challenges of Studying Disorders with Altered Brain Activity?. <i>Current Topics in Behavioral Neurosciences</i> , 2014, 19, 137-157.	0.8	2
651	Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: A randomized study. <i>American Journal on Addictions</i> , 2014, 23, 308-312.	1.3	31
652	Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students. <i>Molecular Psychiatry</i> , 2014, 19, 402-403.	4.1	14
653	Neurologic Complications of Recreational Drugs. , 2014, , 725-735.		0
654	The moderating role of experiential avoidance in the relationship between posttraumatic stress disorder symptom severity and cannabis dependence. <i>Journal of Contextual Behavioral Science</i> , 2014, 3, 273-278.	1.3	36
655	Adding insult to injury: Childhood and adolescent risk factors for psychosis predict lower fractional anisotropy in the superior longitudinal fasciculus in healthy adults. <i>Psychiatry Research - Neuroimaging</i> , 2014, 224, 296-302.	0.9	23
656	Changes in the adolescent brain and the pathophysiology of psychotic disorders. <i>Lancet Psychiatry</i> , 2014, 1, 549-558.	3.7	177
657	Does social defeat mediate the association between childhood trauma and psychosis? Evidence from the NEMESIS study. <i>Acta Psychiatrica Scandinavica</i> , 2014, 129, 467-476.	2.2	65
658	Factors associated with the timing and onset of cannabis use and cannabis use disorder: Results from the 2007 Australian National Survey of Mental Health and Wellbeing. <i>Drug and Alcohol Review</i> , 2014, 33, 555-564.	1.1	44
659	Cannabis Use Among High-Risk Youth in Israel (2004-2011): An Examination of Gender and Country of Origin Status. <i>Journal of Child and Adolescent Psychiatric Nursing</i> , 2014, 27, 14-19.	0.8	2
660	Problems With the Medicalization of Marijuana. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2377.	3.8	40
661	Cannabis and schizophrenia. <i>The Cochrane Library</i> , 2014, 2014, CD004837.	1.5	44

#	ARTICLE	IF	CITATIONS
662	A familial risk enriched cohort as a platform for testing early interventions to prevent severe mental illness. <i>BMC Psychiatry</i> , 2014, 14, 344.	1.1	74
663	Therapeutic Satisfaction and Subjective Effects of Different Strains of Pharmaceutical-Grade Cannabis. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 344-349.	0.7	47
664	Associations of cannabis and cigarette use with psychotic experiences at age 18: findings from the Avon Longitudinal Study of Parents and Children. <i>Psychological Medicine</i> , 2014, 44, 3435-3444.	2.7	86
665	Dominant negative DISC1 mutant mice display specific social behaviour deficits and aberration in BDNF and cannabinoid receptor expression. <i>World Journal of Biological Psychiatry</i> , 2014, 15, 76-82.	1.3	22
666	The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. <i>Psychological Medicine</i> , 2014, 44, 797-810.	2.7	434
667	Common <i>versus</i> psychopathology-specific risk factors for psychotic experiences and depression during adolescence. <i>Psychological Medicine</i> , 2014, 44, 2557-2566.	2.7	30
668	Prognosis of schizophrenia in persons with and without a history of cannabis use. <i>Psychological Medicine</i> , 2014, 44, 2513-2521.	2.7	62
669	Cognitive functioning associated with stimulant use in patients with non-affective psychosis, their unaffected siblings and healthy controls. <i>Psychological Medicine</i> , 2014, 44, 1901-1911.	2.7	8
670	Cannabis use and transition to psychosis in people at ultra-high risk. <i>Psychological Medicine</i> , 2014, 44, 2503-2512.	2.7	83
671	Change in cannabis use, clinical symptoms and social functioning among patients with first-episode psychosis: a 5-year follow-up study of patients in the OPUS trial. <i>Psychological Medicine</i> , 2014, 44, 117-126.	2.7	50
672	Longitudinal associations between childhood and adulthood externalizing and internalizing psychopathology and adolescent substance use. <i>Psychological Medicine</i> , 2014, 44, 1727-1738.	2.7	125
673	Neurocognitive Functioning of Individuals With Schizophrenia: Using and Not Using Drugs. <i>Schizophrenia Bulletin</i> , 2014, 40, 856-867.	2.3	26
674	Psychosocial Correlates of Adolescent Cannabis Use: Data from the Italian Subsample of the Second International Self-Reported Delinquency Study. <i>Journal of Addictive Diseases</i> , 2014, 33, 210-220.	0.8	9
675	Psychometric Properties of the Cannabis Abuse Screening Test in Hungarian Samples of Adolescents and Young Adults. <i>European Addiction Research</i> , 2014, 20, 119-128.	1.3	18
676	Youth marijuana use. <i>Current Opinion in Pediatrics</i> , 2014, 26, 420-427.	1.0	30
677	Patterns of cannabis use and prospective associations with health issues among young males. <i>Addiction</i> , 2014, 109, 937-945.	1.7	26
678	How much do we know about schizophrenia and how well do we know it? Evidence from the Schizophrenia Library. <i>Psychological Medicine</i> , 2014, 44, 3387-3405.	2.7	23
679	Pretreatment measures of brain structure and reward-processing brain function in cannabis dependence: An exploratory study of relationships with abstinence during behavioral treatment1. <i>Drug and Alcohol Dependence</i> , 2014, 140, 33-41.	1.6	50

#	ARTICLE	IF	CITATIONS
680	Temporal trends in marijuana attitudes, availability and use in Colorado compared to non-medical marijuana states: 2003-11. <i>Drug and Alcohol Dependence</i> , 2014, 140, 145-155.	1.6	243
681	Alterations of prefrontal cortex GABAergic transmission in the complex psychotic-like phenotype induced by adolescent delta-9-tetrahydrocannabinol exposure in rats. <i>Neurobiology of Disease</i> , 2014, 63, 35-47.	2.1	120
682	Cannabis use, gender and age of onset of schizophrenia: Data from the A-SOP study. <i>Psychiatry Research</i> , 2014, 215, 528-532.	1.7	80
683	Chronic Effects of Cannabis Use on the Auditory Mismatch Negativity. <i>Biological Psychiatry</i> , 2014, 75, 449-458.	0.7	19
684	Marijuana Use and Well-Being in University Students. <i>Journal of Happiness Studies</i> , 2014, 15, 301-321.	1.9	29
685	Secular Trends in Depressive Symptoms Among Norwegian Adolescents from 1992 to 2010. <i>Journal of Abnormal Child Psychology</i> , 2014, 42, 403-415.	3.5	85
686	The adverse health effects of chronic cannabis use. <i>Drug Testing and Analysis</i> , 2014, 6, 39-45.	1.6	288
687	Dopaminergic Function in Cannabis Users and Its Relationship to Cannabis-Induced Psychotic Symptoms. <i>Biological Psychiatry</i> , 2014, 75, 470-478.	0.7	170
688	The Patterns of Drug and Alcohol Use and Associated Problems Over 30 Years in 397 Men. <i>Alcoholism: Clinical and Experimental Research</i> , 2014, 38, 227-234.	1.4	21
689	No Detectable Association Between Frequency of Marijuana Use and Health or Healthcare Utilization Among Primary Care Patients Who Screen Positive for Drug Use. <i>Journal of General Internal Medicine</i> , 2014, 29, 133-139.	1.3	22
690	Cannabis abuse and age at onset in schizophrenia patients with large, rare copy number variants. <i>Schizophrenia Research</i> , 2014, 155, 21-25.	1.1	15
691	Substance use in clinical high risk for psychosis: a review of the literature. <i>Microbial Biotechnology</i> , 2014, 8, 104-112.	0.9	84
692	At high risk and want to quit: Marijuana use among adults with depression or serious psychological distress. <i>Addictive Behaviors</i> , 2014, 39, 761-767.	1.7	22
693	A critical role for prefrontocortical endocannabinoid signaling in the regulation of stress and emotional behavior. <i>Neuroscience and Biobehavioral Reviews</i> , 2014, 42, 116-131.	2.9	108
694	Systematic meta-analysis of outcomes associated with psychosis and co-morbid substance use. <i>Australian and New Zealand Journal of Psychiatry</i> , 2014, 48, 418-432.	1.3	75
695	The distribution of self-reported psychotic-like experiences in non-psychotic help-seeking mental health patients in the general population; a factor mixture analysis. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2014, 49, 349-358.	1.6	16
696	The emerging molecular architecture of schizophrenia, polygenic risk scores and the clinical implications for GxE research. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2014, 49, 169-182.	1.6	68
697	Cannabidiol as a potential treatment for psychosis. <i>European Neuropsychopharmacology</i> , 2014, 24, 51-64.	0.3	75

#	ARTICLE	IF	CITATIONS
698	Does liberalizing cannabis laws increase cannabis use?. <i>Journal of Health Economics</i> , 2014, 36, 20-32.	1.3	52
699	Role of the endocannabinoid system in brain functions relevant for schizophrenia: An overview of human challenge studies with cannabis or Δ^9 -tetrahydrocannabinol (THC). <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 52, 53-69.	2.5	56
700	Genetic dissection of the psychotomimetic effects of cannabinoid exposure. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 52, 33-40.	2.5	8
701	Neuropathology of substance use disorders. <i>Acta Neuropathologica</i> , 2014, 127, 91-107.	3.9	156
702	Imaging dopamine transmission parameters in cannabis dependence. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 52, 28-32.	2.5	11
703	Differential Neurodevelopmental Trajectories in Patients With Early-Onset Bipolar and Schizophrenia Disorders. <i>Schizophrenia Bulletin</i> , 2014, 40, S138-S146.	2.3	100
705	Influences on Boys' Marijuana Use in High School: A Two-Part Random Intercept Growth Model. <i>Journal of Research on Adolescence</i> , 2014, 24, 117-130.	1.9	18
706	Disrupted Gamma-Band Neural Oscillations During Coherent Motion Perception in Heavy Cannabis Users. <i>Neuropsychopharmacology</i> , 2014, 39, 3087-3099.	2.8	23
707	Violent behavior and the factors associated with the decision to report it: a retrospective study. <i>Journal of Forensic Psychiatry and Psychology</i> , 2014, 25, 574-583.	0.6	3
708	Identifying Patients With Problematic Drug Use in the Emergency Department: Results of a Multisite Study. <i>Annals of Emergency Medicine</i> , 2014, 64, 516-525.	0.3	47
709	Young adult sequelae of adolescent cannabis use: an integrative analysis. <i>Lancet Psychiatry</i> , 2014, 1, 286-293.	3.7	354
710	Implications of Marijuana Legalization for Adolescent Substance Use. <i>Substance Abuse</i> , 2014, 35, 331-335.	1.1	99
711	Morning cortisol levels in schizophrenia and bipolar disorder: A meta-analysis. <i>Psychoneuroendocrinology</i> , 2014, 49, 187-206.	1.3	160
712	Risk and protective factors for depression that adolescents can modify: A systematic review and meta-analysis of longitudinal studies. <i>Journal of Affective Disorders</i> , 2014, 169, 61-75.	2.0	251
713	Permanent suppression of cortical oscillations in mice after adolescent exposure to cannabinoids: Receptor mechanisms. <i>Neuropharmacology</i> , 2014, 86, 161-173.	2.0	35
714	Epidemiological, Neurobiological, and Genetic Clues to the Mechanisms Linking Cannabis Use to Risk for Nonaffective Psychosis. <i>Annual Review of Clinical Psychology</i> , 2014, 10, 767-791.	6.3	44
715	Improving adolescent mental health and resilience through a resilience-based intervention in schools: study protocol for a randomised controlled trial. <i>Trials</i> , 2014, 15, 289.	0.7	38
716	Increased CB2 mRNA and anandamide in human blood after cessation of cannabis abuse. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2014, 387, 691-695.	1.4	16

#	ARTICLE	IF	CITATIONS
717	Cannabis Use is a Better Indicator of Poor Mental Health in Women Than in Men: A Cross-Sectional Study in Young Adults from the General Population. <i>Community Mental Health Journal</i> , 2014, 50, 823-830.	1.1	12
718	Impact of Cannabis Use on the Development of Psychotic Disorders. <i>Current Addiction Reports</i> , 2014, 1, 115-128.	1.6	109
719	A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population- a meta-analysis of 31 studies. <i>BMC Psychiatry</i> , 2014, 14, 136.	1.1	217
720	Dopaminergic function in relation to genes associated with risk for schizophrenia. <i>Progress in Brain Research</i> , 2014, 211, 79-112.	0.9	18
721	Adolescent cannabis use and adverse sequelae in adulthood. <i>Lancet Psychiatry</i> , the, 2014, 1, 249-251.	3.7	0
722	One year follow-up of alcohol and illicit substance use in first-episode psychosis: Does gender matter?. <i>Comprehensive Psychiatry</i> , 2014, 55, 274-282.	1.5	34
723	Association between cannabis use and schizotypal dimensions – A meta-analysis of cross-sectional studies. <i>Psychiatry Research</i> , 2014, 219, 58-66.	1.7	42
724	Flattened cortisol awakening response in chronic patients with schizophrenia onset after cannabis exposure. <i>Psychiatry Research</i> , 2014, 215, 263-267.	1.7	23
725	Adolescent peer aggression and its association with mental health and substance use in an Australian cohort. <i>Journal of Adolescence</i> , 2014, 37, 11-21.	1.2	92
726	Anxiety mediates the association between cannabis use and attenuated positive psychotic symptoms. <i>Psychiatry Research</i> , 2014, 218, 180-186.	1.7	28
727	Preferences for policy options for cannabis in an Australian general population: A discrete choice experiment. <i>International Journal of Drug Policy</i> , 2014, 25, 682-690.	1.6	10
728	Acute administration of δ^9 tetrahydrocannabinol does not prevent enhancement of sensory gating by clozapine in DBA/2 mice. <i>Pharmacology Biochemistry and Behavior</i> , 2014, 118, 22-29.	1.3	6
729	Prevention and Screening, Brief Intervention, and Referral to Treatment for Substance Use in Primary Care. <i>Primary Care - Clinics in Office Practice</i> , 2014, 41, 185-213.	0.7	30
730	Genetic predisposition to schizophrenia associated with increased use of cannabis. <i>Molecular Psychiatry</i> , 2014, 19, 1201-1204.	4.1	168
731	CB1 cannabinoid receptor stimulation during adolescence impairs the maturation of GABA function in the adult rat prefrontal cortex. <i>Molecular Psychiatry</i> , 2014, 19, 536-543.	4.1	149
732	Treatment of refractory substance-induced psychosis in adolescent males with a genetic predisposition to mental illness. <i>International Journal of Adolescent Medicine and Health</i> , 2014, 26, 297-301.	0.6	7
733	Change in cannabis use in the general population: A longitudinal study on the impact on psychotic experiences. <i>Schizophrenia Research</i> , 2014, 157, 266-270.	1.1	27
734	A randomized controlled trial of a brief motivational enhancement for non-treatment-seeking adolescent cannabis users. <i>Journal of Substance Abuse Treatment</i> , 2014, 47, 181-188.	1.5	33

#	ARTICLE	IF	CITATIONS
735	WIN55,212-2 impairs non-associative recognition and spatial memory in rats via CB1 receptor stimulation. <i>Pharmacology Biochemistry and Behavior</i> , 2014, 124, 58-66.	1.3	24
736	Response inhibition and elevated parietal-cerebellar correlations in chronic adolescent cannabis users. <i>Neuropharmacology</i> , 2014, 84, 131-137.	2.0	93
737	Adversity, cannabis use and psychotic experiences: evidence of cumulative and synergistic effects. <i>British Journal of Psychiatry</i> , 2014, 204, 346-353.	1.7	90
738	Psychose et toxicomanie: le cimetière des évidences. <i>Sante Mentale Au Quebec</i> , 0, 39, 75-98.	0.1	4
739	Medical Marijuana Laws and Suicides by Gender and Age. <i>American Journal of Public Health</i> , 2014, 104, 2369-2376.	1.5	84
740	Developing Public Health Regulations for Marijuana: Lessons From Alcohol and Tobacco. <i>American Journal of Public Health</i> , 2014, 104, 1021-1028.	1.5	190
741	Substance use in individuals at clinical high risk of psychosis. <i>Psychological Medicine</i> , 2015, 45, 2275-2284.	2.7	45
742	Time for dabs: Analyzing Twitter data on marijuana concentrates across the U.S.. <i>Drug and Alcohol Dependence</i> , 2015, 155, 307-311.	1.6	101
743	Acupuncture treatment of substance-induced psychosis, addiction and pain: A review with case study. <i>Journal of Traditional Chinese Medical Sciences</i> , 2015, 2, 205-214.	0.1	0
744	Psychosocial interventions for cannabis abuse and/or dependence among persons with co-occurring cannabis use and psychotic disorders. <i>The Cochrane Library</i> , 2015, , .	1.5	0
745	Cannabinoid Receptor 1 (CNR1) Gene Polymorphisms in Schizophrenia Patients: Rs6454674 Polymorphism is Associated with Disease Severity. <i>Journal of Microbiology and Biotechnology</i> , 2015, 25, 341-347.	0.9	4
747	A clinical comparison of schizophrenia with and without pre-onset cannabis use disorder: a retrospective cohort study using categorical and dimensional approaches. <i>Annals of General Psychiatry</i> , 2015, 14, 44.	1.2	2
748	Frequent marijuana use, binge drinking and mental health problems among undergraduates. <i>American Journal on Addictions</i> , 2015, 24, 499-506.	1.3	78
749	Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been. <i>Headache</i> , 2015, 55, 885-916.	1.8	153
750	Evaluating the impact of cannabis use on thalamic connectivity in youth at clinical high risk of psychosis. <i>BMC Psychiatry</i> , 2015, 15, 276.	1.1	18
751	Atypical course in severe catatonic schizophrenia in a cannabis-dependent male adolescent: a case report. <i>Journal of Medical Case Reports</i> , 2015, 9, 200.	0.4	9
752	Potency trends of Δ^9 -tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-2015. <i>Addiction</i> , 2015, 110, 1941-1950.	1.7	82
753	Natural outcome of cannabis use disorder: a 36-year longitudinal follow-up. <i>Addiction</i> , 2015, 110, 1963-1974.	1.7	19

#	ARTICLE	IF	CITATIONS
754	CANNABIS USE AND ITS EFFECTS ON HEALTH, EDUCATION AND LABOR MARKET SUCCESS. Journal of Economic Surveys, 2015, 29, 993-1010.	3.7	31
755	Medical cannabis: time for clear thinking. Medical Journal of Australia, 2015, 202, 74-75.	0.8	6
756	The Effect of Varenicline Administration on Cannabis and Tobacco Use in Cannabis and Nicotine Dependent Individuals ? A Case-Series. Journal of Addiction Research & Therapy, 2015, 06, .	0.2	4
758	Risks Associated With the Non-Medicinal Use of Cannabis. Deutsches Ärzteblatt International, 2015, 112, 271-8.	0.6	92
759	Associations of Cannabis and Cigarette Use with Depression and Anxiety at Age 18: Findings from the Avon Longitudinal Study of Parents and Children. PLoS ONE, 2015, 10, e0122896.	1.1	65
760	Functional Activation and Effective Connectivity Differences in Adolescent Marijuana Users Performing a Simulated Gambling Task. Journal of Addiction, 2015, 2015, 1-11.	0.9	22
761	Psychiatric and Medical Management of Marijuana Intoxication in the Emergency Department. Western Journal of Emergency Medicine, 2015, 16, 414-417.	0.6	29
763	Aetiological stratification as a conceptual framework for gene-by-environment interaction research in psychiatry. Epidemiology and Psychiatric Sciences, 2015, 24, 6-11.	1.8	9
764	The Impact of Cannabis Use on Clinical Outcomes in Recent Onset Psychosis. Schizophrenia Bulletin, 2015, 41, 382-390.	2.3	35
765	Cost-Effectiveness of School-Based Prevention of Cannabis Use. Applied Health Economics and Health Policy, 2015, 13, 525-542.	1.0	12
766	Quality of life and risk of psychiatric disorders among regular users of alcohol, nicotine, and cannabis: An analysis of the National Epidemiological Survey on Alcohol and Related Conditions (NESARC). Journal of Psychiatric Research, 2015, 66-67, 135-141.	1.5	59
767	Cannabis, Cigarettes, and Their Co-Occurring Use: Disentangling Differences in Gray Matter Volume. International Journal of Neuropsychopharmacology, 2015, 18, pyv061.	1.0	39
768	A reexamination of medical marijuana policies in relation to suicide risk. Drug and Alcohol Dependence, 2015, 152, 68-72.	1.6	22
769	Psychosis and Severe Rhabdomyolysis Associated with Synthetic Cannabinoid Use. Clinical Schizophrenia and Related Psychoses, 2015, 8, 205-208.	1.4	40
771	Psychotic versus non-psychotic firestarters: similarities and differences in characteristics. Journal of Forensic Psychiatry and Psychology, 2015, 26, 439-460.	0.6	8
772	Sexual Minority Women in Treatment for Serious Mental Illness: A Literature Review. Journal of Gay and Lesbian Mental Health, 2015, 19, 303-319.	0.8	4
773	Global research challenges and opportunities for mental health and substance-use disorders. Nature, 2015, 527, S172-S177.	13.7	90
774	Evaluating the relationship between cannabis use and IQ in youth and young adults at clinical high risk of psychosis. Psychiatry Research, 2015, 230, 878-884.	1.7	13

#	ARTICLE	IF	CITATIONS
775	Tobacco and psychosis: Not quite a smoking gun. Australian and New Zealand Journal of Psychiatry, 2015, 49, 859-860.	1.3	2
776	Stimulants and Cannabis Use Among a Marginalized Population in British Columbia, Canada. International Journal of Offender Therapy and Comparative Criminology, 2015, 59, 1487-1498.	0.8	10
777	Contextual risks linking parents' adolescent marijuana use to offspring onset. Drug and Alcohol Dependence, 2015, 154, 222-228.	1.6	38
778	Substance Use in Patients With First-Episode Psychosis: Is Gender Relevant?. Journal of Dual Diagnosis, 2015, 11, 153-160.	0.7	19
779	The cannabinoid system and visual processing: A review on experimental findings and clinical presumptions. European Neuropsychopharmacology, 2015, 25, 100-112.	0.3	51
780	Impairment of inhibitory control processing related to acute psychotomimetic effects of cannabis. European Neuropsychopharmacology, 2015, 25, 26-37.	0.3	68
781	Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: A randomised, double-blind, placebo-controlled study in cannabis users. European Neuropsychopharmacology, 2015, 25, 325-334.	0.3	145
782	Comorbid substance use disorders in schizophrenia: A latent class approach. Psychiatry Research, 2015, 225, 395-401.	1.7	24
784	A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophrenia Research, 2015, 162, 153-161.	1.1	200
785	Cannabinoids and the Tourette syndrome. , 2015, , 227-245.		2
786	Cannabinoids and bipolar disorder. , 2015, , 205-225.		1
787	Cannabinoids and schizophrenia. , 2015, , 193-204.		1
788	The Impact of Marijuana Policies on Youth: Clinical, Research, and Legal Update. Pediatrics, 2015, 135, e769-e785.	1.0	139
789	Medical marijuana programs "Why might they matter for public health and why should we better understand their impacts?. Preventive Medicine Reports, 2015, 2, 53-56.	0.8	20
790	Legal highs: staying on top of the flood of novel psychoactive substances. Therapeutic Advances in Psychopharmacology, 2015, 5, 97-132.	1.2	136
791	Cross-national evidence for the clustering and psychosocial correlates of adolescent risk behaviours in 27 countries. European Journal of Public Health, 2015, 25, 50-56.	0.1	42
792	Much ado about much: Stress, dynamic biomarkers and HPA axis dysregulation along the trajectory to psychosis. Schizophrenia Research, 2015, 162, 253-260.	1.1	60
794	The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. Journal of Psychopharmacology, 2015, 29, 254-263.	2.0	211

#	ARTICLE	IF	CITATIONS
795	GABA Deficits Enhance the Psychotomimetic Effects of δ^9 -THC. <i>Neuropsychopharmacology</i> , 2015, 40, 2047-2056.	2.8	29
796	Cannabis Abuse Effects on Prepulse Inhibition in Patients With First Episode Psychosis in Schizophrenia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2015, 27, 48-53.	0.9	5
797	The case for medical marijuana: An issue of relief. <i>Drug and Alcohol Dependence</i> , 2015, 149, 293-297.	1.6	3
798	The Impact of Marijuana Policies on Youth: Clinical, Research, and Legal Update. <i>Pediatrics</i> , 2015, 135, 584-587.	1.0	79
799	The Avon Longitudinal Study of Parents and Children (ALSPAC) birth cohort as a resource for studying psychopathology in childhood and adolescence: a summary of findings for depression and psychosis. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2015, 50, 1017-1027.	1.6	45
800	Tobacco smoking is causally associated with antipsychotic medication use and schizophrenia, but not with antidepressant medication use or depression. <i>International Journal of Epidemiology</i> , 2015, 44, 566-577.	0.9	51
801	Age, sex and personality in early cannabis use. <i>European Psychiatry</i> , 2015, 30, 469-473.	0.1	12
802	Rethinking cigarette smoking, cannabis use, and psychosis. <i>Lancet Psychiatry</i> , the, 2015, 2, 581-582.	3.7	9
803	Hemispheric Language Asymmetry in First Episode Psychosis and Schizotypy: The Role of Cannabis Consumption and Cognitive Disorganization. <i>Schizophrenia Bulletin</i> , 2015, 41, S455-S464.	2.3	11
804	Potent questions about cannabis and mental health. <i>Lancet Psychiatry</i> , the, 2015, 2, 195-196.	3.7	6
805	Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. <i>Lancet Psychiatry</i> , the, 2015, 2, 233-238.	3.7	429
806	Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 2474.	3.8	419
808	Anxiety and substance use disorders: A worrying combination. <i>Australasian Psychiatry</i> , 2015, 23, 382-387.	0.4	11
809	Brain volume in male patients with recent onset schizophrenia with and without cannabis use disorders. <i>Journal of Psychiatry and Neuroscience</i> , 2015, 40, 197-206.	1.4	21
810	What is the impact of genome-wide supported risk variants for schizophrenia and bipolar disorder on brain structure and function? A systematic review. <i>Psychological Medicine</i> , 2015, 45, 2461-2480.	2.7	82
811	The relationship between cannabis involvement and suicidal thoughts and behaviors. <i>Drug and Alcohol Dependence</i> , 2015, 150, 98-104.	1.6	42
812	Cannabis and psychosis. <i>Lancet Psychiatry</i> , the, 2015, 2, 380.	3.7	11
813	Intent to abuse addictive substances in regions with serious drug abuse among early adolescents. <i>Journal of Substance Use</i> , 2015, 20, 417-423.	0.3	0

#	ARTICLE	IF	CITATIONS
814	WHO's Global Clinical Practice Network for mental health. <i>Lancet Psychiatry</i> , 2015, 2, 379-380.	3.7	58
815	Cannabis and psychosis – Authors' reply. <i>Lancet Psychiatry</i> , 2015, 2, 382.	3.7	11
816	Hospitalization in a Cohort Seeking Treatment for Illicit Drug Use in Finland. <i>Journal of Substance Abuse Treatment</i> , 2015, 53, 64-70.	1.5	17
817	Delta-9-tetrahydrocannabinol, neural oscillations above 20 Hz and induced acute psychosis. <i>Psychopharmacology</i> , 2015, 232, 519-528.	1.5	23
818	The epidemiology and progression time from transient to permanent psychiatric disorders of substance-induced psychosis in Taiwan. <i>Addictive Behaviors</i> , 2015, 47, 1-4.	1.7	15
819	High potency cannabis. <i>BMJ</i> , 2015, 350, h1205-h1205.	3.0	39
820	Sensorimotor gating, cannabis use and the risk of psychosis. <i>Schizophrenia Research</i> , 2015, 164, 21-27.	1.1	13
821	Heterogeneity in men's marijuana use in the 20s: Adolescent antecedents and consequences in the 30s. <i>Development and Psychopathology</i> , 2015, 27, 279-291.	1.4	14
822	Childhood trauma is associated with a specific admixture of affective, anxiety, and psychosis symptoms cutting across traditional diagnostic boundaries. <i>Psychological Medicine</i> , 2015, 45, 1277-1288.	2.7	131
823	Further human evidence for striatal dopamine release induced by administration of Δ^9 -tetrahydrocannabinol (THC): selectivity to limbic striatum. <i>Psychopharmacology</i> , 2015, 232, 2723-2729.	1.5	103
824	Can Cannabis Cause Psychosis?. <i>Clinical Neuropharmacology</i> , 2015, 38, 63-64.	0.2	2
825	Does cannabis affect dopaminergic signaling in the human brain? A systematic review of evidence to date. <i>European Neuropsychopharmacology</i> , 2015, 25, 1201-1224.	0.3	53
826	Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis. <i>Schizophrenia Bulletin</i> , 2015, 41, 1171-1182.	2.3	73
827	Medical Marijuana. <i>Journal of Developmental and Behavioral Pediatrics</i> , 2015, 36, 115-123.	0.6	66
828	Evidence that the presence of psychosis in non-psychotic disorder is environment-dependent and mediated by severity of non-psychotic psychopathology. <i>Psychological Medicine</i> , 2015, 45, 2389-2401.	2.7	72
829	Marijuana: A Time-Honored but Untested Treatment for Epilepsy. <i>Canadian Journal of Neurological Sciences</i> , 2015, 42, 88-91.	0.3	5
830	Adolescent Initiation of Cannabis use and Early-Onset Psychosis. <i>Substance Abuse</i> , 2015, 36, 524-533.	1.1	79
831	Prodromal symptoms and remission following first episode psychosis. <i>Schizophrenia Research</i> , 2015, 168, 30-36.	1.1	13

#	ARTICLE	IF	CITATIONS
832	Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse. <i>Pharmacological Reviews</i> , 2015, 67, 872-1004.	7.1	125
833	Alcohol confounds relationship between cannabis misuse and psychosis conversion in a high-risk sample. <i>Acta Psychiatrica Scandinavica</i> , 2015, 132, 60-68.	2.2	44
834	Psychosis, psychedelic substance misuse and head injury: A case report and 23 year follow-up. <i>Brain Injury</i> , 2015, 29, 1383-1386.	0.6	12
835	The association between cannabis abuse and subsequent schizophrenia: a Swedish national co-relative control study. <i>Psychological Medicine</i> , 2015, 45, 407-414.	2.7	58
836	Prevalence of medical marijuana use in California, 2012. <i>Drug and Alcohol Review</i> , 2015, 34, 141-146.	1.1	64
837	Dose-dependent effects of cannabis on the neural correlates of error monitoring in frequent cannabis users. <i>European Neuropsychopharmacology</i> , 2015, 25, 1943-1953.	0.3	14
838	Increasing Endocannabinoid Levels in the Ventral Pallidum Restore Aberrant Dopamine Neuron Activity in the Subchronic PCP Rodent Model of Schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyu035-pyu035.	1.0	23
839	Associations between psychotic symptoms and substance use in young offenders. <i>Drug and Alcohol Review</i> , 2015, 34, 673-682.	1.1	21
840	Medical use of cannabis: an addiction medicine perspective. <i>Internal Medicine Journal</i> , 2015, 45, 677-680.	0.5	7
841	Genetic moderation of the effects of cannabis: Catechol-O-methyltransferase (COMT) affects the impact of Δ^9 -tetrahydrocannabinol (THC) on working memory performance but not on the occurrence of psychotic experiences. <i>Journal of Psychopharmacology</i> , 2015, 29, 1146-1151.	2.0	35
842	Cannabinoids and Schizophrenia: Risks and Therapeutic Potential. <i>Neurotherapeutics</i> , 2015, 12, 816-824.	2.1	41
843	Neurocognitive and social cognitive predictors of cannabis use in first-episode psychosis. <i>Schizophrenia Research</i> , 2015, 168, 231-237.	1.1	20
844	Safety and Toxicology of Cannabinoids. <i>Neurotherapeutics</i> , 2015, 12, 735-746.	2.1	93
845	Substance use disorders in New Zealand adults with severe mental illness: descriptive study of an acute inpatient population. <i>Australasian Psychiatry</i> , 2015, 23, 236-240.	0.4	10
846	Trends in cannabis-related ambulance presentations from 2000 to 2013 in Melbourne, Australia. <i>Drug and Alcohol Dependence</i> , 2015, 155, 24-30.	1.6	15
847	Relationship between cannabis and psychosis: Reasons for use and associated clinical variables. <i>Psychiatry Research</i> , 2015, 229, 70-74.	1.7	43
848	Long-term risk factors for substance-induced and primary psychosis after release from prison. A longitudinal study of substance users. <i>Schizophrenia Research</i> , 2015, 168, 185-190.	1.1	26
849	Cannabis use and mental health-related quality of life among individuals with depressive disorders. <i>Psychiatry Research</i> , 2015, 230, 341-349.	1.7	37

#	ARTICLE	IF	CITATIONS
850	Adolescent Substance Misusers with and without Delinquency: Death, Mental and Physical Disorders, and Criminal Convictions from Age 21 to 45. <i>Journal of Substance Abuse Treatment</i> , 2015, 59, 1-9.	1.5	7
851	Closing the translational gap between mutant mouse models and the clinical reality of psychotic illness. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 58, 19-35.	2.9	30
853	Cannabis and adolescent brain development. , 2015, 148, 1-16.		255
854	Neighbourhood crime and adolescent cannabis use in Canadian adolescents. <i>Drug and Alcohol Dependence</i> , 2015, 146, 68-74.	1.6	12
855	Toward a translational approach to targeting the endocannabinoid system in posttraumatic stress disorder: A critical review of preclinical research. <i>Biological Psychology</i> , 2015, 104, 8-18.	1.1	33
856	Co-occurring Addictive and Psychiatric Disorders. , 2015, , .		13
857	Development of Sensory Gamma Oscillations and Cross-Frequency Coupling from Childhood to Early Adulthood. <i>Cerebral Cortex</i> , 2015, 25, 1509-1518.	1.6	82
858	Altered Cortical Expression of GABA-Related Genes in Schizophrenia: Illness Progression vs Developmental Disturbance. <i>Schizophrenia Bulletin</i> , 2015, 41, 180-191.	2.3	117
859	Cannabinoid Modulation of Functional Connectivity within Regions Processing Attentional Salience. <i>Neuropsychopharmacology</i> , 2015, 40, 1343-1352.	2.8	101
860	The association between cannabis use and mood disorders: A longitudinal study. <i>Journal of Affective Disorders</i> , 2015, 172, 211-218.	2.0	131
861	Psychopathology in Women. , 2015, , .		2
862	Measuring change in cannabis use. <i>Addiction Research and Theory</i> , 2015, 23, 43-49.	1.2	7
863	Probability and predictors of the cannabis gateway effect: A national study. <i>International Journal of Drug Policy</i> , 2015, 26, 135-142.	1.6	121
864	Cannabis use and mania symptoms: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2015, 171, 39-47.	2.0	170
865	What has research over the past two decades revealed about the adverse health effects of recreational cannabis use?. <i>Addiction</i> , 2015, 110, 19-35.	1.7	440
867	<i>Toxoplasma gondii</i> and Schizophrenia: A Relationship That Is Not Ruled Out. , 0, , .		1
868	Cannabis Use Disorders and Brain Morphology. , 2016, , 773-785.		1
869	Legalizing and Regulating Marijuana in Canada: Review of Potential Economic, Social, and Health Impacts. <i>International Journal of Health Policy and Management</i> , 2016, 5, 453-456.	0.5	65

#	ARTICLE	IF	CITATIONS
870	Substance-Induced Psychosis. , 2016, , 50-57.		2
871	Prevalencia y factores asociados al consumo de marihuana en estudiantes de 18 a 25 años de una universidad pública, Colombia. Universidad Y Salud, 2016, 18, 525.	0.3	1
872	Imaging Dopamine Alterations in Cannabis Dependence. , 2016, , 786-794.		0
873	lloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy. Core Evidence, 2016, Volume 11, 49-61.	4.7	18
874	The Neurobiology of Comorbid Drug Abuse in Schizophrenia and Psychotic Disorders. , 2016, , 82-88.		59
875	Drug Induced Psychosis or Schizophrenia?. Dual Diagnosis (Foster City), 2016, 01, .	0.0	1
876	Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy. Parkinson's Disease, 2016, 2016, 1-19.	0.6	17
878	Schizophrenia spectrum disorders. , 0, , 65-77.		1
879	Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence. Frontiers in Pharmacology, 2016, 7, 422.	1.6	75
880	Neuropsychological Consequences of Chronic Drug Use: Relevance to Treatment Approaches. Frontiers in Psychiatry, 2015, 6, 189.	1.3	69
881	Utility of Washington Early Recognition Center Self-Report Screening Questionnaires in the Assessment of Patients with Schizophrenia and Bipolar Disorder. Frontiers in Psychiatry, 2016, 7, 149.	1.3	14
882	Gene – Environment Interactions in Schizophrenia: Evidence from Genetic Mouse Models. Neural Plasticity, 2016, 2016, 1-23.	1.0	265
883	A Virtue Analysis of Recreational Marijuana Use. Linacre quarterly, The, 2016, 83, 158-173.	0.1	12
884	The association between cannabis use and suicidality among men and women: A population-based longitudinal study. Journal of Affective Disorders, 2016, 205, 216-224.	2.0	39
885	Course of auditory vocal hallucinations in childhood: 11-year follow-up study. Acta Psychiatrica Scandinavica, 2016, 134, 6-15.	2.2	46
886	Increased prevalence of self-reported psychotic illness predicted by crystal methamphetamine use: Evidence from a high-risk population. International Journal of Drug Policy, 2016, 38, 16-20.	1.6	27
887	Prevalence and correlates of vaping cannabis in a sample of young adults.. Psychology of Addictive Behaviors, 2016, 30, 915-921.	1.4	91
888	Are adolescents more vulnerable to the harmful effects of cannabis than adults? A placebo-controlled study in human males. Translational Psychiatry, 2016, 6, e961-e961.	2.4	72

#	ARTICLE	IF	CITATIONS
889	How have systematic reviews and meta-analyses benefited psychiatry?. BJ Psych Advances, 2016, 22, 142-144.	0.5	0
891	Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study. BMJ Open, 2016, 6, e009888.	0.8	109
892	Abnormalities in neuroendocrine stress response in psychosis: the role of endocannabinoids. Psychological Medicine, 2016, 46, 27-45.	2.7	32
893	Medicinal Uses of Marijuana and Cannabinoids. Critical Reviews in Plant Sciences, 2016, 35, 378-405.	2.7	46
894	A Prediction Modelling and Pattern Detection Approach for the First-Episode Psychosis Associated to Cannabis Use. , 2016, , .		5
895	The Relationships of Cigarette and Alcohol Use With the Initiation, Reinitiation, and Persistence of Cannabis Use. Journal of Studies on Alcohol and Drugs, 2016, 77, 113-120.	0.6	11
896	Physiological markers of biased decision-making in problematic Internet users. Journal of Behavioral Addictions, 2016, 5, 510-517.	1.9	22
897	Cannabis and Amphetamine-type Stimulant-induced Psychoses: A Systematic Overview. Addictive Disorders and Their Treatment, 2016, 15, 190-200.	0.5	8
900	Student-run free clinics: the USA's psychiatry recruitment solution?. Lancet Psychiatry,the, 2016, 3, 321-322.	3.7	5
901	Where next with theory and research on how the school environment influences young people's substance use?. Health and Place, 2016, 40, 91-97.	1.5	8
902	Differential effects of childhood trauma and cannabis use disorders in patients suffering from schizophrenia. Schizophrenia Research, 2016, 175, 161-167.	1.1	26
903	Cannabis use and transition to psychosis in individuals at ultra-high risk: review and meta-analysis. Psychological Medicine, 2016, 46, 673-681.	2.7	103
904	Neighbourhood level social deprivation and the risk of psychotic disorders: a systematic review. Social Psychiatry and Psychiatric Epidemiology, 2016, 51, 941-950.	1.6	75
905	Towards diagnostic markers for the psychoses. Lancet Psychiatry,the, 2016, 3, 375-385.	3.7	16
906	Keep off the grass? Cannabis, cognition and addiction. Nature Reviews Neuroscience, 2016, 17, 293-306.	4.9	315
907	Cannabis and mental illness in adolescents: a review. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2016, 58, S18-S21.	0.2	9
908	Psychosocial treatments in bipolar disorder. Lancet Psychiatry,the, 2016, 3, 321.	3.7	3
909	Cannabis Use Disorders and Altered Brain Morphology: Where Is the Evidence?. Current Addiction Reports, 2016, 3, 189-198.	1.6	6

#	ARTICLE	IF	CITATIONS
910	Cingulo-opercular Network Efficiency Mediates the Association Between Psychotic-like Experiences and Cognitive Ability in the General Population. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2016, 1, 498-506.	1.1	36
911	The need for health warnings about cannabis and psychosis. <i>Lancet Psychiatry</i> , the, 2016, 3, 322.	3.7	2
912	COMT Val 158 Met genotype and cannabis use in people with an At Risk Mental State for psychosis: Exploring Gene x Environment interactions. <i>Schizophrenia Research</i> , 2016, 174, 24-28.	1.1	22
913	Cannabis, Psychosis, and Mortality: A Cohort Study of 50,373 Swedish Men. <i>American Journal of Psychiatry</i> , 2016, 173, 790-798.	4.0	22
914	Concurrent and Sustained Cumulative Effects of Adolescent Marijuana Use on Subclinical Psychotic Symptoms. <i>American Journal of Psychiatry</i> , 2016, 173, 781-789.	4.0	63
915	Developmental course of subclinical positive and negative psychotic symptoms and their associations with genetic risk status and impairment. <i>Schizophrenia Research</i> , 2016, 174, 177-182.	1.1	8
916	Qualitative research in Spanish cannabis social clubs: "The moment you enter the door, you are minimising the risks". <i>International Journal of Drug Policy</i> , 2016, 34, 49-57.	1.6	33
917	Psychosis as a transdiagnostic and extended phenotype in the general population. <i>World Psychiatry</i> , 2016, 15, 118-124.	4.8	397
918	Cannabis and psychosis: understanding the smoke signals. <i>Lancet Psychiatry</i> , the, 2016, 3, 909-910.	3.7	3
919	Volumetric, relaxometric and diffusometric correlates of psychotic experiences in a non-clinical sample of young adults. <i>NeuroImage: Clinical</i> , 2016, 12, 550-558.	1.4	15
921	Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. <i>World Psychiatry</i> , 2016, 15, 195-204.	4.8	201
922	Characteristics of Cannabis-Only and Other Drug Users Who Visit the Emergency Department. <i>Cannabis and Cannabinoid Research</i> , 2016, 1, 149-153.	1.5	5
923	Attitudes to cannabis and patterns of use among Canadians with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 10, 123-126.	0.9	33
924	The Effects of Cannabis on Inpatient Agitation, Aggression, and Length of Stay. <i>Journal of Dual Diagnosis</i> , 2016, 12, 244-251.	0.7	18
925	Compared to high and low cannabis use, moderate use is associated with fewer cognitive deficits in psychosis. <i>Schizophrenia Research: Cognition</i> , 2016, 6, 15-21.	0.7	16
926	Genetic and Environmental Contributions to the Association Between Cannabis Use and Psychotic-Like Experiences in Young Adult Twins. <i>Schizophrenia Bulletin</i> , 2016, 43, sbw101.	2.3	25
927	Substance use associated with short sleep duration in patients with schizophrenia or schizoaffective disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2016, 171, 525-533.	1.1	3
928	Peer-led interventions to prevent tobacco, alcohol and/or drug use among young people aged 11-21 years: a systematic review and meta-analysis. <i>Addiction</i> , 2016, 111, 391-407.	1.7	169

#	ARTICLE	IF	CITATIONS
929	Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study. <i>Lancet Psychiatry</i> , 2016, 3, 947-953.	3.7	120
930	Characterization of peripheral cannabinoid receptor expression and clinical correlates in schizophrenia. <i>Psychiatry Research</i> , 2016, 245, 346-353.	1.7	16
931	MicroRNA: Small RNA mediators of the brains genomic response to environmental stress. <i>Progress in Neurobiology</i> , 2016, 143, 61-81.	2.8	102
932	U-shaped curve of psychosis according to cannabis use: New evidence from a snowball sample. <i>Journal of Psychopharmacology</i> , 2016, 30, 1331-1338.	2.0	7
933	Family-Based Treatments for Adolescent Substance Use. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2016, 25, 603-628.	1.0	23
934	Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis. <i>Journal of Psychopharmacology</i> , 2016, 30, 1321-1330.	2.0	71
935	Considering Organic Pathology. , 2016, , 109-127.		0
936	Premorbid cannabis use is associated with more symptoms and poorer functioning in schizophrenia spectrum disorder. <i>Psychological Medicine</i> , 2016, 46, 3127-3136.	2.7	37
937	Normative Perceptions of Cannabis Use Among European University Students: Associations of Perceived Peer Use and Peer Attitudes With Personal Use and Attitudes. <i>Journal of Studies on Alcohol and Drugs</i> , 2016, 77, 740-748.	0.6	33
938	Cannabis use related to early psychotic onset: Role of premorbid function. <i>Neuroscience Letters</i> , 2016, 633, 55-61.	1.0	9
939	The Psychiatric Interview for Differential Diagnosis. , 2016, , .		24
940	The incidence of schizophrenia and schizophrenia spectrum disorders in Denmark in the period 2000-2012. A register-based study. <i>Schizophrenia Research</i> , 2016, 176, 533-539.	1.1	46
941	Substance Use Disorders and Schizophrenia. <i>Focus (American Psychiatric Publishing)</i> , 2016, 14, 333-342.	0.4	2
942	Thinking Adult in Adolescent Psychiatry. , 2016, , 247-255.		1
943	Cannabis Use and Psychiatric Disorders: Implications for Mental Health and Addiction Treatment. <i>Current Addiction Reports</i> , 2016, 3, 450-462.	1.6	9
944	Routine Drug Screening for Patients in the Emergency Department of a State Psychiatric Hospital: A Naturalistic Cohort Study. <i>Journal of Dual Diagnosis</i> , 2016, 12, 218-226.	0.7	3
945	Association between cannabis use and treatment outcomes in patients receiving methadone maintenance treatment: a systematic review protocol. <i>Systematic Reviews</i> , 2016, 5, 139.	2.5	12
947	The burden of disease attributable to cannabis use in Canada in 2012. <i>Addiction</i> , 2016, 111, 653-662.	1.7	83

#	ARTICLE	IF	CITATIONS
948	Characteristics of Marijuana Acquisition Among a National Sample of Adolescent Users. <i>American Journal of Health Education</i> , 2016, 47, 126-135.	0.3	11
949	Commentary: Adolescent Marijuana Use and Mental Health Amidst a Changing Legal Climate. <i>Journal of Pediatric Psychology</i> , 2016, 41, 287-289.	1.1	6
951	Medical Comorbidity and Complications. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2016, 25, 533-548.	1.0	2
952	A Qualitative Exploration of U.K. Prisoners's Experiences of Substance Misuse and Mental Health Difficulties, and the Breaking Free Health and Justice Interventions. <i>Journal of Drug Issues</i> , 2016, 46, 198-215.	0.6	10
953	Relation between cannabis use and subcortical volumes in people at clinical high risk of psychosis. <i>Psychiatry Research - Neuroimaging</i> , 2016, 254, 3-9.	0.9	8
954	Cannabinoids. , 2016, , 48-70.		0
955	Prenatal, perinatal, and adolescent exposure to marijuana: Relationships with aggressive behavior. <i>Neurotoxicology and Teratology</i> , 2016, 58, 60-77.	1.2	17
956	Solitary cannabis use frequency mediates the relationship between social anxiety and cannabis use and related problems. <i>American Journal on Addictions</i> , 2016, 25, 99-104.	1.3	34
957	Crude estimates of cannabis-attributable mortality and morbidity in Canada—implications for public health focused intervention priorities. <i>Journal of Public Health</i> , 2016, 38, 183-188.	1.0	54
958	The Effects of Low Self-Control and Delinquent Peers on Alcohol, Tobacco, and Drug Use in a Sample of Saudi Arabian Youth. <i>International Journal of Offender Therapy and Comparative Criminology</i> , 2016, 60, 1569-1587.	0.8	17
959	Marijuana use in the immediate 5-year premorbid period is associated with increased risk of onset of schizophrenia and related psychotic disorders. <i>Schizophrenia Research</i> , 2016, 171, 62-67.	1.1	54
960	Cannabis use, depression and anxiety: A 3-year prospective population-based study. <i>Journal of Affective Disorders</i> , 2016, 193, 103-108.	2.0	78
961	Schizophrenia. <i>Lancet, The</i> , 2016, 388, 86-97.	6.3	1,328
962	The need for health warnings about cannabis and psychosis. <i>Lancet Psychiatry, the</i> , 2016, 3, 188-189.	3.7	5
963	Cognitive endophenotypes, gene-environment interactions and experience-dependent plasticity in animal models of schizophrenia. <i>Biological Psychology</i> , 2016, 116, 82-89.	1.1	34
964	Acute and Chronic Effects of Cannabinoids on Human Cognition—A Systematic Review. <i>Biological Psychiatry</i> , 2016, 79, 557-567.	0.7	499
965	Therapeutic Potential of Cannabinoids in Psychosis. <i>Biological Psychiatry</i> , 2016, 79, 604-612.	0.7	73
966	Suicide among individuals with schizophrenia: A risk factor model. <i>Social Work in Mental Health</i> , 2016, 14, 112-132.	0.7	7

#	ARTICLE	IF	CITATIONS
967	Effect of cannabis on glutamate signalling in the brain: A systematic review of human and animal evidence. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 64, 359-381.	2.9	117
968	Alteration of transcriptional networks in the entorhinal cortex after maternal immune activation and adolescent cannabinoid exposure. <i>Brain, Behavior, and Immunity</i> , 2016, 56, 187-196.	2.0	24
969	Marijuana use trajectories during college predict health outcomes nine years post-matriculation. <i>Drug and Alcohol Dependence</i> , 2016, 159, 158-165.	1.6	57
970	AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers. <i>Translational Psychiatry</i> , 2016, 6, e738-e738.	2.4	76
971	Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis. <i>Schizophrenia Bulletin</i> , 2016, 42, 1262-1269.	2.3	615
972	Shifting the Paradigm: Adolescent Cannabis Abuse and the Need for Early Intervention. <i>Journal of Psychoactive Drugs</i> , 2016, 48, 24-27.	1.0	9
973	A literature review and meta-analyses of cannabis use and suicidality. <i>Journal of Affective Disorders</i> , 2016, 195, 63-74.	2.0	150
974	Cannabis-induced psychosis associated with high potency <i>â€œwax dabsâ€</i> . <i>Schizophrenia Research</i> , 2016, 172, 211-212.	1.1	67
975	Why young people's substance use matters for global health. <i>Lancet Psychiatry</i> , the, 2016, 3, 265-279.	3.7	230
976	Phenotypic Manifestation of Genetic Risk for Schizophrenia During Adolescence in the General Population. <i>JAMA Psychiatry</i> , 2016, 73, 221.	6.0	197
977	Patterns of Drug Use and Drug-related Hospital Admissions in HIV-Positive and -Negative Gay and Bisexual Men. <i>AIDS and Behavior</i> , 2016, 20, 2372-2386.	1.4	9
978	Older, Less Regulated Medical Marijuana Programs Have Much Greater Enrollment Rates Than Newer <i>â€œMedicalizedâ€™</i> Programs. <i>Health Affairs</i> , 2016, 35, 480-488.	2.5	82
979	The association between cannabis use and anxiety disorders: Results from a population-based representative sample. <i>European Neuropsychopharmacology</i> , 2016, 26, 493-505.	0.3	74
980	Characteristics of Child Maltreatment and Adolescent Marijuana Use. <i>Child Maltreatment</i> , 2016, 21, 16-25.	2.0	38
981	Prevalence of substance use disorders in psychiatric patients: a nationwide Danish population-based study. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2016, 51, 129-140.	1.6	147
982	<i>â€œStressing outâ€</i> : defining severity of cannabis withdrawal symptoms in Australian indigenous inmates. <i>Journal of Substance Use</i> , 2016, 21, 368-373.	0.3	2
983	Age at first tobacco use and risk of subsequent psychosis-related outcomes: A birth cohort study. <i>Australian and New Zealand Journal of Psychiatry</i> , 2016, 50, 577-583.	1.3	39
984	At the Tip of an Iceberg: Prenatal Marijuana and Its Possible Relation to Neuropsychiatric Outcome in the Offspring. <i>Biological Psychiatry</i> , 2016, 79, e33-e45.	0.7	73

#	ARTICLE	IF	CITATIONS
985	Animal models of gene-environment interaction in schizophrenia: A dimensional perspective. <i>Progress in Neurobiology</i> , 2016, 136, 1-27.	2.8	67
986	THC and endocannabinoids differentially regulate neuronal activity in the prefrontal cortex and hippocampus in the subchronic PCP model of schizophrenia. <i>Journal of Psychopharmacology</i> , 2016, 30, 169-181.	2.0	14
987	Cannabis use disorder is associated with greater illness severity in tobacco smoking patients with bipolar disorder. <i>Journal of Affective Disorders</i> , 2016, 190, 286-293.	2.0	26
988	Attitudes and perceived risk of cannabis use in Irish adolescents. <i>Irish Journal of Medical Science</i> , 2016, 185, 643-647.	0.8	16
989	Does Cannabis Cause, Exacerbate or Ameliorate Psychiatric Disorders? An Oversimplified Debate Discussed. <i>Neuropsychopharmacology</i> , 2016, 41, 393-401.	2.8	53
990	Association Between Cannabis and Psychosis: Epidemiologic Evidence. <i>Biological Psychiatry</i> , 2016, 79, 549-556.	0.7	285
991	Attentional dysfunction in abstinent long-term cannabis users with and without schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 409-421.	1.8	6
992	Deficits in striatal dopamine release in cannabis dependence. <i>Molecular Psychiatry</i> , 2017, 22, 68-75.	4.1	107
993	Cannabis use and symptoms of anxiety in adolescence and the moderating effect of the serotonin transporter gene. <i>Addiction Biology</i> , 2017, 22, 1081-1089.	1.4	18
994	Do cognitive schema mediate the association between childhood trauma and being at ultra-high risk for psychosis?. <i>Journal of Psychiatric Research</i> , 2017, 88, 89-96.	1.5	53
995	Short communication: Genetic association between schizophrenia and cannabis use. <i>Drug and Alcohol Dependence</i> , 2017, 171, 117-121.	1.6	61
996	Psychotic Symptoms in Attention-Deficit/Hyperactivity Disorder: An Analysis of the MTA Database. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2017, 56, 336-343.	0.3	17
997	The positive link between executive function and lifetime cannabis use in schizophrenia is not explained by current levels of superior social cognition. <i>Psychiatry Research</i> , 2017, 250, 92-98.	1.7	10
998	Cannabis use, COMT, BDNF and age at first-episode psychosis. <i>Psychiatry Research</i> , 2017, 250, 38-43.	1.7	26
999	Pregnenolone blocks cannabinoid-induced acute psychotic-like states in mice. <i>Molecular Psychiatry</i> , 2017, 22, 1594-1603.	4.1	50
1000	Cannabis use and the course and outcome of major depressive disorder: A population based longitudinal study. <i>Psychiatry Research</i> , 2017, 251, 225-234.	1.7	97
1001	Cannabis exacerbates depressive symptoms in rat model induced by reserpine. <i>Behavioural Brain Research</i> , 2017, 324, 41-50.	1.2	22
1002	Older adults who use or have used marijuana: Help-seeking for marijuana and other substance use problems. <i>Journal of Substance Abuse Treatment</i> , 2017, 77, 185-192.	1.5	13

#	ARTICLE	IF	CITATIONS
1003	Association of cannabis use with the development of elevated anxiety symptoms in the general population: a meta-analysis. <i>Journal of Epidemiology and Community Health</i> , 2017, 71, 811-816.	2.0	48
1004	Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 443-455.	1.3	66
1005	Association between alcohol, cannabis, and other illicit substance abuse and risk of developing schizophrenia: a nationwide population based register study. <i>Psychological Medicine</i> , 2017, 47, 1668-1677.	2.7	68
1006	Building smart cannabis policy from the science up. <i>International Journal of Drug Policy</i> , 2017, 42, 39-49.	1.6	24
1007	Cannabis use and adherence to antipsychotic medication: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2017, 47, 1691-1705.	2.7	53
1008	Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: A literature review. <i>Depression and Anxiety</i> , 2017, 34, 207-216.	2.0	59
1009	Psychiatric Complications of Cannabis Oil Use in Cancer Patients: Whose Responsibility Is It To Manage?. <i>Journal of Palliative Medicine</i> , 2017, 20, 448-448.	0.6	0
1010	Development and validation of the cannabis experiences questionnaire "Intoxication effects checklist (CEQ-I) short form. <i>Schizophrenia Research</i> , 2017, 189, 91-96.	1.1	18
1011	Heavy cannabis use prior psychosis in schizophrenia: clinical, cognitive and neurological evidences for a new endophenotype?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 629-638.	1.8	21
1012	BDNF overexpression prevents cognitive deficit elicited by adolescent cannabis exposure and host susceptibility interaction. <i>Human Molecular Genetics</i> , 2017, 26, 2462-2471.	1.4	41
1013	Interactions between cannabis and schizophrenia in humans and rodents. <i>Reviews in the Neurosciences</i> , 2017, 28, 811-823.	1.4	9
1014	Longitudinal Studies on the Etiology of Cannabis Use Disorder: A Review. <i>Current Addiction Reports</i> , 2017, 4, 43-52.	1.6	25
1015	Primary psychosis with comorbid drug abuse and drug-induced psychosis: Diagnostic and clinical evolution at follow up. <i>Asian Journal of Psychiatry</i> , 2017, 29, 117-122.	0.9	20
1016	Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia vs Non-Psychiatric Controls. <i>Neuropsychopharmacology</i> , 2017, 42, 2259-2271.	2.8	28
1017	Cross-Cultural Effects of Cannabis Use Disorder: Evidence to Support a Cultural Neuroscience Approach. <i>Current Addiction Reports</i> , 2017, 4, 100-109.	1.6	9
1018	Legalizing Marijuana and Its Effect on Adolescent Behavior and Health in the USA: Risk and Opportunity. , 2017, , 267-292.		0
1019	The role of marijuana use disorder in predicting emergency department and inpatient encounters: A retrospective cohort study. <i>Drug and Alcohol Dependence</i> , 2017, 178, 170-175.	1.6	25
1020	Does Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition. <i>Current Addiction Reports</i> , 2017, 4, 62-74.	1.6	115

#	ARTICLE	IF	CITATIONS
1021	Acute memory and psychotomimetic effects of cannabis and tobacco both "joint"™ and individually: a placebo-controlled trial. <i>Psychological Medicine</i> , 2017, 47, 2708-2719.	2.7	75
1022	The relationship between cannabis use and cortisol levels in youth at ultra high-risk for psychosis. <i>Psychoneuroendocrinology</i> , 2017, 83, 58-64.	1.3	19
1023	Drug-Avoidance Self-Efficacy Among Exclusive Cannabis Users vs. Other Drug Users Visiting the Emergency Department. <i>Substance Use and Misuse</i> , 2017, 52, 1222-1228.	0.7	1
1025	Association between cannabis use and methadone maintenance treatment outcomes: an investigation into sex differences. <i>Biology of Sex Differences</i> , 2017, 8, 8.	1.8	30
1026	Daily use of high-potency cannabis is associated with an increased risk of admission and more intervention after first-episode psychosis. <i>Evidence-Based Mental Health</i> , 2017, 20, 58-58.	2.2	8
1027	Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn's Disease, a Randomized Controlled Trial. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1615-1620.	1.1	142
1028	Long lasting effects of chronic heavy cannabis abuse. <i>American Journal on Addictions</i> , 2017, 26, 335-342.	1.3	19
1029	Cannabis Use, Polysubstance Use, and Psychosis Spectrum Symptoms in a Community-Based Sample of U.S. Youth. <i>Journal of Adolescent Health</i> , 2017, 60, 653-659.	1.2	26
1030	Motivational changes of cannabis use prior to and during the course of schizophrenia. <i>American Journal on Addictions</i> , 2017, 26, 122-128.	1.3	4
1031	Childhood sexual abuse and substance abuse: A gender paradox?. <i>Child Abuse and Neglect</i> , 2017, 63, 284-294.	1.3	44
1032	Evidence for the Risks and Consequences of Adolescent Cannabis Exposure. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2017, 56, 214-225.	0.3	164
1033	Assessing causality in associations between cannabis use and schizophrenia risk: a two-sample Mendelian randomization study. <i>Psychological Medicine</i> , 2017, 47, 971-980.	2.7	182
1034	Cannabis-induced attenuated psychotic symptoms: implications for prognosis in young people at ultra-high risk for psychosis. <i>Psychological Medicine</i> , 2017, 47, 616-626.	2.7	41
1035	Cannabis and Young Users" A Brief Intervention to Reduce Their Consumption (CANABIC): A Cluster Randomized Controlled Trial in Primary Care. <i>Annals of Family Medicine</i> , 2017, 15, 131-139.	0.9	27
1036	Canadian Schizophrenia Guidelines: Schizophrenia and Other Psychotic Disorders with Coexisting Substance Use Disorders. <i>Canadian Journal of Psychiatry</i> , 2017, 62, 624-634.	0.9	80
1037	Influence of depressive symptoms on distress related to positive psychotic-like experiences in women. <i>Psychiatry Research</i> , 2017, 258, 469-475.	1.7	9
1038	The association between regular marijuana use and adult mental health outcomes. <i>Drug and Alcohol Dependence</i> , 2017, 179, 109-116.	1.6	59
1039	Cannabis and Canada's children and youth. <i>Paediatrics and Child Health</i> , 2017, 22, 98-102.	0.3	52

#	ARTICLE	IF	CITATIONS
1040	Sex Differences in Cannabis Use Disorder Diagnosis Involved Hospitalizations in the United States. <i>Journal of Addiction Medicine</i> , 2017, 11, 357-367.	1.4	32
1041	Cannabis use and psychotic-like experiences trajectories during early adolescence: the coevolution and potential mediators. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2017, 58, 1360-1369.	3.1	27
1042	The Effects of Cannabis Among Adults With Chronic Pain and an Overview of General Harms. <i>Annals of Internal Medicine</i> , 2017, 167, 319.	2.0	232
1043	Investigation of the <i>COMT</i> Val158Met variant association with age of onset of psychosis, adjusting for cannabis use. <i>Brain and Behavior</i> , 2017, 7, e00850.	1.0	14
1044	Using molecular imaging to understand early schizophrenia-related psychosis neurochemistry: a review of human studies. <i>International Review of Psychiatry</i> , 2017, 29, 555-566.	1.4	6
1045	Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. <i>American Journal of Public Health</i> , 2017, 107, e1-e12.	1.5	295
1046	Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and Comorbid Substance Abuse. <i>Clinical Therapeutics</i> , 2017, 39, 1380-1395.e4.	1.1	21
1047	Characterizing marijuana concentrate users: A web-based survey. <i>Drug and Alcohol Dependence</i> , 2017, 178, 399-407.	1.6	53
1049	Neuroimaging and Genetics of the Acute and Chronic Effects of Cannabis. , 2017, , e42-e52.		1
1050	The Impact of Cannabinoids on Motor Activity and Neurochemical Correlates. <i>NeuroMethods</i> , 2017, , 341-365.	0.2	0
1051	The consequences of chronic cannabis smoking in vulnerable adolescents. <i>Paediatric Respiratory Reviews</i> , 2017, 24, 44-53.	1.2	2
1052	The Epidemiology of First-Episode Psychosis in Early Intervention in Psychosis Services: Findings From the Social Epidemiology of Psychoses in East Anglia [SEPEA] Study. <i>American Journal of Psychiatry</i> , 2017, 174, 143-153.	4.0	96
1053	The genetic basis of the comorbidity between cannabis use and major depression. <i>Addiction</i> , 2017, 112, 113-123.	1.7	28
1054	Trajectories of cannabis use disorder: risk factors, clinical characteristics and outcomes. <i>Addiction</i> , 2017, 112, 279-287.	1.7	29
1055	Cannabis and development of dual diagnoses: A literature review. <i>American Journal of Drug and Alcohol Abuse</i> , 2017, 43, 442-455.	1.1	57
1056	Medical cannabis and mental health: A guided systematic review. <i>Clinical Psychology Review</i> , 2017, 51, 15-29.	6.0	168
1057	Alcohol and cannabis: Comparing their adverse health effects and regulatory regimes. <i>International Journal of Drug Policy</i> , 2017, 42, 57-62.	1.6	46
1058	Adverse Structural and Functional Effects of Marijuana on the Brain: Evidence Reviewed. <i>Pediatric Neurology</i> , 2017, 66, 12-20.	1.0	50

#	ARTICLE	IF	CITATIONS
1059	Cognitive motor deficits in cannabis users. <i>Current Opinion in Behavioral Sciences</i> , 2017, 13, 1-7.	2.0	33
1060	Increasing Plant Concentrations of THC and Implications on Health Related Disorders. , 2017, , 24-32.		2
1062	Putative Role of Endocannabinoids in Schizophrenia. , 2017, , 83-113.		0
1063	The Endocannabinoid System and Human Brain Functions. , 2017, , 115-186.		3
1064	Le cannabis et les enfants et adolescents canadiens. <i>Paediatrics and Child Health</i> , 2017, 22, 103-108.	0.3	3
1065	Dual Disorders in Cannabis Misuse. , 2017, , 61-69.		0
1066	Lifetime Cannabis Use and Cognition in Psychosis Spectrum Disorders. , 2017, , 44-52.		2
1067	Stress Response in Cannabis Users and Psychosis. , 2017, , 278-287.		0
1068	Marijuana's Role in The Adolescent Population. <i>Journal of Addiction Research & Therapy</i> , 2017, S11, .	0.2	1
1070	Cannabis Use and Well-Being. , 2017, , 308-316.		3
1071	Illicit Drugs: Patterns of Use, Dependence, and Contribution to Disease Burden in Developed Countries. , 2017, , 134-145.		2
1072	Le cannabis: addiction. Conséquences aiguës et chroniques. <i>Pratiques En Santé Mentale</i> , 2017, 63e anné, 15-20.	0.1	0
1073	Cannabis, Migration, and Psychosis Onset. , 2017, , 79-88.		0
1074	Cannabis use in male and female first episode of non-affective psychosis patients: Long-term clinical, neuropsychological and functional differences. <i>PLoS ONE</i> , 2017, 12, e0183613.	1.1	12
1075	Neurological soft signs in Tunisian patients with first-episode psychosis and relation with cannabis use. <i>Annals of General Psychiatry</i> , 2017, 16, 30.	1.2	4
1077	Marijuana Use and Perceptions of Risk and Harm: A Survey among Canadians in 2016. <i>Healthcare Policy</i> , 2017, 13, 17-27.	0.3	14
1078	Mood and coping flexibility in a group of adolescents using marijuana. <i>Alkoholizm I Narkomania</i> , 2017, 30, 85-102.	0.3	6
1080	Gray Matter, Lateral Ventricle Volumes, and Executive Functioning in Cannabis Users with First-Episode Psychosis. , 2017, , e53-e63.		0

#	ARTICLE	IF	CITATIONS
1081	Cannabis and Psychosis: Correlation, Causality, and Consequences. , 2017, , 413-421.		1
1082	Cannabis Smoking in Adult Schizophrenia: A Cognitive and Functional Magnetic Resonance Imaging Perspective. , 2017, , 357-371.		0
1083	Cannabis Users and Premorbid Intellectual Quotient. , 2017, , 223-233.		1
1084	Cannabis use in persons with traumatic spinal cord injury in Denmark. Journal of Rehabilitation Medicine, 2017, 49, 152-160.	0.8	16
1085	Cannabis Use and Its Association to Mental Illness: A Focus on Mood and Anxiety Disorders. , 2017, , 298-307.		9
1086	Mental Health and Cannabis Abusers of Kashmir Valley. , 2017, 07, .		2
1087	Pharmacology of Marijuana. Journal of Addiction Research & Therapy, 0, S11, .	0.2	6
1088	Evidence for the use of "medical marijuana" in psychiatric and neurologic disorders. Mental Health Clinician, 2017, 7, 29-38.	0.5	20
1089	Potency of ⁹ tetrahydrocannabinol and other cannabinoids in cannabis in England in 2016: Implications for public health and pharmacology. Drug Testing and Analysis, 2018, 10, 628-635.	1.6	59
1091	Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of ⁹ -THC. Psychological Medicine, 2018, 48, 2748-2756.	2.7	11
1092	Adolescent cannabis use, baseline prodromal symptoms and the risk of psychosis. British Journal of Psychiatry, 2018, 212, 227-233.	1.7	72
1093	Does thinner right entorhinal cortex underlie genetic liability to cannabis use?. Psychological Medicine, 2018, 48, 2766-2775.	2.7	11
1094	Does integrated academic and health education prevent substance use? <sc>S</sc>ystematic review and meta-analyses. Child: Care, Health and Development, 2018, 44, 516-530.	0.8	12
1095	Clinical and functional outcomes of cannabis use among individuals with anxiety disorders: A 3-year population-based longitudinal study. Depression and Anxiety, 2018, 35, 490-501.	2.0	18
1096	Marijuana Use by Adolescents and Young Adults with Inflammatory Bowel Disease. Journal of Pediatrics, 2018, 199, 99-105.	0.9	30
1097	Mental Health and Substance Use Disorder Comorbidity among Methamphetamine-Using Men Who have Sex with Men. Journal of Psychoactive Drugs, 2018, 50, 206-213.	1.0	27
1098	Developmental sensitivity to cannabis use patterns and risk for major depressive disorder in mid-life: findings from 40 years of follow-up. Psychological Medicine, 2018, 48, 2169-2176.	2.7	47
1099	Commentary on Degenhardt <i>et al.</i> (2018): Cause or consequence? Disentangling the relationship between psychosis and substance use. Addiction, 2018, 113, 935-936.	1.7	4

#	ARTICLE	IF	CITATIONS
1100	Medical cannabis: An oxymoron? Physicians'™ perceptions of medical cannabis. <i>International Journal of Drug Policy</i> , 2018, 57, 4-10.	1.6	62
1101	Gene's environment interplay in the etiology of psychosis. <i>Psychological Medicine</i> , 2018, 48, 1925-1936.	2.7	89
1102	Association of Combined Patterns of Tobacco and Cannabis Use in Adolescence With Psychotic Experiences. <i>JAMA Psychiatry</i> , 2018, 75, 240.	6.0	46
1103	Cannabinoids and the Brain: The Effects of Endogenous and Exogenous Cannabinoids on Brain Systems and Function. , 2018, , 37-74.		6
1104	Psychotomimetic and Cognitive Effects of Cannabis Use in the General Population. , 2018, , 129-155.		3
1105	Effects of Cannabis Use in Those at Ultra-High Risk for Psychosis. , 2018, , 167-181.		4
1106	Time to acknowledge the mixed effects of cannabis on health: a summary and critical review of the NASEM 2017 report on the health effects of cannabis and cannabinoids. <i>Addiction</i> , 2018, 113, 958-966.	1.7	35
1107	Evidence that reduced gray matter volume in psychotic disorder is associated with exposure to environmental risk factors. <i>Psychiatry Research - Neuroimaging</i> , 2018, 271, 100-110.	0.9	21
1108	Drug-Use Disorders. , 0, , 243-262.		3
1109	From Maps to Multi-dimensional Network Mechanisms of Mental Disorders. <i>Neuron</i> , 2018, 97, 14-31.	3.8	146
1110	Association of Substance Use Disorders With Conversion From Schizotypal Disorder to Schizophrenia. <i>JAMA Psychiatry</i> , 2018, 75, 733.	6.0	21
1111	Effects of Co-occurring marijuana use and anxiety on brain structure and functioning: A systematic review of adolescent studies. <i>Journal of Adolescence</i> , 2018, 65, 177-188.	1.2	6
1112	Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users: A Pragmatic Open-Label Clinical Trial. <i>Cannabis and Cannabinoid Research</i> , 2018, 3, 21-34.	1.5	93
1113	Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders. <i>Journal of Psychopharmacology</i> , 2018, 32, 825-849.	2.0	37
1114	Residual effects of cannabis use in adolescent and adult brains – A meta-analysis of fMRI studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 88, 26-41.	2.9	69
1115	Social integration and substance use: assessing the effects of an early intervention programme for youth. <i>Microbial Biotechnology</i> , 2018, 12, 426-432.	0.9	1
1116	Substance use and at-risk mental state for psychosis in 2102 prisoners: the case for early detection and early intervention in prison. <i>Microbial Biotechnology</i> , 2018, 12, 400-409.	0.9	11
1117	Interaction between cannabis consumption and childhood abuse in psychotic disorders: preliminary findings on the role of different patterns of cannabis use. <i>Microbial Biotechnology</i> , 2018, 12, 135-142.	0.9	27

#	ARTICLE	IF	CITATIONS
1118	The effects of cannabis use on salience attribution: a systematic review. <i>Acta Neuropsychiatrica</i> , 2018, 30, 43-57.	1.0	23
1119	The relative prevalence of schizophrenia among cannabis and cocaine users attending addiction services. <i>Schizophrenia Research</i> , 2018, 194, 13-17.	1.1	15
1120	Cannabis use and risk of schizophrenia: a Mendelian randomization study. <i>Molecular Psychiatry</i> , 2018, 23, 1287-1292.	4.1	167
1121	Effects of extended cannabis abstinence on clinical symptoms in cannabis dependent schizophrenia patients versus non-psychiatric controls. <i>Schizophrenia Research</i> , 2018, 194, 55-61.	1.1	18
1122	Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study. <i>Schizophrenia Research</i> , 2018, 194, 32-38.	1.1	20
1123	Pharmacogenetics of Cannabinoids. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2018, 43, 1-12.	0.6	69
1124	Gene-environment interaction and psychiatric disorders: Review and future directions. <i>Seminars in Cell and Developmental Biology</i> , 2018, 77, 133-143.	2.3	199
1125	Sensorimotor gating deficits in "two-hit" models of schizophrenia risk factors. <i>Schizophrenia Research</i> , 2018, 198, 68-83.	1.1	34
1126	Psychosocial and cessation-related differences between tobacco-marijuana co-users and single product users in a college student population. <i>Addictive Behaviors</i> , 2018, 77, 21-27.	1.7	15
1127	Risk factors in early and late onset schizophrenia. <i>Comprehensive Psychiatry</i> , 2018, 80, 155-162.	1.5	58
1128	Intra-individual variability and psychotic-like experiences in adolescents: Findings from the ALSPAC cohort. <i>Schizophrenia Research</i> , 2018, 195, 154-159.	1.1	4
1129	Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis. <i>American Journal of Psychiatry</i> , 2018, 175, 343-350.	4.0	153
1130	Treated Incidence of Psychotic Disorders in the Multinational EU-GEI Study. <i>JAMA Psychiatry</i> , 2018, 75, 36.	6.0	235
1131	The efficacy of computerized interventions to reduce cannabis use: A systematic review and meta-analysis. <i>Addictive Behaviors</i> , 2018, 79, 52-60.	1.7	39
1132	Cortical thickness, cortical surface area and subcortical volumes in schizophrenia and bipolar disorder patients with cannabis use. <i>European Neuropsychopharmacology</i> , 2018, 28, 37-47.	0.3	13
1133	Motivation, health-related lifestyles and depression among university students: A longitudinal analysis. <i>Psychiatry Research</i> , 2018, 260, 412-417.	1.7	25
1134	Is there a common vulnerability in cannabis phenomenology and schizotypy? The role of the N170 ERP. <i>Schizophrenia Research</i> , 2018, 197, 444-450.	1.1	2
1135	Negative affectivity as a mechanism underlying perceived distress tolerance and cannabis use problems, barriers to cessation, and self-efficacy for quitting among urban cannabis users. <i>Addictive Behaviors</i> , 2018, 78, 216-222.	1.7	13

#	ARTICLE	IF	CITATIONS
1136	Long lasting effects of chronic WIN55,212-2 treatment on mesostriatal dopaminergic and cannabinoid systems in the rat brain. <i>Neuropharmacology</i> , 2018, 129, 1-15.	2.0	17
1137	Incidence of child and adolescent mental disorders in children aged 0-17 with familial high risk for severe mental illness - A Danish register study. <i>Schizophrenia Research</i> , 2018, 197, 298-304.	1.1	52
1138	PASS: School-based prevention addressing cannabis culture-related beliefs. <i>Drugs: Education, Prevention and Policy</i> , 2018, 25, 164-172.	0.8	1
1139	Pharmacies as potential providers of harm reduction services: A preliminary online survey. <i>Drug Science, Policy and Law</i> , 2018, 4, 205032451876744.	0.6	4
1141	Drug Use Disorders. , 0, , 236-250.		0
1143	Cannabis Use Among Remote Indigenous Australians: Opportunities to Support Change Identified in Two Waves of Sampling. <i>Frontiers in Public Health</i> , 2018, 6, 310.	1.3	0
1144	A Budding Cannabis Cottage-Industry has set the stage for an Impending Public Health Crisis. <i>Pharmaceutical Regulatory Affairs: Open Access</i> , 2018, 07, .	0.2	0
1145	Sex and Age Differences in Risk Factors of Marijuana Involvement During Adolescence. <i>Addictive Disorders and Their Treatment</i> , 2018, 17, 29-39.	0.5	7
1146	Cannabis consumption and psychosis or schizophrenia development. <i>International Journal of Social Psychiatry</i> , 2018, 64, 690-704.	1.6	66
1147	Examining the Association and Directionality between Mental Health Disorders and Substance Use among Adolescents and Young Adults in the U.S. and Canadaâ€”A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2018, 7, 543.	1.0	74
1148	Mental health profile and health-related behavior among Hong Kong Chinese university students. <i>Health Psychology Open</i> , 2018, 5, 205510291878686.	0.7	16
1150	New Perspectives on the Use of Cannabis in the Treatment of Psychiatric Disorders. <i>Medicines (Basel)</i> , Tj ETQq1 1 0,784314 rBT /Overl	0.7	30
1151	Maternal Cannabis Use During a Child's Lifetime Associated With Earlier Initiation. <i>American Journal of Preventive Medicine</i> , 2018, 55, 592-602.	1.6	15
1152	A Biological/Genetic Perspective: The Addicted Brain. <i>Issues in Children's and Families' Lives</i> , 2018, , 23-65.	0.2	0
1153	Neurocognitive effects of cannabis: Lessons learned from human experimental studies. <i>Progress in Brain Research</i> , 2018, 242, 179-216.	0.9	16
1154	Le cannabis et ses effets d'Ã©tÃ©res : pour un dÃ©bat plus nuancÃ©. <i>Drogues, SantÃ© Et SociÃ©tÃ©</i> , 0, 16, 5-30.		2
1155	Hallucinations in the Substance-Induced Psychosis. , 2018, , 57-83.		0
1157	Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis. <i>JAMA Psychiatry</i> , 2018, 75, 1107.	6.0	113

#	ARTICLE	IF	CITATIONS
1159	Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. <i>Pain</i> , 2018, 159, 1932-1954.	2.0	321
1160	The relationship between the level of exposure to stress factors and cannabis in recent onset psychosis. <i>Schizophrenia Research</i> , 2018, 201, 352-359.	1.1	24
1161	Genetic vulnerability to schizophrenia is associated with cannabis use patterns during adolescence. <i>Drug and Alcohol Dependence</i> , 2018, 190, 143-150.	1.6	29
1162	Impact of cannabis legalization on treatment and research priorities for cannabis use disorder. <i>International Review of Psychiatry</i> , 2018, 30, 216-225.	1.4	17
1163	Disturbances of postural sway components in cannabis users. <i>Drug and Alcohol Dependence</i> , 2018, 190, 54-61.	1.6	17
1164	Modulation of acute effects of delta-9-tetrahydrocannabinol on psychotomimetic effects, cognition and brain function by previous cannabis exposure. <i>European Neuropsychopharmacology</i> , 2018, 28, 850-862.	0.3	22
1165	Cannabis use and the development of tolerance: a systematic review of human evidence. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 93, 1-25.	2.9	101
1166	Brief interventions for cannabis use in emerging adults: protocol for a systematic review, meta-analysis, and evidence map. <i>Systematic Reviews</i> , 2018, 7, 106.	2.5	12
1167	The role of cannabinoids in pain control: the good, the bad, and the ugly. <i>Minerva Anestesiologica</i> , 2018, 84, 955-969.	0.6	21
1168	Larger Gray Matter Volume in the Basal Ganglia of Heavy Cannabis Users Detected by Voxel-Based Morphometry and Subcortical Volumetric Analysis. <i>Frontiers in Psychiatry</i> , 2018, 9, 175.	1.3	28
1169	Medical cannabis legalization and state-level prevalence of serious mental illness in the National Survey on Drug Use and Health (NSDUH) 2008-2015. <i>International Review of Psychiatry</i> , 2018, 30, 203-215.	1.4	12
1170	The Pediatrician and Marijuana. <i>Advances in Pediatrics</i> , 2018, 65, 159-171.	0.5	2
1171	Marijuana and Psychosis: Policy Implications for Treatment Providers. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2018, 57, 613-614.	0.3	6
1172	Epidemiology of adolescent substance use in Norfolk schools. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2018, 111, 699-706.	0.2	5
1173	Cannabis Use, Psychotic Like Experiences and Aberrant Salience in a Sample of Belgian Students. <i>Journal of Nervous and Mental Disease</i> , 2018, 206, 493-500.	0.5	13
1174	Maternal and paternal cannabis use during pregnancy and the risk of psychotic-like experiences in the offspring. <i>Schizophrenia Research</i> , 2018, 202, 322-327.	1.1	38
1175	Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention. <i>CNS Drugs</i> , 2018, 32, 605-619.	2.7	36
1176	Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: Systematic review and meta-analysis. <i>Drug and Alcohol Dependence</i> , 2018, 191, 234-258.	1.6	271

#	ARTICLE	IF	CITATIONS
1177	GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal effect of schizophrenia liability. <i>Nature Neuroscience</i> , 2018, 21, 1161-1170.	7.1	436
1178	Longitudinal assessment of the effect of cannabis use on hospital readmission rates in early psychosis: A 6-year follow-up in an inpatient cohort. <i>Psychiatry Research</i> , 2018, 268, 381-387.	1.7	28
1179	The adverse health effects and harms related to marijuana use: an overview review. <i>CMAJ Open</i> , 2018, 6, E339-E346.	1.1	79
1180	Psychosis and synthetic cannabinoids. <i>Psychiatry Research</i> , 2018, 268, 400-412.	1.7	48
1181	Psychological mediators of the association between childhood adversities and psychosis: A systematic review. <i>Clinical Psychology Review</i> , 2018, 65, 175-196.	6.0	76
1182	Substance abuse and dependence. , 2018, , 675-688.		0
1183	Probing the endocannabinoid system in healthy volunteers: Cannabidiol alters fronto-striatal resting-state connectivity. <i>European Neuropsychopharmacology</i> , 2018, 28, 841-849.	0.3	41
1184	Psychosis in Emerging Adulthood: Phenomenological, Diagnostic, and Clinical Considerations. <i>Evidence-Based Practice in Child and Adolescent Mental Health</i> , 2019, 4, 141-156.	0.7	10
1185	The interaction between the ZNF804A gene and cannabis use on the risk of psychosis in a non-clinical sample. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 89, 174-180.	2.5	11
1186	Cannabidiol (CBD) use in psychiatric disorders: A systematic review. <i>NeuroToxicology</i> , 2019, 74, 282-298.	1.4	107
1187	A review of the anesthetic implications of marijuana use. <i>Baylor University Medical Center Proceedings</i> , 2019, 32, 364-371.	0.2	29
1188	Novel Biological Treatment Strategies. , 2019, , 221-240.		0
1189	Brief Interventions for Cannabis Problems in the Postsecondary Setting: a Systematic Review. <i>International Journal of Mental Health and Addiction</i> , 2019, 17, 681-698.	4.4	3
1191	Reward, Control & Decision-Making in Cannabis Use Disorder: Insights from Functional MRI. <i>British Journal of Radiology</i> , 2019, 92, 20190165.	1.0	7
1192	Schizophrenia is associated with increased risk of subsequent substance abuse diagnosis: A nationwide population-based register study. <i>Addiction</i> , 2019, 114, 2217-2226.	1.7	20
1194	A Psychometric Evaluation of User-Generated Cannabis Use Motives in German University Students. <i>International Journal of Mental Health and Addiction</i> , 2019, 17, 445-466.	4.4	1
1196	The efficacy of spiritual/religious interventions for substance use problems: A systematic review and meta-analysis of randomized controlled trials. <i>Drug and Alcohol Dependence</i> , 2019, 202, 134-148.	1.6	48
1197	The association between health conditions and cannabis use in patients with opioid use disorder receiving methadone maintenance treatment. <i>BJPsych Open</i> , 2019, 5, e91.	0.3	7

#	ARTICLE	IF	CITATIONS
1198	Kynurenines and the Endocannabinoid System in Schizophrenia: Common Points and Potential Interactions. <i>Molecules</i> , 2019, 24, 3709.	1.7	16
1199	Brief interventions for cannabis use in emerging adults: A systematic review, meta-analysis, and evidence map. <i>Drug and Alcohol Dependence</i> , 2019, 204, 107565.	1.6	56
1200	Active cannabis marketing and adolescent past-year cannabis use. <i>Drug and Alcohol Dependence</i> , 2019, 204, 107548.	1.6	29
1201	Cannabis, Brain Impact, and Legalization in the United States. <i>Archives of Medical Research</i> , 2019, 50, 269-270.	1.5	1
1202	Public health implications of legalising the production and sale of cannabis for medicinal and recreational use. <i>Lancet, The</i> , 2019, 394, 1580-1590.	6.3	224
1204	Cannabis use and physical activity among 89,777 adolescents aged 12-15 years from 21 low- and middle-income countries. <i>Drug and Alcohol Dependence</i> , 2019, 205, 107584.	1.6	7
1205	Implementing social justice in the transition from illicit to legal cannabis. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 673-688.	1.1	51
1206	Guidelines for public health and safety metrics to evaluate the potential harms and benefits of cannabis regulation in Canada. <i>Drug and Alcohol Review</i> , 2019, 38, 606-621.	1.1	21
1207	Relationships between Problematic Cannabis Use and Risky Behaviors in Spanish Adolescents. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 3029.	1.2	6
1208	Does the Fast Track Intervention Prevent Later Psychosis Symptoms?. <i>Prevention Science</i> , 2019, 20, 1255-1264.	1.5	2
1209	An Investigation of Neurochemical Changes in Chronic Cannabis Users. <i>Frontiers in Human Neuroscience</i> , 2019, 13, 318.	1.0	13
1210	Legalized Cannabis in Colorado Emergency Departments: A Cautionary Review of Negative Health and Safety Effects. <i>Western Journal of Emergency Medicine</i> , 2019, 20, 557-572.	0.6	42
1211	Insights into the role of cannabis in the management of inflammatory bowel disease. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481987097.	1.4	25
1212	Association of Genetic Liability to Psychotic Experiences With Neuropsychotic Disorders and Traits. <i>JAMA Psychiatry</i> , 2019, 76, 1256.	6.0	112
1213	Relationships between intra-individual variability and subclinical psychosis. <i>Psychiatry Research</i> , 2019, 281, 112592.	1.7	7
1214	Prevalence and correlates of cannabis poisoning diagnosis in a national emergency department sample. <i>Drug and Alcohol Dependence</i> , 2019, 204, 107564.	1.6	15
1215	A randomised controlled trial of vaporised δ^9 -tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 17-35.	1.8	136
1216	The Relationship Between Dissociative Experiences and Cannabis Use: a Systematic Review. <i>Current Addiction Reports</i> , 2019, 6, 21-33.	1.6	6

#	ARTICLE	IF	CITATIONS
1217	Impact of Medical Marijuana Legalization on Opioid Use, Chronic Opioid Use, and High-risk Opioid Use. <i>Journal of General Internal Medicine</i> , 2019, 34, 1419-1426.	1.3	46
1218	The Indian Hemp Drugs Commission 1893â€“1894. <i>Addiction</i> , 2019, 114, 1679-1682.	1.7	5
1219	Association of smoked cannabis with treatment resistance in schizophrenia. <i>Psychiatry Research</i> , 2019, 278, 242-247.	1.7	8
1220	High-potency cannabis and incident psychosis: correcting the causal assumption. <i>Lancet Psychiatry</i> , 2019, 6, 464-465.	3.7	5
1221	Incidence of treated first episode psychosis from an Australian early intervention service and its association with neighbourhood characteristics. <i>Schizophrenia Research</i> , 2019, 209, 206-211.	1.1	24
1222	Introducing the evidence-based population health tool of the Lower-Risk Cannabis Use Guidelines to Brazil. <i>Revista Brasileira De Psiquiatria</i> , 2019, 41, 550-555.	0.9	12
1223	Pesticides and trace elements in cannabis: Analytical and environmental challenges and opportunities. <i>Journal of Environmental Sciences</i> , 2019, 85, 82-93.	3.2	31
1224	Descriptive Psychopathology of the Acute Effects of Intravenous Delta-9-Tetrahydrocannabinol Administration in Humans. <i>Brain Sciences</i> , 2019, 9, 93.	1.1	17
1225	Hospital Stay in Synthetic Cannabinoid Users With Bipolar Disorder, Schizophrenia, or Other Psychotic Disorders Compared With Cannabis Users. <i>Journal of Studies on Alcohol and Drugs</i> , 2019, 80, 230-235.	0.6	3
1226	Effects in rats of adolescent exposure to cannabis smoke or THC on emotional behavior and cognitive function in adulthood. <i>Psychopharmacology</i> , 2019, 236, 2773-2784.	1.5	58
1227	International incidence of psychotic disorders, 2002â€“17: a systematic review and meta-analysis. <i>Lancet Public Health</i> , 2019, 4, e229-e244.	4.7	176
1228	Detection and early intervention for psychosis. <i>InnovAiT</i> , 2019, 12, 67-71.	0.0	3
1229	Trends of Major Depressive Episode among People with Cannabis Use: Findings from the National Survey on Drug use and Health 2006â€“2015. <i>Substance Abuse</i> , 2019, 40, 178-184.	1.1	14
1230	The adverse effects of marijuana use: The present state and future directions. <i>Journal of Child and Adolescent Substance Abuse</i> , 2019, 28, 65-72.	0.5	1
1231	Cannabinoids, interoception, and anxiety. <i>Pharmacology Biochemistry and Behavior</i> , 2019, 180, 60-73.	1.3	24
1232	Illicit drug use and prescription drug misuse among young adult medical cannabis patients and non-patient users in Los Angeles. <i>Drug and Alcohol Dependence</i> , 2019, 198, 21-27.	1.6	17
1233	Screen of drug use: Diagnostic accuracy for cannabis use disorder. <i>Addictive Behaviors</i> , 2019, 95, 184-188.	1.7	6
1234	Acute effects of Δ^9 -tetrahydrocannabinol (THC) on resting state brain function and their modulation by COMT genotype. <i>European Neuropsychopharmacology</i> , 2019, 29, 766-776.	0.3	20

#	ARTICLE	IF	CITATIONS
1235	The Potential of Cannabinoid-Based Treatments in Tourette Syndrome. <i>CNS Drugs</i> , 2019, 33, 417-430.	2.7	24
1236	Epidemiology and Historical Drug Use Patterns. , 2019, , 3-14.		0
1237	Analyzing DNA methylation patterns in subjects diagnosed with schizophrenia using machine learning methods. <i>Journal of Psychiatric Research</i> , 2019, 114, 41-47.	1.5	19
1238	Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis. <i>Psychopharmacology</i> , 2019, 236, 2677-2685.	1.5	26
1239	Cannabinoid interventions for PTSD: Where to next?. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 93, 124-140.	2.5	52
1240	Cannabis, a potential treatment option in pediatric IBD? Still a long way to go. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 355-361.	1.3	3
1241	Exploring the association between alcohol, marijuana, and secondhand effects with rural college students. <i>Journal of Human Behavior in the Social Environment</i> , 2019, 29, 161-176.	1.1	2
1242	Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood. <i>JAMA Psychiatry</i> , 2019, 76, 426.	6.0	519
1244	The Relevance of Sex in the Association of Synthetic Cannabinoid Use With Psychosis and Agitation in an Inpatient Population. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	1.1	10
1245	Intrinsic Frontolimbic Connectivity and Mood Symptoms in Young Adult Cannabis Users. <i>Frontiers in Public Health</i> , 2019, 7, 311.	1.3	12
1246	Facilitators and Barriers to Participating in a Randomized Controlled Trial of a Psychological Therapy for Substance Use. <i>Journal of Nervous and Mental Disease</i> , 2019, 207, 487-496.	0.5	4
1247	Psychotic Disorders in Patients Who Use Synthetic Cannabinoids. <i>Journal of Psychiatric Practice</i> , 2019, 25, 485-490.	0.3	2
1248	Acute Mental Health Symptoms in Adolescent Marijuana Users. <i>JAMA Pediatrics</i> , 2019, 173, 185.	3.3	17
1249	The Association Between Cannabinoids and Psychosis. , 2019, , 127-155.		8
1250	Critical period plasticity-related transcriptional aberrations in schizophrenia and bipolar disorder. <i>Schizophrenia Research</i> , 2019, 207, 12-21.	1.1	15
1252	A systematic review of phytocannabinoid exposure on the endocannabinoid system: Implications for psychosis. <i>European Neuropsychopharmacology</i> , 2019, 29, 330-348.	0.3	33
1253	Cannabinoid receptor as a potential therapeutic target for Parkinson's Disease. <i>Brain Research Bulletin</i> , 2019, 146, 244-252.	1.4	20
1254	Implications of climate variability and change on urban and human health: A review. <i>Cities</i> , 2019, 91, 213-223.	2.7	59

#	ARTICLE	IF	CITATIONS
1255	Increased BDNF-TrkB signaling in the nucleus accumbens plays a role in the risk for psychosis after cannabis exposure during adolescence. <i>Pharmacology Biochemistry and Behavior</i> , 2019, 177, 61-68.	1.3	7
1256	The neuropsychopharmacology of cannabis: A review of human imaging studies. , 2019, 195, 132-161.		165
1257	Specific aspects of cognitive impulsivity are longitudinally associated with lower treatment retention and greater relapse in therapeutic community treatment. <i>Journal of Substance Abuse Treatment</i> , 2019, 96, 33-38.	1.5	40
1258	Genetic Predisposition vs Individual-Specific Processes in the Association Between Psychotic-like Experiences and Cannabis Use. <i>JAMA Psychiatry</i> , 2019, 76, 87.	6.0	40
1259	Cannabis-related cognitive impairment. <i>Anti-Cancer Drugs</i> , 2019, 30, 91-97.	0.7	14
1260	Medical Cannabis for Older Patients. <i>Drugs and Aging</i> , 2019, 36, 39-51.	1.3	69
1261	Cannabis and Cannabinoid Intoxication and Toxicity. , 2019, , 103-111.		3
1262	Functional hemispheric asymmetry and nicotine dependency as variables mediating neurobiological vulnerability to schizotypy in a non-clinical population of college students. <i>Personality and Individual Differences</i> , 2019, 137, 165-172.	1.6	0
1263	Interrelationships among depression, anxiety, flourishing, and cannabis use in youth. <i>Addictive Behaviors</i> , 2019, 89, 206-215.	1.7	29
1264	Addicted Media. , 2019, , 61-74.		0
1265	Age-varying effects of cannabis use frequency and disorder on symptoms of psychosis, depression and anxiety in adolescents and adults. <i>Addiction</i> , 2019, 114, 278-293.	1.7	78
1266	Psychotic-like experiences with cannabis use predict cannabis cessation and desire to quit: a cannabis discontinuation hypothesis. <i>Psychological Medicine</i> , 2019, 49, 103-112.	2.7	17
1267	Attitudes of Irish patients with chronic pain towards medicinal cannabis. <i>Irish Journal of Medical Science</i> , 2019, 188, 267-272.	0.8	5
1268	Complement system biomarkers in first episode psychosis. <i>Schizophrenia Research</i> , 2019, 204, 16-22.	1.1	53
1269	Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis. <i>Molecular Psychiatry</i> , 2020, 25, 3231-3240.	4.1	62
1270	Self-reported Cannabis Use and Changes in Body Mass Index, CD4 T-Cell Counts, and HIV-1 RNA Suppression in Treated Persons with HIV. <i>AIDS and Behavior</i> , 2020, 24, 1275-1280.	1.4	8
1271	Medical Marijuana Laws and Suicide. <i>Archives of Suicide Research</i> , 2020, 24, 204-217.	1.2	10
1272	Valuing the Relationship Between Drug and Alcohol Use and Life Satisfaction: Findings from the Crime Survey for England and Wales. <i>Journal of Happiness Studies</i> , 2020, 21, 877-898.	1.9	5

#	ARTICLE	IF	CITATIONS
1273	First break psychosis in a young military veteran with cannabis use disorder: an educational case report. <i>International Journal of Adolescent Medicine and Health</i> , 2020, 32, .	0.6	0
1274	Cannabis use and psychosis: a review of reviews. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 403-412.	1.8	123
1275	Cannabis Use and the Risk for Psychosis and Affective Disorders. <i>Journal of Dual Diagnosis</i> , 2020, 16, 22-42.	0.7	85
1276	Development of an addiction index and delineation 15-year trends of illicit drugs from the Taiwan national drug enhancement database. <i>Journal of Psychiatric Research</i> , 2020, 120, 131-136.	1.5	7
1277	Urbanicity: The need for new avenues to explore the link between urban living and psychosis. <i>Microbial Biotechnology</i> , 2020, 14, 398-409.	0.9	31
1278	Effects of Cannabis Use in Youth and Young Adults With Type 1 Diabetes: The Highs, the Lows, the Don't Knows. <i>Canadian Journal of Diabetes</i> , 2020, 44, 121-127.	0.4	11
1279	Altered Corticolimbic Control of the Nucleus Accumbens by Long-term δ^9 -Tetrahydrocannabinol Exposure. <i>Biological Psychiatry</i> , 2020, 87, 619-631.	0.7	20
1280	Childhood trauma and being at-risk for psychosis are associated with higher peripheral endocannabinoids. <i>Psychological Medicine</i> , 2020, 50, 1862-1871.	2.7	13
1281	Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use. <i>Schizophrenia Bulletin</i> , 2020, 46, 517-529.	2.3	14
1282	Spontaneous discontinuation of distressing auditory verbal hallucinations in a school-based sample of adolescents: a longitudinal study. <i>European Child and Adolescent Psychiatry</i> , 2020, 29, 777-790.	2.8	5
1283	The Changing Legal Landscape of Cannabis Use and Its Role in Youth-onset Psychosis. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2020, 29, 145-156.	1.0	13
1284	Evidence for causal effects of lifetime smoking on risk for depression and schizophrenia: a Mendelian randomisation study. <i>Psychological Medicine</i> , 2020, 50, 2435-2443.	2.7	324
1285	Cannabis use in early adulthood is prospectively associated with prescriptions of antipsychotics, mood stabilizers, and antidepressants. <i>Acta Psychiatrica Scandinavica</i> , 2020, 141, 149-156.	2.2	6
1286	Life-course trajectories of cannabis use: a latent class analysis of a New Zealand birth cohort. <i>Addiction</i> , 2020, 115, 279-290.	1.7	30
1287	Adolescent-onset heavy cannabis use associated with significantly reduced glial but not neuronal markers and glutamate levels in the hippocampus. <i>Addiction Biology</i> , 2020, 25, e12827.	1.4	11
1288	Standard THC units™: a proposal to standardize dose across all cannabis products and methods of administration. <i>Addiction</i> , 2020, 115, 1207-1216.	1.7	129
1289	Adverse events following cannabis for medical use in Tuscany: An analysis of the Italian Phytovigilance database. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 106-120.	1.1	25
1290	δ^9 -Tetrahydrocannabinol Increases Dopamine D1-D2 Receptor Heteromer and Elicits Phenotypic Reprogramming in Adult Primate Striatal Neurons. <i>iScience</i> , 2020, 23, 100794.	1.9	22

#	ARTICLE	IF	CITATIONS
1291	Marijuana use in undergraduate students: the short-term relationship between motives and frequency of use. <i>Journal of Substance Use</i> , 2020, 25, 284-289.	0.3	4
1292	Cannabis Use in Children With Pantothenate Kinase-Associated Neurodegeneration. <i>Journal of Child Neurology</i> , 2020, 35, 259-264.	0.7	2
1293	Rapid increase in the prevalence of cannabis use among people with depression in the United States, 2005-2017: the role of differentially changing risk perceptions. <i>Addiction</i> , 2020, 115, 935-943.	1.7	52
1294	Moderating role of cannabis use between insight and depression in early psychosis. <i>Schizophrenia Research</i> , 2020, 215, 61-65.	1.1	6
1295	Mental Health and Medical Cannabis Use among Youth and Young Adults in Canada. <i>Substance Use and Misuse</i> , 2020, 55, 582-589.	0.7	7
1296	Contexts of Marijuana Use and Cessation among Frequently-Using Youth in Primary Care. <i>Youth and Society</i> , 2022, 54, 43-67.	1.3	2
1297	The Safety of Phytocannabinoids and Cannabinoids in Clinical Practice. , 2020, , 55-69.		0
1298	Hazardous or not? Cannabis use and early labor market experiences of young men. <i>Health Economics (United Kingdom)</i> , 2020, 29, 1148-1160.	0.8	3
1299	Cannabis use-related working memory deficit mediated by lower left hippocampal volume. <i>Addiction Biology</i> , 2021, 26, e12984.	1.4	5
1300	Genetic counselling for the prevention of mental health consequences of cannabis use: A randomized controlled trial within a cohort. <i>Microbial Biotechnology</i> , 2020, 15, 1306-1314.	0.9	1
1301	Early cannabis initiation: Substance use and mental health profiles of service-seeking youth. <i>Journal of Adolescence</i> , 2020, 83, 112-121.	1.2	34
1302	Network analysis of psychotic manifestations among cocaine users. <i>Journal of Psychiatric Research</i> , 2020, 130, 300-305.	1.5	2
1303	The Effects of Cannabis Use on the Development of Adolescents and Young Adults. <i>Annual Review of Developmental Psychology</i> , 2020, 2, 461-483.	1.4	37
1304	The effects of Cannabis on hallucinations in Parkinson's disease patients. <i>Journal of the Neurological Sciences</i> , 2020, 419, 117206.	0.3	5
1305	Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Emotion, Cognition, and Attention: A Double-Blind, Placebo-Controlled, Randomized Experimental Trial in Healthy Volunteers. <i>Frontiers in Psychiatry</i> , 2020, 11, 576877.	1.3	20
1306	Cannabis use and the risk of anxiety and depression in women: A comparison of three Swedish cohorts. <i>Drug and Alcohol Dependence</i> , 2020, 216, 108332.	1.6	4
1307	Caractéristiques et particularités des homicides commis par des schizophréniques. <i>Annales Medico-Psychologiques</i> , 2020, , .	0.2	0
1308	Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. <i>Psychological Medicine</i> , 2021, 51, 2074-2082.	2.7	7

#	ARTICLE	IF	CITATIONS
1309	THC Exposure is Reflected in the Microstructure of the Cerebral Cortex and Amygdala of Young Adults. <i>Cerebral Cortex</i> , 2020, 30, 4949-4963.	1.6	7
1310	Persistent cannabis use among young adults with early psychosis receiving coordinated specialty care in the United States. <i>Schizophrenia Research</i> , 2020, 222, 274-282.	1.1	15
1311	Too young for Cannabis? Choice of minimum legal age for legalized non-medical Cannabis in Canada. <i>BMC Public Health</i> , 2020, 20, 557.	1.2	4
1312	Association of High-Potency Cannabis Use With Mental Health and Substance Use in Adolescence. <i>JAMA Psychiatry</i> , 2020, 77, 1044.	6.0	100
1313	Examining pathways between genetic liability for schizophrenia and patterns of tobacco and cannabis use in adolescence. <i>Psychological Medicine</i> , 2022, 52, 132-139.	2.7	7
1314	Measuring individual benefits of psychiatric treatment using longitudinal binary outcomes: Application to antipsychotic benefits in non-cannabis and cannabis users. <i>Journal of Biopharmaceutical Statistics</i> , 2020, 30, 916-940.	0.4	3
1315	The effect of the AKT1 gene and cannabis use on cognitive performance in healthy subjects. <i>Journal of Psychopharmacology</i> , 2020, 34, 990-998.	2.0	5
1317	A genetically informed study on the association of cannabis, alcohol, and tobacco smoking with suicide attempt. <i>Molecular Psychiatry</i> , 2021, 26, 5061-5070.	4.1	32
1318	Is there sufficient evidence that cannabis use is a risk factor for psychosis?. , 2020, , 305-331.		8
1319	The blind men and the elephant: Systematic review of systematic reviews of cannabis use related health harms. <i>European Neuropsychopharmacology</i> , 2020, 33, 1-35.	0.3	90
1320	Association of Marijuana, Mental Health, and Tobacco in Colorado. <i>Journal of Addiction Medicine</i> , 2020, 14, 48-55.	1.4	5
1321	Î”9-tetrahydrocannabinol: harmful even in low doses?. <i>Lancet Psychiatry</i> ,the, 2020, 7, 296-297.	3.7	3
1322	The interplay between childhood trauma, cognitive biases, and cannabis use on the risk of psychosis in nonclinical young adults in Poland. <i>European Psychiatry</i> , 2020, 63, e35.	0.1	20
1323	Associations between Recent and Cumulative Cannabis Use and Internalizing Problems in Boys from Adolescence to Young Adulthood. <i>Journal of Abnormal Child Psychology</i> , 2020, 48, 771-782.	3.5	11
1324	Cholecystokinin-Expressing Interneurons of the Medial Prefrontal Cortex Mediate Working Memory Retrieval. <i>Journal of Neuroscience</i> , 2020, 40, 2314-2331.	1.7	47
1326	Psychiatric Diagnoses and Treatment Preceding Schizophrenia in Adolescents Aged 9â€“17 Years. <i>Frontiers in Psychiatry</i> , 2020, 11, 487.	1.3	3
1327	Changes in patient health questionnaire (PHQ-9) scores in adults with medical authorization for cannabis. <i>BMC Public Health</i> , 2020, 20, 987.	1.2	10
1328	Adolescent cannabinoid exposure interacts with other risk factors in schizophrenia: A review of the evidence from animal models. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 116, 202-220.	2.9	11

#	ARTICLE	IF	CITATIONS
1329	Cannabis use among U.S. adolescents in the era of marijuana legalization: a review of changing use patterns, comorbidity, and health correlates. <i>International Review of Psychiatry</i> , 2020, 32, 221-234.	1.4	98
1330	Efficacy of the "Mismo" (Be Yourself) Program in Prevention of Cannabis Use in Adolescents. <i>International Journal of Mental Health and Addiction</i> , 2020, 19, 1214.	4.4	6
1331	Assessing the Role of Cannabis Use on Cortical Surface Structure in Adolescents and Young Adults: Exploring Gender and Aerobic Fitness as Potential Moderators. <i>Brain Sciences</i> , 2020, 10, 117.	1.1	10
1332	Cannabis use and nonuse in patients with first-episode psychosis: A systematic review and meta-analysis of studies comparing neurocognitive functioning. <i>European Psychiatry</i> , 2020, 63, e6.	0.1	17
1333	Factors Moderating the Association between Cannabis Use and Psychosis Risk: A Systematic Review. <i>Brain Sciences</i> , 2020, 10, 97.	1.1	47
1334	Predictors of bullying reported by perpetrators in a sample of senior school students in Benin City, Nigeria. <i>South African Journal of Psychiatry</i> , 2020, 26, 1359.	0.2	7
1335	Principles of risk, screening, and prevention in psychiatry. , 2020, , 11-43.		2
1336	Psychotic-like experiences in the general population. , 2020, , 119-141.		3
1337	Investigating the gut-brain axis in a neurodevelopmental rodent model of schizophrenia. <i>Brain, Behavior, & Immunity - Health</i> , 2020, 3, 100048.	1.3	11
1338	Substance use disorders before, at and after first episode psychosis hospitalizations in a young national Swedish cohort. <i>Drug and Alcohol Dependence</i> , 2020, 209, 107919.	1.6	3
1339	Do the effects of cannabis on the hippocampus and striatum increase risk for psychosis?. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 112, 324-335.	2.9	4
1340	Association between polygenic liability for schizophrenia and substance involvement: A nationwide population-based study in Taiwan. <i>Genes, Brain and Behavior</i> , 2020, 19, e12639.	1.1	9
1341	Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review. <i>BMC Psychiatry</i> , 2020, 20, 24.	1.1	130
1343	Parenting styles and metacognitions as predictors of cannabis use. <i>Addictive Behaviors Reports</i> , 2020, 11, 100259.	1.0	9
1344	Recreational Cannabis Usage Among Young Adults Living with Diabetes: Protocol for a Mixed Methods Study. <i>Diabetes Therapy</i> , 2020, 11, 1407-1417.	1.2	0
1345	A systematic review of technology-based psychotherapeutic interventions for decreasing cannabis use in patients with psychosis. <i>Psychiatry Research</i> , 2020, 288, 112940.	1.7	18
1346	Cannabis and the Developing Adolescent Brain. <i>Current Treatment Options in Psychiatry</i> , 2020, 7, 144-161.	0.7	20
1347	Cannabis Use Disorder Among First-Year Undergraduate Students in Gaborone, Botswana. <i>Substance Abuse: Research and Treatment</i> , 2020, 14, 117822182090413.	0.5	3

#	ARTICLE	IF	CITATIONS
1348	Adolescent cannabis use, cognition, brain health and educational outcomes: A review of the evidence. <i>European Neuropsychopharmacology</i> , 2020, 36, 169-180.	0.3	81
1349	L'expertise d'une équipe de liaison en addictologie pour adolescents en établissement soigné. <i>Neuropsychiatrie De L'Enfance Et De L'Adolescence</i> , 2020, 68, 175-184.	0.1	1
1350	Genome-wide DNA methylation analysis of heavy cannabis exposure in a New Zealand longitudinal cohort. <i>Translational Psychiatry</i> , 2020, 10, 114.	2.4	28
1351	Nitrous Oxide Inhalant Use Disorder Preceding Symptoms Concerning for Primary Psychotic Illness. <i>American Journal on Addictions</i> , 2020, 29, 525-527.	1.3	8
1352	Associations between Psychiatric Disorders and Cannabis-Related Disorders Documented in Electronic Health Records. <i>Journal of Psychoactive Drugs</i> , 2020, 52, 228-236.	1.0	5
1353	A Cumulative Substance Use Score as a Novel Measure to Predict Risk of Criminal Recidivism in Forensic Juvenile Male Outpatients. <i>Child Psychiatry and Human Development</i> , 2021, 52, 30-40.	1.1	5
1354	Youth marijuana use: a review of causes and consequences. <i>Current Opinion in Psychology</i> , 2021, 38, 11-18.	2.5	28
1355	Cerebellar thickness changes associated with heavy cannabis use: A 3-year longitudinal study. <i>Addiction Biology</i> , 2021, 26, e12931.	1.4	10
1356	Risk of psychotic disorders in migrants to Australia. <i>Psychological Medicine</i> , 2021, 51, 1192-1200.	2.7	21
1357	Fatty acid amide hydrolase is lower in young cannabis users. <i>Addiction Biology</i> , 2021, 26, e12872.	1.4	21
1358	Differential Methylation Pattern of Schizophrenia Candidate Genes in Tetrahydrocannabinol-Consuming Treatment-Resistant Schizophrenic Patients Compared to Non-Consumer Patients and Healthy Controls. <i>Neuropsychobiology</i> , 2021, 80, 36-44.	0.9	5
1359	Hit the chronic physical activity: are cannabis associated mental health changes in adolescents attenuated by remaining active?. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2021, 56, 141-152.	1.6	3
1360	Cannabis, the cannabis referendum and Māori youth: a review from a lifecourse perspective. <i>Kotuitui: New Zealand Journal of Social Sciences Online</i> , 2021, 16, 1-17.	0.7	1
1361	Associations Between Prenatal Cannabis Exposure and Childhood Outcomes. <i>JAMA Psychiatry</i> , 2021, 78, 64.	6.0	156
1362	Cannabis Use and Prospective Long-Term Association with Anxiety: A Systematic Review and Meta-Analysis of Longitudinal Studies: Usage du cannabis et association prospective à long terme avec l'anxiété: une revue systématique et une méta-analyse d'études longitudinales. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 126-138.	0.9	25
1363	Cannabis use and mental health among young sexual and gender minority men: A qualitative study. <i>International Journal of Drug Policy</i> , 2021, 91, 102980.	1.6	10
1364	Marijuana, but not alcohol, use frequency associated with greater loneliness, psychological distress, and less flourishing among young adults. <i>Drug and Alcohol Dependence</i> , 2021, 218, 108404.	1.6	27
1365	Adolescent Gender Identity, Sexual Orientation, and Cannabis Use: Potential Mediations by Internalizing Disorder Risk. <i>Health Education and Behavior</i> , 2021, 48, 82-92.	1.3	5

#	ARTICLE	IF	CITATIONS
1366	Neuropathology of Drug Abuse. , 2021, , .		1
1367	Risk Factors for Cannabis-Related Mental Health Harms in Older Adults: A Review. Clinical Gerontologist, 2021, 44, 3-15.	1.2	15
1368	Cannabinoid use and self-injurious behaviours: A systematic review and meta-analysis. Journal of Affective Disorders, 2021, 278, 85-98.	2.0	26
1369	Systematic Review of Electronic Cigarette Use (Vaping) and Mental Health Comorbidity Among Adolescents and Young Adults. Nicotine and Tobacco Research, 2021, 23, 415-425.	1.4	85
1370	Annual incidence of cannabis-induced psychosis, other substance-induced psychoses and dually diagnosed schizophrenia and cannabis use disorder in Denmark from 1994 to 2016. Psychological Medicine, 2021, 51, 617-622.	2.7	27
1371	No evidence of associations between genetic liability for schizophrenia and development of cannabis use disorder. Psychological Medicine, 2021, 51, 479-484.	2.7	12
1372	Cannabis Policy and Use. , 2021, , .		0
1373	Motives and Perceptions of Cannabis Use among a Sample of Employed Graduates in Malaysia: A Qualitative Study. Emerging Trends in Drugs, Addictions, and Health, 2021, 1, 100013.	0.5	2
1374	Cannabis use and patterns among middle and older aged Canadians prior to legalization: a sex-specific analysis of the Canadian Tobacco, Alcohol and Drugs Survey. BMC Public Health, 2021, 21, 26.	1.2	8
1375	Adolescent neurocognitive development and cannabis use. , 2021, , 537-550.		1
1376	Psychosen, Schizophrenie. , 2021, , 195-209.		0
1377	The Experiences of People Who Use Drugs and Their Encounters with the Police in Ghana. , 2021, , 231-258.		0
1378	Effects of cannabis on visual function and self-perceived visual quality. Scientific Reports, 2021, 11, 1655.	1.6	16
1379	Endocannabinoid-serotonin systems interaction in health and disease. Progress in Brain Research, 2021, 259, 83-134.	0.9	14
1380	Cannabis and Psychosis: A Causal Association. , 2021, , 599-611.		0
1381	Cannabinoid-Related Adverse Events and Impairment. , 2021, , 293-306.		2
1382	Relaci3n entre consumo de sustancias y rasgos esquizot3picos en adolescentes escolarizados. Revista De Psicología De La Salud, 2021, 33, 19.	0.2	3
1383	Third external replication of an individualised transdiagnostic prediction model for the automatic detection of individuals at risk of psychosis using electronic health records. Schizophrenia Research, 2021, 228, 403-409.	1.1	10

#	ARTICLE	IF	CITATIONS
1384	Symptomatology and neurocognition among first-episode psychosis patients with and without cannabis use in the three months prior to first hospitalization. <i>Schizophrenia Research</i> , 2021, 228, 83-88.	1.1	5
1385	Cannabis use in Adolescence and Risk of Psychosis: Are there Factors that Moderate this Relationship? A Systematic Review and Meta-Analysis. <i>Substance Abuse</i> , 2021, 42, 527-542.	1.1	42
1386	Cannabis: A Toxin-Producing Plant with Potential Therapeutic Uses. <i>Toxins</i> , 2021, 13, 117.	1.5	55
1387	Are psychotic-like experiences related to a discontinuation of cannabis consumption in young adults?. <i>Schizophrenia Research</i> , 2021, 228, 271-279.	1.1	3
1388	Using epidemiological evidence to forecast population need for early treatment programmes in mental health: a generalisable Bayesian prediction methodology applied to and validated for first-episode psychosis in England. <i>British Journal of Psychiatry</i> , 2021, 219, 383-391.	1.7	16
1389	The Impact of Cannabis Abuse on Psychotic Symptoms and Their Severity among Cannabis Associated Psychosis Subjects: An Indian Experience. <i>Psychocentrum Review</i> , 2021, 3, 31-38.	0.0	0
1390	Prospects for the Use of Cannabinoids in Psychiatric Disorders. <i>Frontiers in Psychiatry</i> , 2021, 12, 620073.	1.3	17
1391	Bipolar disorder and cannabis use: A bidirectional two-sample Mendelian randomization study. <i>Addiction Biology</i> , 2021, 26, e13030.	1.4	9
1392	The Association between Recent Cannabis Use and Suicidal Ideation in Adults: A Population-based Analysis of the NHANES from 2005 to 2018. <i>Canadian Journal of Psychiatry</i> , 2022, 67, 260-268.	0.9	17
1393	Duration of Neurocognitive Impairment With Medical Cannabis Use: A Scoping Review. <i>Frontiers in Psychiatry</i> , 2021, 12, 638962.	1.3	21
1394	Cannabis Use and Nonfatal Opioid Overdose among Patients Enrolled in Methadone Maintenance Treatment. <i>Substance Use and Misuse</i> , 2021, 56, 697-703.	0.7	0
1395	Cannabis use among military veterans: A great deal to gain or lose?. <i>Clinical Psychology Review</i> , 2021, 84, 101958.	6.0	20
1396	Cannabis Effect on Female Reproductive Health. , 0, , .		1
1397	Cannabis use in patients treated for opioid use disorder pre- and post-recreational cannabis legalization in Canada. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2021, 16, 34.	1.0	3
1398	The Lived Experiences of Addiction Counselors After Marijuana Legalization. <i>Journal of Addictions and Offender Counseling</i> , 2021, 42, 35-49.	0.3	2
1400	Cannabidiol modulation of hippocampal glutamate in early psychosis. <i>Journal of Psychopharmacology</i> , 2021, 35, 814-822.	2.0	20
1401	Cannabis use, self-perceived risk, perceived peer approval and parental attitudes among youth at clinical high-risk for psychosis. <i>Microbial Biotechnology</i> , 2022, 16, 264-271.	0.9	3
1402	From heavy cannabis use to psychosis: is it time to take action?. <i>Irish Journal of Psychological Medicine</i> , 2023, 40, 13-18.	0.7	2

#	ARTICLE	IF	CITATIONS
1403	Schizophrenia: a classic battle ground of nature versus nurture debate. <i>Science Bulletin</i> , 2021, 66, 1037-1046.	4.3	4
1404	The Relationship Between Childhood Physical and Sexual Abuse and Adolescent Cannabis Use: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2021, 12, 631245.	1.3	18
1405	Cannabidiol for at risk for psychosis youth: A randomized controlled trial. <i>Microbial Biotechnology</i> , 2022, 16, 419-432.	0.9	9
1406	"Considerations for the Use of Medical Cannabis: An Overview of Benefits and Harms". <i>Biomedical Journal of Scientific & Technical Research</i> , 2021, 36, .	0.0	2
1407	Molecular Targets of Cannabinoids Associated with Depression. <i>Current Medicinal Chemistry</i> , 2022, 29, 1827-1850.	1.2	2
1408	Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review. <i>IBRO Neuroscience Reports</i> , 2021, 10, 109-118.	0.7	9
1409	Quemaduras en el contexto de un trastorno psicótico compartido en un centro de referencia colombiano: reporte de caso. <i>Revista Colombiana De Psiquiatría</i> , 2021, , .	0.1	0
1410	Substance use is associated with worse mental health and altered resting state functional connectivity in female university athletes at baseline: A pilot study. <i>PLoS ONE</i> , 2021, 16, e0253261.	1.1	3
1411	Associations of cannabis use frequency and cannabis use disorder with receiving a substance use screen and healthcare professional discussion of substance use. <i>American Journal on Addictions</i> , 2021, 30, 485-495.	1.3	1
1412	Cigarette Use and Cannabis Use Disorder Onset, Persistence, and Relapse. <i>Journal of Clinical Psychiatry</i> , 2021, 82, .	1.1	6
1413	Structural variations in the sulco-gyral pattern of the orbitofrontal cortex. <i>Translational Research in Anatomy</i> , 2021, 23, 100121.	0.3	0
1414	Medicinal cannabis: knowledge, beliefs, and attitudes of Colombian psychiatrists. <i>Journal of Cannabis Research</i> , 2021, 3, 26.	1.5	4
1415	Paliperidone to Treat Psychotic Disorders. <i>Neurology International</i> , 2021, 13, 343-358.	1.3	5
1416	A systematic review and meta-analysis of sex differences in cannabis use disorder amongst people with comorbid mental illness. <i>American Journal of Drug and Alcohol Abuse</i> , 2021, 47, 535-547.	1.1	13
1417	Adolescent cannabis use, depression and anxiety disorders in the Northern Finland Birth Cohort 1986. <i>BJPsych Open</i> , 2021, 7, .	0.3	6
1418	The New Jersey Perspective on Cannabis Legalization. <i>Adolescent Psychiatry (Hilversum, Netherlands)</i> , 2021, 11, .	0.1	0
1419	Wonder or evil?: Multifaceted health hazards and health benefits of Cannabis sativa and its phytochemicals. <i>Saudi Journal of Biological Sciences</i> , 2021, 28, 7290-7313.	1.8	24
1420	Do the Transmissible Liability Index (TLI) and Adolescent Cannabis Use Predict Paranoid and Schizotypal Symptoms at Young Adulthood?. <i>Substance Use and Misuse</i> , 2021, 56, 1-9.	0.7	2

#	ARTICLE	IF	CITATIONS
1421	A Review of the Potential Use of Pinene and Linalool as Terpene-Based Medicines for Brain Health: Discovering Novel Therapeutics in the Flavours and Fragrances of Cannabis. <i>Frontiers in Psychiatry</i> , 2021, 12, 583211.	1.3	48
1422	Early, Chronic, and Acute Cannabis Exposure and Their Relationship With Cognitive and Behavioral Harms. <i>Frontiers in Psychiatry</i> , 2021, 12, 643556.	1.3	3
1423	Religiosity and substance use in U.S. adults: Findings from a large-scale national survey. <i>Drug and Alcohol Dependence</i> , 2021, 225, 108796.	1.6	12
1424	Incidence rates and employment trends in schizophrenia spectrum disorders, bipolar affective disorders and recurrent depression in the years 2000–2013: a Danish nationwide register-based study. <i>Nordic Journal of Psychiatry</i> , 2022, 76, 225-232.	0.7	4
1425	THC-induced behavioral stereotypy in zebrafish as a model of psychosis-like behavior. <i>Scientific Reports</i> , 2021, 11, 15693.	1.6	5
1426	Medicinal cannabis in children and adolescents with autism spectrum disorder: A scoping review. <i>Child: Care, Health and Development</i> , 2022, 48, 33-44.	0.8	7
1427	Adolescent cannabis use and adult psychoticism: A longitudinal co-twin control analysis using data from two cohorts.. <i>Journal of Abnormal Psychology</i> , 2021, 130, 691-701.	2.0	5
1428	Independent contribution of polygenic risk for schizophrenia and cannabis use in predicting psychotic-like experiences in young adulthood: testing gene–environment moderation and mediation. <i>Psychological Medicine</i> , 2023, 53, 1759-1769.	2.7	7
1429	Development Over Time of the Population-Attributable Risk Fraction for Cannabis Use Disorder in Schizophrenia in Denmark. <i>JAMA Psychiatry</i> , 2021, 78, 1013.	6.0	41
1430	Effects of Cannabis Use on Psychotic and Mood Symptoms: A Systematic Review. <i>Canadian Journal of Addiction</i> , 2021, 12, 10-21.	0.2	5
1431	Generalized Anxiety Disorder 7-Item (GAD-7) Scores in Medically Authorized Cannabis Patients—Ontario and Alberta, Canada. <i>Canadian Journal of Psychiatry</i> , 2022, 67, 470-480.	0.9	10
1432	Cannabis and mental health: Prevalence of use and modes of cannabis administration by mental health status. <i>Addictive Behaviors</i> , 2021, 121, 106991.	1.7	18
1433	Associations between primary care recorded cannabis use and mental ill health in the UK: a population-based retrospective cohort study using UK primary care data. <i>Psychological Medicine</i> , 2021, , 1-10.	2.7	1
1434	Frequent teenage cannabis use: Prevalence across adolescence and associations with young adult psychopathology and functional well-being in an urban cohort. <i>Drug and Alcohol Dependence</i> , 2021, 228, 109063.	1.6	23
1435	Medical cannabis and cannabis-based medicine show both potential efficacy and potential harms: Cross-sectional comparison with controls on self-rated and interviewer-rated outcomes within the Danish pilot program on medical cannabis. <i>Complementary Therapies in Clinical Practice</i> , 2021, 45, 101476.	0.7	3
1436	The role of aberrant salience in the association between cannabis use frequency and psychotic experiences among racial and ethnic minoritized youth. <i>Schizophrenia Research</i> , 2021, 238, 36-43.	1.1	3
1437	Impaired P100 among regular cannabis users in response to magnocellular biased visual stimuli. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 113, 110437.	2.5	6
1438	Cannabis-Based Medicines in Fibromyalgia. , 2021, , 255-266.		0

#	ARTICLE	IF	CITATIONS
1441	Groundwork for the Treatment of Voices: Introducing the Coping-With-Voices Protocol. , 2012, , 375-384.		1
1443	Substance Misuse. Autism and Child Psychopathology Series, 2014, , 205-223.	0.1	4
1444	Investigation of Schizophrenia with Human Induced Pluripotent Stem Cells. Advances in Neurobiology, 2020, 25, 155-206.	1.3	11
1445	Cannabis and Depression. Advances in Experimental Medicine and Biology, 2021, 1264, 67-80.	0.8	38
1446	Substance-Induced Psychosis and Co-occurring Psychotic Disorders. Current Clinical Psychiatry, 2019, , 111-124.	0.2	3
1447	Understanding and Responding to Adolescent Risk-Taking Behaviours and Addictions in the School Setting. , 2017, , 435-455.		1
1448	Epidemiological Perspectives on Comorbidity Between Substance Use Disorders and Other Mental Disorders. , 2015, , 3-12.		17
1450	Medikamente zur Behandlung von AbhÄngigkeitserkrankungen und abhÄngigem Verhalten. , 2017, , 661-743.		1
1451	Adolescent and Substance Abuse. , 2015, , 2219-2247.		2
1452	Is a Neuroprotective Therapy Suitable for Schizophrenia Patients?. , 2010, , 343-395.		2
1455	Schizophrenia and related disorders. , 2012, , 259-286.		1
1457	Cannabis use during adolescence and the occurrence of depression, suicidality and anxiety disorder across adulthood: Findings from a longitudinal cohort study over 30 years. Journal of Affective Disorders, 2020, 272, 98-103.	2.0	36
1464	Chronic adolescent marijuana use as a risk factor for physical and mental health problems in young adult men.. Psychology of Addictive Behaviors, 2015, 29, 552-563.	1.4	90
1466	The use of cannabinoids for sleep: A critical review on clinical trials.. Experimental and Clinical Psychopharmacology, 2019, 27, 383-401.	1.3	79
1467	Consommation de cannabis: quels sont les risquesÂ?. Toxicologie Analytique Et Clinique, 2008, 20, 183-205.	0.1	8
1468	Harm Reduction Policies for Cannabis. , 2014, , 692-709.		1
1469	Co-Occurring Addiction and Psychiatric Disorders. , 2012, , 47-52.		3
1470	Adverse effects of heavy cannabis use. Pain, 2020, Publish Ahead of Print, S97-S104.	2.0	14

#	ARTICLE	IF	CITATIONS
1471	General risks of harm with cannabinoids, cannabis, and cannabis-based medicine possibly relevant to patients receiving these for pain management: an overview of systematic reviews. <i>Pain</i> , 2021, 162, S80-S96.	2.0	32
1473	Symptoms, adverse events, and outcomes in the use of medicinal cannabis in children and adolescents with autism spectrum disorder: a scoping review protocol. <i>JB Evidence Synthesis</i> , 2021, 19, 1251-1258.	0.6	1
1474	Severe multisystem dysfunction in a case of high level exposure to smoked cannabis. <i>BMJ Case Reports</i> , 2009, 2009, bcr0820080798-bcr0820080798.	0.2	6
1475	Misconceptions about gene-environment interactions in psychiatry. <i>Evidence-Based Mental Health</i> , 2010, 13, 65-68.	2.2	25
1476	Regional Variation in Attitude of Mental Health Professionals Towards Tackling Illicit Drug-use and Drug-related Disorders. <i>International Journal of Public Health Science</i> , 2017, 6, 172.	0.1	1
1477	Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies. <i>Journal of Clinical Investigation</i> , 2009, 119, 706-716.	3.9	202
1478	Stability of the diagnosis of first-episode drug-induced psychosis. <i>The Psychiatrist</i> , 2011, 35, 224-227.	0.3	13
1479	Neuropathic Pain. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2017, 23, 512-532.	0.4	64
1480	Adolescent THC exposure does not sensitize conditioned place preferences to subthreshold d-amphetamine in male and female rats. <i>F1000Research</i> , 2018, 7, 342.	0.8	4
1481	Adolescent THC exposure does not sensitize conditioned place preferences to subthreshold d-amphetamine in male and female rats. <i>F1000Research</i> , 2018, 7, 342.	0.8	5
1482	Reversible Disruption of Pre-Pulse Inhibition in Hypomorphic-Inducible and Reversible CB1 ^{-/-} Mice. <i>PLoS ONE</i> , 2012, 7, e35013.	1.1	8
1483	Structural and Functional Imaging Studies in Chronic Cannabis Users: A Systematic Review of Adolescent and Adult Findings. <i>PLoS ONE</i> , 2013, 8, e55821.	1.1	334
1484	Social Functioning Trajectories of Young First-Episode Psychosis Patients with and without Cannabis Misuse: A 30-Month Follow-Up Study. <i>PLoS ONE</i> , 2015, 10, e0122404.	1.1	20
1485	Subclinical Depressive Symptoms and Continued Cannabis Use: Predictors of Negative Outcomes in First Episode Psychosis. <i>PLoS ONE</i> , 2015, 10, e0123707.	1.1	22
1486	Cannabis Liberalization and Adolescent Cannabis Use: A Cross-National Study in 38 Countries. <i>PLoS ONE</i> , 2015, 10, e0143562.	1.1	61
1487	Grey Matter Changes Associated with Heavy Cannabis Use: A Longitudinal sMRI Study. <i>PLoS ONE</i> , 2016, 11, e0152482.	1.1	62
1488	Cannabinoids and Opioids in the Treatment of Inflammatory Bowel Diseases. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00120.	1.3	42
1489	The antitumor action of cannabinoids on glioma tumorigenesis. <i>Histology and Histopathology</i> , 2015, 30, 629-45.	0.5	7

#	ARTICLE	IF	CITATIONS
1490	The Devil Is in the Details! On Regulating Cannabis Use in Canada Based on Public Health Criteria Comment on "Legalizing and Regulating Marijuana in Canada: Review of Potential Economic, Social, and Health Impacts". <i>International Journal of Health Policy and Management</i> , 2017, 6, 173-176.	0.5	7
1492	Psychotic spectrum disorders: Definitions, classifications, neural correlates and clinical profiles. <i>Annals of Psychiatry and Treatment</i> , 2020, , 070-084.	1.3	20
1493	Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction. <i>Oncotarget</i> , 2016, 7, 55840-55862.	0.8	66
1494	Experiências percebidas de discriminação e Saúde Mental: resultados em estudantes universitários brasileiros. <i>Serviço Social E Saúde</i> , 2017, 15, 273.	0.1	2
1495	Experiencias psíquicas atenuadas y consumo de sustancias en universitarios. <i>Revista De Psicología De La Salud</i> , 2016, 28, 144.	0.2	9
1496	The Effects of Cannabis Use on Physical and Mental Health. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
1497	The Association between Regular Cannabis Exposure and Alterations of Human Brain Morphology: An Updated Review of the Literature. <i>Current Pharmaceutical Design</i> , 2014, 20, 2138-2167.	0.9	80
1498	Acute and Non-acute Effects of Cannabis on Human Memory Function: A Critical Review of Neuroimaging Studies. <i>Current Pharmaceutical Design</i> , 2014, 20, 2114-2125.	0.9	68
1499	Highlighting the Role of Cognitive and Brain Reserve in the Substance use Disorder Field. <i>Current Neuropharmacology</i> , 2019, 17, 1056-1070.	1.4	10
1500	Cannabis and Psychosis: A Systematic Review of Genetic Studies. <i>Current Psychiatry Reviews</i> , 2013, 9, 302-315.	0.9	6
1501	The Check Your Cannabis Screener: A New Online Personalized Feedback Tool. <i>Open Medical Informatics Journal</i> , 2009, 3, 27-31.	1.0	11
1502	New Developments in Understanding and Treating Adolescent Marijuana Dependence. <i>Adolescent Psychiatry (Hilversum, Netherlands)</i> , 2014, 3, 297-306.	0.1	13
1503	Environmental Risk and Protective Factors and Their Influence on the Emergence of Psychosis. <i>Adolescent Psychiatry (Hilversum, Netherlands)</i> , 2012, 2, 163-171.	0.1	21
1504	Is Cannabis Harmless? Focus on Brain Function. <i>Current Drug Research Reviews</i> , 2019, 11, 33-39.	0.7	6
1505	A Web-Based Program for Cannabis Use and Psychotic Experiences in Young People (Keep It Real): Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2020, 9, e15803.	0.5	14
1506	Adverse Reactions Associated With Cannabis Consumption as Evident From Search Engine Queries. <i>JMIR Public Health and Surveillance</i> , 2017, 3, e77.	1.2	19
1507	The Relationship between Psychoactive Drugs, the Brain and Psychosis. <i>International Archives of Addiction Research and Medicine</i> , 2015, 1, .	0.2	2
1508	Psychotic disorder and cannabis use: Canadian hospitalization trends, 2006–2015. <i>Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice</i> , 2020, 40, 176-183.	0.8	15

#	ARTICLE	IF	CITATIONS
1509	Frequency of Cannabis Use Among Primary Care Patients in Washington State. <i>Journal of the American Board of Family Medicine</i> , 2017, 30, 795-805.	0.8	33
1510	The epidemiology of schizophrenia: replacing dogma with knowledge. <i>Dialogues in Clinical Neuroscience</i> , 2010, 12, 305-315.	1.8	97
1511	The costs and benefits of cannabis control policies. <i>Dialogues in Clinical Neuroscience</i> , 2020, 22, 281-287.	1.8	22
1512	A health promotion intervention to improve lifestyle choices and health outcomes in people with psychosis: a research programme including the IMPaCT RCT. <i>Programme Grants for Applied Research</i> , 2020, 8, 1-124.	0.4	3
1514	Cannabis Use, Cannabis Use Disorder, and Comorbid Psychiatric Illness: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 15.	1.0	63
1515	Stronger evidence is needed before accepting that cannabis plays an important role in the aetiology of schizophrenia in the population. <i>F1000 Medicine Reports</i> , 2013, 5, 2.	2.9	65
1517	Risky Recreation: Synthetic Cannabinoids Have Dangerous Effects. <i>Journal of Psychosocial Nursing and Mental Health Services</i> , 2012, 50, 16-18.	0.3	26
1518	Continued Cannabis Use and Outcome in First-Episode Psychosis. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 632-638.	1.1	31
1519	Complementary and Alternative Medicine (CAM). <i>Journal of Clinical Psychiatry</i> , 2009, 70, 4-6.	1.1	102
1520	Psychotic Disorders in Children and Adolescents: A Primer on Contemporary Evaluation and Management. <i>primary care companion for CNS disorders, The</i> , 2014, 16, .	0.2	22
1521	Cannabis and psychopathology: The meandering journey of the last decade. <i>Indian Journal of Psychiatry</i> , 2015, 57, 140.	0.4	8
1522	A review of Indian research on co-occurring cannabis use disorders& psychiatric disorders. <i>Indian Journal of Medical Research</i> , 2017, 146, 186.	0.4	13
1523	Marijuana Use and Depressive Symptoms among Young People: Examining Unidirectional and Bidirectional Effects. <i>Health</i> , 2018, 10, 1066-1078.	0.1	6
1524	Association between Severity of Cannabis Dependence and Depression. <i>Psychology</i> , 2010, 01, 233-237.	0.3	3
1525	Cannabis and Pain Treatmentâ€”A Review of the Clinical Utility and a Practical Approach in Light of Uncertainty. <i>Rambam Maimonides Medical Journal</i> , 2020, 11, e0002.	0.4	9
1526	Using the Confidence Interval-Based Estimation of Relevance Approach to Identify Determinants of Cannabis Use among High School Students in the Netherlands. <i>Health Psychology Bulletin</i> , 0, 4, .	0.3	1
1527	Capgras syndrome after use of synthetic cannabinoids: an adolescent case. <i>Dusunen Adam</i> , 2016, , 374-378.	0.0	7
1528	Medical marijuana: a public health perspective. <i>International Journal of Basic and Clinical Pharmacology</i> , 2013, 2, 136.	0.0	4

#	ARTICLE	IF	CITATIONS
1529	Examining the Impact of Marijuana Legalization on Harms Associated with Marijuana Use. , 2010, , .		4
1530	A Rare Case of Cannabis-induced Acute Pancreatitis. Cureus, 2019, 11, e4878.	0.2	5
1531	Acute Psychosis Following 1,1-Difluoroethane Inhalation. Cureus, 2019, 11, e5565.	0.2	3
1532	Association of Cannabis Useâ€“Related Predictor Variables and Self-Reported Psychotic Disorders: U.S. Adults, 2001â€“2002 and 2012â€“2013. American Journal of Psychiatry, 2022, 179, 36-45.	4.0	19
1533	Cannabisâ€“based medicines and medical cannabis for patients with neuropathic pain and other pain disorders: Nationwide registerâ€“based pharmacoepidemiologic comparison with propensity score matched controls. European Journal of Pain, 2021, , .	1.4	5
1534	Neurological Soft Signs in Cannabis Use Disorder with or without Psychosis: A Comparative Study from India. Journal of Dual Diagnosis, 2021, 17, 1-10.	0.7	0
1535	Psychotherapeutic interventions for cannabis use disorder. What do we know and what should we do?. L'Encephale, 2022, 48, 70-77.	0.3	4
1536	A rapid assay provides on-site quantification of tetrahydrocannabinol in oral fluid. Science Translational Medicine, 2021, 13, eabe2352.	5.8	12
1537	Cannabis use disorder and dissociation: A report from a prospective first-episode psychosis study. Drug and Alcohol Dependence, 2021, 229, 109118.	1.6	23
1538	Les DiffÃ©rents Ã©tats Psychotiques. , 2008, , 319-354.		0
1539	5 Schizofrenie en andere psychotische stoornissen. , 2008, , 155-193.		0
1540	Tripmiddelen: cannabis. , 2008, , 337-368.		0
1541	Should drugs be decriminalised?. BMJ, The, 2008, 336, 0802054.	3.0	0
1542	Cannabis : de nouvelles inquiÃ©tudes. Bulletin De L'Academie Nationale De Medecine, 2008, 192, 583-587.	0.0	1
1548	Dopamine D3 Receptor Antagonist SB-277011A Influences Cell Firing in the Rat Ventral Tegmental Area, Parallel Role with the Cannabinoid System in Addiction and Neuropsychiatry Disorders?. The Open Neuropsychopharmacology Journal, 2009, 2, 86-92.	0.3	1
1549	Cannabis: A Clue or a Distraction in the Search for â€œCausesâ€™ of Psychosis?. , 2010, , 367-376.		0
1550	Impact of Contextual Environmental Mechanisms on the Incidence of Schizophrenia and Other Psychoses. , 2010, , 67-96.		1
1552	10.2 Neuropharmacological Profiles of Antipsychotic Drugs. , 2009, , 520-539.		0

#	ARTICLE	IF	CITATIONS
1554	Potential Pharmacotherapies for Cannabis Dependence. , 2010, , 1063-1082.		0
1555	Krigen mot narkotika gÅr mot slutten. , 2010, 27, 142-153.	0.1	2
1556	Managing schizophrenia: the role of primary care. Independent Nurse, 2010, 2010, .	0.0	0
1558	O consumo de cannabis na adolescÃncia: dados de um estudo portuguÃs. Revista Portuguesa De Pedagogia, 0, , 61-79.	0.1	1
1561	The Interface of Cannabis Misuse and Schizophrenia-Spectrum Disorders. , 2011, , 289-320.		1
1562	Substance Misuse. , 2011, , 357-399.		0
1565	Chapter 8 Does Higher Potency of Cannabis Mean Higher Risk for Psychosis?. , 2012, , 97-101.		0
1567	Schizophrenie. , 2012, , 437-496.		0
1568	Maladies mentales et addictions: En finir avec les clichÃs. , 2012, , 117-132.		0
1569	Nouvelles drogues. , 2012, , 507-547.		1
1570	Cannabis sativa variÃtÃ indica. , 2012, , 299-320.		3
1571	Diagnosis, classification, and differential diagnosis of schizophrenia. , 2012, , 534-540.		0
1572	MCQanswers. , 2012, , 479-484.		0
1574	Does Higher Potency of Cannabis Mean Higher Risk for Psychosis?. , 2013, , 101-105.		0
1575	The Development of Cannabidiol as a Psychiatric Therapeutic: A Review of Its Antipsychotic Efficacy and Possible Underlying Pharmacodynamic Mechanisms. International Neuropsychiatric Disease Journal, 2013, 1, 113-147.	0.1	2
1576	Cannabinoids, Monoamines, COMT and Schizophrenia: Pathobiological Mechanisms in Psychosis. , 2013, , 297-323.		0
1578	Literaturverzeichnis zu Voderholzer, Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 9. Auflage. , 2014, , 1-91.		0
1579	Cannabis Use and its Effects on Health, Education and Labor Market Success. SSRN Electronic Journal, 0, , .	0.4	1

#	ARTICLE	IF	CITATIONS
1582	Chapitre 8. Les comorbidités dans l'adolescence. , 2014, , 127-151.		1
1583	Chapitre 12. Addiction au cannabis et troubles psychiatriques. , 2014, , 207-221.		0
1584	Gender and First Psychotic Episodes in Adolescence. , 2015, , 611-620.		0
1586	Psychotic Disorders and Substance Use Disorders. , 2015, , 2013-2034.		0
1587	Profile of Patients with Dual Diagnosis: Experience from an Integrated Dual Diagnosis Clinic in North India. Journal of Alcoholism and Drug Dependence, 2015, 03, .	0.2	2
1588	Literaturverzeichnis zu Voderholzer, Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 10. Auflage. , 2015, , e1-e96.		0
1589	CHAPTER 5. Modelling Schizophrenia: Strategies for Identifying Improved Platforms for Drug Discovery. RSC Drug Discovery Series, 2015, , 89-114.	0.2	0
1591	Rodent Models of Multiple Environmental Exposures with Relevance to Schizophrenia. Handbook of Behavioral Neuroscience, 2016, 23, 361-371.	0.7	1
1592	Therapie der Cannabisabhängigkeit. , 2016, , 1-13.		0
1593	Recovery-Oriented Vocational Rehabilitation Services for Individuals With Co-Occurring Psychiatric Disabilities and Substance Use Disorders. Rehabilitation Research Policy and Education, 2016, 30, 243-258.	0.2	5
1594	CANNABIS (BHANG, CHARAS) CONSUMPTION; EMOTIONAL AND COGNITIVE DISTURBANCES AND DEPRESSIVE SYMPTOMS IN YOUNG ADULTS. The Professional Medical Journal, 2016, 23, 597-602.	0.0	0
1596	Cannabis Chemistry: Cannabinoids in Cannabis, Humans, and Other Species. , 2016, , 229-252.		0
1598	Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 13. Auflage. , 2017, , 1-111.		0
1599	Hallucinations. , 2017, , 1-11.		0
1600	Psychosocial Issues in Intestinal Transplantation. , 2017, , 1-17.		0
1601	3 Emergency Psychiatry: An Emergency Physician's Perspective. , 2017, , 27-38.		0
1602	11 Psychotic Disorders in Emergency Departments. , 2017, , 177-198.		0
1603	Substance Abuse Profiles of Patients Admitted to the Alcohol and Drug Addiction Research, Treatment, and Education Center in Turkey. Turkish Journal of Pharmaceutical Sciences, 2017, 14, 294-303.	0.6	0

#	ARTICLE	IF	CITATIONS
1604	Therapie der Cannabisabhängigkeit. , 2018, , 487-496.		0
1605	Les différents États psychotiques. , 2018, , 447-503.		0
1609	Why Are There People With Psychosis And People Without? Is It All Due To Genetic And Vulnerability Factors?. , 2018, , .		0
1610	Hallucinations. , 2018, , 1692-1702.		0
1611	Beyond the Bong: Edible Marijuana Use among College Students. Cannabis (Research Society on) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.3	0
1612	A Critical Systematic Review of Evidence for Cannabinoids in the Treatment of Schizophrenia. Psychiatric Annals, 2018, 48, 214-223.	0.1	1
1614	Troubles psychiatriques et addiction au cannabis : À travers la littérature. French Journal of Psychiatry, 2018, 1, S125-S126.	0.1	0
1615	A case of brief psychosis upon cannabis withdrawal. MOJ Addiction Medicine & Therapy, 2018, 5, .	0.1	2
1616	Medical Marijuana Laws and Suicide. SSRN Electronic Journal, 0, , .	0.4	1
1617	Cannabiskonsum zum Freizeitgebrauch. , 2019, , 65-264.		1
1619	Psychosocial Issues in Intestinal Transplantation. Organ and Tissue Transplantation, 2019, , 397-413.	0.0	0
1621	Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 14. Auflage. , 2019, , 1-119.		0
1622	Quelle est la place de la consommation de substances dans les troubles psychotiques émergents?. , 2019, , 71-81.		0
1623	Attenuated Psychosis in Youth and Adolescents: Clinical and Cultural Considerations from India. , 2019, , 323-332.		0
1625	Cannabis : enjeux et risques en médecine de la douleur. Douleur Et Analgesie, 2019, 32, 73-78.	0.2	0
1626	A Feasibility Test of the In Vivo Driving Impairment Research Method: Examining Cannabinoid Concentrations as Predictors of Risky Drinking. Cannabis (Research Society on Marijuana), 2019, 2, 144-150.	0.3	2
1628	Interventions integrating health and academic education in schools to prevent substance misuse and violence: a systematic review. Public Health Research, 2019, 7, 1-244.	0.5	8
1630	Prácticas usadas en los colegios de Bogotá para prevenir consumo de sustancias psicoactivas y agresión por estudiantes de secundaria y media. Revista Colombiana De Educacion, 2020, 1, .	0.0	0

#	ARTICLE	IF	CITATIONS
1631	American Glaucoma Society Position Statement on Cannabinoid Use in Pediatric Glaucoma Patients. <i>Ophthalmology Glaucoma</i> , 2019, 2, 365-366.	0.9	0
1633	Estabilidad diagn3stica en la psicosis inducida por sustancias. <i>Revista De Psiquiatr3a Y Salud Mental</i> , 2020, , .	1.0	6
1634	Cannabis and Neuropsychiatric Effects. , 2020, , 65-132.		0
1635	Introduction: The Cannabis Challenge. , 2020, , 1-14.		0
1636	Beyond the "self" in self-regulation: Family interaction modulates situational self-control by adolescent drug users.. <i>Journal of Family Psychology</i> , 2020, 34, 322-332.	1.0	1
1637	A Brief Screen to Detect Cannabis Use Disorder Among Incarcerated Youth. <i>Journal of Child and Adolescent Substance Abuse</i> , 2020, 29, 189-196.	0.5	1
1640	Marijuana Use in Young Adults: What Do We Know?. <i>Current Psychopharmacology</i> , 2020, 9, 103-114.	0.1	1
1646	Potentially exploring homelessness among refugees: a systematic review and meta-analysis. <i>Journal of Social Distress and the Homeless</i> , 2023, 32, 135-150.	0.7	2
1647	Acute effects of Δ9-tetrahydrocannabinol and cannabidiol on auditory mismatch negativity. <i>Psychopharmacology</i> , 2022, 239, 1409-1424.	1.5	2
1648	Cannabis (Marijuana) and Cannabinoids. , 2020, , 470-483.e5.		1
1649	Young Adults With Higher Motives and Expectancies of Regular Cannabis Use Show Poorer Psychosocial Functioning. <i>Frontiers in Psychiatry</i> , 2020, 11, 599365.	1.3	7
1652	Cannabis and Psychosis: A Review of the Risk Factors Involved. <i>American Journal of Plant Sciences</i> , 2020, 11, 1949-1990.	0.3	1
1653	Acute Emergency Department Presentations Related to Cannabis. , 2020, , 157-170.		1
1654	Poisoning by drugs and chemicals. , 2020, , 1725-1777.		0
1655	Looking at Marijuana Through the Lens of Public Health. , 2020, , 453-491.		1
1656	Economics of Suicide. , 2020, , 1-26.		0
1657	Development of Group Counseling Guidelines for Student Self Control Improvement in Prevention of Drug Abuse. <i>Jurnal Aplikasi IPTEK Indonesia</i> , 2020, 4, 24-31.	0.2	0
1660	Cannabis use, polysubstance use, and psychosis prodrome among first-degree relatives of patients with schizophrenia. <i>Journal of Substance Use</i> , 2022, 27, 658-666.	0.3	2

#	ARTICLE	IF	CITATIONS
1661	8.7 Bipolair syndroom. , 2018, , 365-374.		0
1662	8.8 Psychosesyndroom. , 2018, , 375-385.		0
1677	Basic Substance Characteristics and Neuropathological Findings in Drug Abusers. , 2021, , 23-87.		0
1678	Troubles anxieux, troubles d'agressifs, conduites suicidaires et cannabis. La Presse Médicale Formation, 2020, 1, 384-393.	0.1	0
1680	Models of substance use in adolescents with and without psychosis. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2008, 17, 202-9.	0.7	4
1681	Cannabis and Psychosis: What Can Daily Diaries Tell Us About Who is Vulnerable?. Primary Psychiatry First in Applied Psychiatric Medicine, 2009, 16, 44-48.	1.0	2
1682	Effects of Δ^9 -THC on Working Memory: Implications for Schizophrenia?. Primary Psychiatry First in Applied Psychiatric Medicine, 2009, 16, 51-99.	1.0	12
1683	Paliperidone: the evidence of its therapeutic value in schizophrenia. Core Evidence, 2008, 2, 261-71.	4.7	12
1685	Bath salts-induced psychosis: a case report. Innovations in Clinical Neuroscience, 2013, 10, 10-1.	0.1	3
1686	Approach to cannabis use disorder in primary care: focus on youth and other high-risk users. Canadian Family Physician, 2014, 60, 801-8, e423-32.	0.1	10
1687	TextHunter--A User Friendly Tool for Extracting Generic Concepts from Free Text in Clinical Research. AMIA ... Annual Symposium proceedings, 2014, 2014, 729-38.	0.2	25
1688	Appraising the risks of reefer madness. Cerebrum: the Dana Forum on Brain Science, 2015, 2015, 1.	0.1	2
1689	U.S. Policy Responses to Calls for the Medical Use of Cannabis. Yale Journal of Biology and Medicine, 2015, 88, 257-64.	0.2	11
1690	Medical and recreational marijuana: commentary and review of the literature. Missouri Medicine, 2013, 110, 524-8.	0.3	6
1691	Legalization, decriminalization & medicinal use of cannabis: a scientific and public health perspective. Missouri Medicine, 2012, 109, 90-8.	0.3	25
1692	Marijuana Use in the Era of Changing Cannabis Laws: What Are the Risks? Who is Most at Risk?. Missouri Medicine, 2018, 115, 398-404.	0.3	7
1693	Emergent Medical Illnesses Related to Cannabis Use. Missouri Medicine, 2019, 116, 226-228.	0.3	6
1694	Top 10 Self Learning articles from 2017. Canadian Family Physician, 2019, 65, 711-716.	0.1	0

#	ARTICLE	IF	CITATIONS
1696	Cannabis Use and Misuse in Older Adults. <i>Clinics in Geriatric Medicine</i> , 2022, 38, 67-83.	1.0	8
1697	Sociodemographic Characteristics Associated With and Prevalence and Frequency of Cannabis Use Among Adults in the US. <i>JAMA Network Open</i> , 2021, 4, e2136571.	2.8	54
1698	Superlatives in news articles reporting non-FDA approved indications for use of cannabis and cannabis products with a focus on psychiatric disorders: a cross-sectional analysis. <i>Journal of Mental Health</i> , 2022, 31, 109-114.	1.0	0
1699	Chronic exposure to Δ^9 -tetrahydrocannabinol in adolescence decreases social play behaviours. <i>F1000Research</i> , 2021, 10, 1191.	0.8	3
1700	Multimodal MRI data fusion reveals distinct structural, functional and neurochemical correlates of heavy cannabis use. <i>Addiction Biology</i> , 2022, 27, e13113.	1.4	14
1701	More harm than good? Cannabis, harm and the misuse of drugs act. <i>Drugs and Alcohol Today</i> , 2021, 21, 277-288.	0.3	0
1702	The Beginning of Psychosis: Psychological and Environmental Factors That Lead To Psychosis and Their Relationship to Biological Factors. <i>International Journal of Medical Science and Clinical Research Studies</i> , 2021, 01, .	0.0	0
1703	Cannabis-Based Medicines and Medical Cannabis in the Treatment of Nociceptive Pain. <i>Drugs</i> , 2021, 81, 2103-2116.	4.9	16
1704	Risk and protective factors of drug abuse among adolescents: a systematic review. <i>BMC Public Health</i> , 2021, 21, 2088.	1.2	92
1705	Age- and Sex-Related Cortical Gray Matter Volume Differences in Adolescent Cannabis Users: A Systematic Review and Meta-Analysis of Voxel-Based Morphometry Studies. <i>Frontiers in Psychiatry</i> , 2021, 12, 745193.	1.3	7
1706	Chapitre 11. Thérapies psychosociales et thérapies cognitives et comportementales dans la psychose d'adulte. , 2015, , 171-195.		0
1707	Attenuated Psychotic Symptoms in Adolescents With Chronic Cannabis and MDMA Use. <i>Frontiers in Psychiatry</i> , 2021, 12, 696133.	1.3	3
1708	Using Virtual Reality to Examine the Association Between Respiratory Sinus Arrhythmia and Adolescent Substance Use. <i>Child Psychiatry and Human Development</i> , 2023, 54, 1055-1063.	1.1	1
1709	Adolescent cannabis use and later development of schizophrenia: An updated systematic review of longitudinal studies. <i>Journal of Clinical Psychology</i> , 2022, 78, 1331-1340.	1.0	13
1710	Association Between Hormonal Birth Control, Substance Use, and Depression. <i>Frontiers in Psychiatry</i> , 2022, 13, 772412.	1.3	1
1711	Cannabis use and suicidal ideation among youth: Can we democratize school policies using digital citizen science?. <i>PLoS ONE</i> , 2022, 17, e0263533.	1.1	6
1712	Sex differences across developmental domains among children with a familial risk of severe mental disorders. <i>Psychological Medicine</i> , 2022, , 1-16.	2.7	2
1713	Cannabis and Mental Health: Adverse Outcomes and Self-Reported Impact of Cannabis Use by Mental Health Status. <i>Substance Use and Misuse</i> , 2022, 57, 719-729.	0.7	5

#	ARTICLE	IF	CITATIONS
1714	The Construct of Medical and Non-Medical Marijuanaâ€”Critical Review. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 2769.	1.2	3
1715	Socio-demographic, health and drug use characteristics among people with different frequency patterns of cannabis use in Brazil. <i>Drugs: Education, Prevention and Policy</i> , 2023, 30, 425-433.	0.8	1
1716	Risk-thresholds for the association between frequency of cannabis use and the development of psychosis: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2023, 53, 3858-3868.	2.7	19
1717	Lifetime Cannabis Use Is Not Associated With Negative Beliefs About Medication in Patients With First Treatment Psychosis. <i>Frontiers in Psychiatry</i> , 2022, 13, 824051.	1.3	0
1718	Gender Differences in Dual Diagnoses Associated with Cannabis Use: A Review. <i>Brain Sciences</i> , 2022, 12, 388.	1.1	8
1720	Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 719-742.	1.3	40
1721	Young adultsâ€™ familiarity with different cannabis product terms: the need for standardized cannabis surveys. <i>Journal of Cannabis Research</i> , 2022, 4, 14.	1.5	0
1722	Premorbid characteristics of patients with DSM-IV psychotic disorders. <i>Comprehensive Psychiatry</i> , 2022, 115, 152310.	1.5	2
1723	The association between the five-factor model of personality and problem cannabis use: A meta-analysis. <i>Personality and Individual Differences</i> , 2022, 193, 111635.	1.6	6
1724	Frequent Cannabis Use Moderates the Relationship Between Sexual Dysfunction and Depression Among Female German Adults. <i>Journal of Sexual Medicine</i> , 2022, 19, 940-949.	0.3	1
1725	Brain Anatomical Alterations in Young Cannabis Users: Is it All Hype? A Meta-Analysis of Structural Neuroimaging Studies. <i>Cannabis and Cannabinoid Research</i> , 2023, 8, 184-196.	1.5	6
1726	Association between cannabis use and suicidal behavior: A systematic review of cohort studies. <i>Psychiatry Research</i> , 2022, 312, 114555.	1.7	6
1729	Exploraci3n psicom3trica sobre deficiencia motivacional en consumidores de marihuana. <i>Interdisciplinaria</i> , 2020, 37, .	0.1	0
1733	The Cannabis Ask: What's a Psychiatrist to Do?. <i>Journal of the Canadian Academy of Child and Adolescent Psychiatry</i> , 2022, 31, 28-37.	0.7	0
1734	A network approach to relationships between cannabis use characteristics and psychopathology in the general population. <i>Scientific Reports</i> , 2022, 12, 7163.	1.6	1
1735	Cariprazine in the treatment of psychosis with comorbid cannabis use: A case report. <i>Psychiatry Research Communications</i> , 2022, 2, 100048.	0.2	2
1736	Cannabis induced psychosis: A systematic review on the role of genetic polymorphisms. <i>Pharmacological Research</i> , 2022, 181, 106258.	3.1	14
1737	Associations of Cannabis Use across Adolescence and Early Adulthood With Health and Psychosocial Adjustment in Early Adulthood and Midadulthood in Men. <i>Substance Abuse: Research and Treatment</i> , 2022, 16, 117822182210961.	0.5	1

#	ARTICLE	IF	CITATIONS
1738	A bibliometric analysis of the cannabis and cannabinoid research literature. <i>Journal of Cannabis Research</i> , 2022, 4, .	1.5	5
1739	Effects of Tetrahydrocannabinol and Cannabidiol on Brain-Derived Neurotrophic Factor and Tropomyosin Receptor Kinase B Expression in the Adolescent Hippocampus. <i>Cannabis and Cannabinoid Research</i> , 2023, 8, 612-622.	1.5	6
1740	Childhood maltreatment mediates the effect of the genetic background on psychosis risk in young adults. <i>Translational Psychiatry</i> , 2022, 12, .	2.4	7
1743	Substance-use disorders in children and adolescents. <i>Deutsches A&#x0308;rzteblatt International</i> , 0, , .	0.6	1
1744	Cannabis Use in Patients With Cancer: A Clinical Review. <i>JCO Oncology Practice</i> , 2022, 18, 743-749.	1.4	15
1745	Cannabinoids and Brain Damage: A Systematic Review on a Frequently Overlooked Issue. <i>Current Pharmaceutical Biotechnology</i> , 2023, 24, 741-757.	0.9	3
1746	Gutâ€™microbiotaâ€™brain axis in the vulnerability to psychosis in adulthood after repeated cannabis exposure during adolescence. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 1297-1309.	1.8	13
1747	Cannabis use and risks of respiratory and all-cause morbidity and mortality: a population-based, data-linkage, cohort study. <i>BMJ Open Respiratory Research</i> , 2022, 9, e001216.	1.2	9
1748	The CannTeen Study: Cannabis use disorder, depression, anxiety, and psychotic-like symptoms in adolescent and adult cannabis users and age-matched controls. <i>Journal of Psychopharmacology</i> , 2022, 36, 1350-1361.	2.0	11
1749	Marijuana use in children: An update focusing on pediatric tetrahydrocannabinol and cannabidiol use. <i>Journal of the American College of Emergency Physicians Open</i> , 2022, 3, .	0.4	1
1750	Cannabis smoking increases the risk of suicide ideation and suicide attempt in young individuals of 11â€™21 years: A systematic review and meta-analysis. <i>Journal of Psychiatric Research</i> , 2022, 153, 90-98.	1.5	14
1751	Cannabis Use in Autism: Reasons for Concern about Risk for Psychosis. <i>Healthcare (Switzerland)</i> , 2022, 10, 1553.	1.0	4
1752	Can cannabis kill? Characteristics of deaths following cannabis use in England (1998â€™2020). <i>Journal of Psychopharmacology</i> , 0, , 026988112211157.	2.0	3
1753	Anhedonia, Apathy, Pleasure, and Effort-Based Decision-Making in Adult and Adolescent Cannabis Users and Controls. <i>International Journal of Neuropsychopharmacology</i> , 2023, 26, 9-19.	1.0	6
1754	Cannabis et schizophrÃ©nie. <i>Psychotropes (discontinued)</i> , 2022, Vol. 28, 135-142.	0.0	0
1755	Low income and schizophrenia risk: A narrative review. <i>Behavioural Brain Research</i> , 2022, 435, 114047.	1.2	5
1756	Cannabis in the Child and Adolescent Emergency and Inpatient Psychiatric Settings. <i>Psychiatry Update</i> , 2022, , 69-80.	0.1	0
1757	Molecular mechanisms underlying cannabis-induced risk of psychosis. , 2022, , 197-242.		0

#	ARTICLE	IF	CITATIONS
1758	Grundlegende Substanzmerkmale und neuropathologische Befunde bei Drogenkonsumenten. , 2022, , 23-90.		0
1759	Comparative harms assessments for cannabis, alcohol, and tobacco: Risk for psychosis, cognitive impairment, and traffic accident. <i>Drug Science, Policy and Law</i> , 2022, 8, 205032452210952.	0.6	4
1760	How adolescent cannabinoid exposure sets the stage for long-term emotional and cognitive dysregulation: Impacts on molecular and neuronal risk pathways. , 2022, , 171-196.		0
1761	A Meta-Analysis of fMRI Studies of Youth Cannabis Use: Alterations in Executive Control, Social Cognition/Emotion Processing, and Reward Processing in Cannabis Using Youth. <i>Brain Sciences</i> , 2022, 12, 1281.	1.1	4
1763	Diagnostic progression to schizophrenia: A nationwide cohort study of 11% adolescents and young adults with autism spectrum disorder. <i>Psychiatry and Clinical Neurosciences</i> , 2022, 76, 644-651.	1.0	7
1764	Prefrontal cortex and putamen grey matter alterations in cannabis and tobacco users. <i>Journal of Psychopharmacology</i> , 2022, 36, 1315-1323.	2.0	3
1765	Understanding Lower-Risk Cannabis Consumption from the Consumers'™ Perspective: A Rapid Evidence Assessment. <i>Substance Use and Misuse</i> , 0, , 1-11.	0.7	1
1766	Variations of cannabis-related adverse mental health and addiction outcomes across adolescence and adulthood: A scoping review. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	3
1767	Helping Women Suffering from Drug Addiction: Needs, Barriers, and Challenges. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 14039.	1.2	5
1768	Hippocampal CB1 receptor mediates antidepressant-like effect of synthetic cannabinoid-HU210 in acute despair reaction model in mice. <i>Neuroscience Letters</i> , 2023, 792, 136953.	1.0	1
1769	Imaging in Schizophrenia: Looking Back and Peering Ahead. <i>Annals of the Academy of Medicine, Singapore</i> , 2009, 38, 440-441.	0.2	6
1770	Consumer perceptions of legal cannabis products in Canada, 2019–2021: a repeat cross-sectional study. <i>BMC Public Health</i> , 2022, 22, .	1.2	6
1771	Cannabis and Intentional Self-injury: a Narrative Review. <i>Current Addiction Reports</i> , 0, , .	1.6	0
1772	Diagnostic stability in substance-induced psychosis. <i>Revista De Psiquiatria Y Salud Mental (English)</i> Tj ETQq1 1 0.784314 rgBT /Overl	0.2	1
1773	Thirty years of research on negative symptoms of schizophrenia: A scientometric analysis of hotspots, bursts, and research trends. <i>Neuroscience and Biobehavioral Reviews</i> , 2023, 144, 104979.	2.9	20
1774	Culturally sensitive prevention programs for substance use among adolescents of color: A systematic review and meta-analysis of randomized controlled trials. <i>Clinical Psychology Review</i> , 2023, 99, 102233.	6.0	1
1775	Cannabis use, risk behaviours and harms in Brazil: A comprehensive review of available data indicators. <i>Drug and Alcohol Review</i> , 2023, 42, 318-336.	1.1	1
1776	Lurasidone use in Cannabis-Induced Psychosis: A Novel Therapeutic Strategy and Clinical Considerations in Four Cases Report. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 16057.	1.2	5

#	ARTICLE	IF	CITATIONS
1777	Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use – a post hoc analysis of the ReLiAM study. <i>BMC Psychiatry</i> , 2022, 22, .	1.1	1
1779	Trends in emergency department visits associated with cannabis use among older adults in California, 2005–2019. <i>Journal of the American Geriatrics Society</i> , 2023, 71, 1267-1274.	1.3	4
1780	The impact of recreational cannabis markets on motor vehicle accident, suicide, and opioid overdose fatalities. <i>Social Science and Medicine</i> , 2023, , 115680.	1.8	2
1781	Minimizing policy-biased appraisals of the evidence on cannabis and psychosis. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	0
1782	Cannabis use during the early COVID-19 pandemic: Use patterns, predictors, and subjective experiences. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	0
1783	Mental health and cannabis use among Canadian youth: Integrated findings from cross-sectional and longitudinal analyses. <i>International Journal of Drug Policy</i> , 2023, 112, 103926.	1.6	2
1784	Chemical Profiling of Hashish Resin and its Possible Role in Forensic Cases Involving Violence in Jazan, Saudi Arabia. <i>Arab Journal of Forensic Sciences and Forensic Medicine</i> , 2022, 4, 77-88.	0.1	0
1785	Therapeutic Benefits of Medical Cannabis. <i>Physician Assistant Clinics</i> , 2023, 8, 281-291.	0.1	0
1786	Cannabis Use in Transplantation. , 2022, , 167-176.		1
1787	Incidence of mental disorders in the general population aged 1–30 years disaggregated by gender and socioeconomic status. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2023, 58, 961-971.	1.6	2
1788	First episode psychosis with and without the use of cannabis and synthetic cannabinoids: Psychopathology, global functioning and suicidal ideation. <i>Psychiatry Research</i> , 2023, 320, 115053.	1.7	4
1789	Prevalence and association of non-medical cannabis use with post-procedural healthcare utilisation in patients undergoing surgery or interventional procedures: a retrospective cohort study. <i>EClinicalMedicine</i> , 2023, 57, 101831.	3.2	3
1790	Probable depression and its correlates among undergraduate students in Johannesburg, South Africa. <i>Frontiers in Psychiatry</i> , 0, 14, .	1.3	1
1791	Prevalence of cannabis use disorder among individuals using medical cannabis at admission to inpatient treatment for substance use disorders. <i>Addictive Behaviors</i> , 2023, 142, 107667.	1.7	1
1792	Integrative Roles of Dopamine Pathway and Calcium Channels Reveal a Link between Schizophrenia and Opioid Use Disorder. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4088.	1.8	0
1793	Multinational Association of Supportive Care in Cancer (MASCC) guidelines: cannabis for psychological symptoms including insomnia, anxiety, and depression. <i>Supportive Care in Cancer</i> , 2023, 31, .	1.0	8
1794	Cannabis Use Is Associated With Depression Severity and Suicidality in the National Comorbidity Survey–Adolescent Supplement. , 2023, 1, 24-35.		5
1795	Long-term development and outcome of early-onset psychosis. , 2023, , 299-318.		0

#	ARTICLE	IF	CITATIONS
1796	Early risk factors in early-onset psychosis. , 2023, , 81-105.		0
1798	An Individuality of Response to Cannabinoids: Challenges in Safety and Efficacy of Cannabis Products. Molecules, 2023, 28, 2791.	1.7	6
1799	Marijuana, i.e., Cannabis sativa. Advances in Medical Diagnosis, Treatment, and Care, 2023, , 153-171.	0.1	0
1800	Cannabis use and psychotic disorders in diverse settings in the Global South: findings from INTREPID II. Psychological Medicine, 2023, 53, 7062-7069.	2.7	2
1801	Old Dog, New Tricks: A Review of Identifying and Addressing Youth Cannabis Vaping in the Pediatric Clinical Setting. Clinical Medicine Insights Pediatrics, 2023, 17, .	0.7	0
1803	Neurobehavioral risk factors influence prevalence and severity of hazardous substance use in youth at genetic and clinical high risk for psychosis. Frontiers in Psychiatry, 0, 14, .	1.3	1
1804	Cannabis etÂtroubles psychotiques. Information Psychiatrique, 2009, Volume 85, 641-645.	0.1	1
1816	Genetic variation and acute responses to cannabis. , 2023, , 313-327.		0
1817	Medicinal use of Cannabis: Adverse events as a balanced perspective. , 2023, , 135-145.		0
1847	Cannabis: A Useful Psychotropic for Pain, PTSD and Sleep or a Gateway to Schizophrenia?. , 2023, , 159-163.		0
1853	Rewiring the future: drugs abused in adolescence may predispose to mental illness in adult life by altering dopamine axon growth. Journal of Neural Transmission, 0, , .	1.4	0
1871	Towards Data-Driven Artificial Intelligence Models for Monitoring, Modelling and Predicting Illicit Substance Use. Lecture Notes in Networks and Systems, 2024, , 361-379.	0.5	0
1877	Dual Diagnosis: Substance Use Disorders and Co-Occurring Psychiatric Illnesses. , 2024, , .		0